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Abstract
Insulin-like growth factors induce the proliferation of transformed cells. IGF binding 
proteins (IGFBP) are involved in their local tissue regulation. In this project, the 
effects of early and late administration of IGFBP-4 gene were assessed on colon 
cancer model in vivo. Nude mice were subcutaneously inoculated with HT-29 colon 
adenocarcinoma cells. In the early gene transfer model, IGFBP-4 gene was 
administered along with cancer cells. In the late gene transfer model, cancer was 
induced first and IGFBP-4 gene was administered when the tumour became visible 
(one week after inoculation). Animals received either mammalian expression vector 
containing IGFBP-4 cDNA, or vector alone, or PBS as peritumoral injection. 
Tumour size was measured at different time periods during the experiment. After 
three to four weeks of IGFBP-4 induction, the mice were sacrificed and tumour 
tissues were collected for further examinations. Tumour proliferative activity was 
determined by counting mitotic cells. Tumour apoptosis was investigated by TUNEL 
assay and electron microscopy. Results showed that tumour tissues had large necrotic 
areas, significantly increased numbers of apoptotic cells, and decreased cells 
undergoing mitosis following treatment with IGFBP-4 gene, in both early and late 
gene transfer model. Despite increased apoptosis and decreased mitosis in IGFBP-4 
treated tumours, tumour volume was not significantly altered, possibly due to cellular 
debris filling the centre of tumours. There was an increase in Bax protein levels after 
IGFBP-4 gene therapy in both models. When IGFBP-4 gene was administered late, 
tumours showed higher expression of IGFBP-4 protein levels as well as IGF-IR 
levels when compared with controls. However, in the early gene transfer model, 
when IGFBP-4 gene was administered along with cancer cells, the tumours did not 
show such an increase in IGFBP-4 levels compared with controls. Although the 
tumours of the late group showed a reduction in Bcl-2 protein levels, the early gene 
transfer model did not show a similar reduction. In fact the Bcl-2 was elevated after 
IGFBP-4 gene therapy.
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Chapter 1 Introduction
The incidence of colorectal cancer has been increasing rapidly since 1975, with 
about 300,000 new cases and 200,000 deaths in Europe and the USA each year 
[Midgley and Kerr, 1999;Boyle and Langman, 2000]. It is the second commonest 
cause of death from any cancer in men in the European Union [Boyle and Langman, 
2000]. Long-term survival of colorectal cancer is related to the stage o f the disease. 
If detected early, it may be curable by surgery [Dorudi et al., 2002]. But once 
métastasés develop the prognosis becomes poor. At least 50% of patients with 
colorectal cancer develop recurrence or métastasés during their illness [Midgley and 
Kerr, 2000]. Though various combinations of surgery, radiotherapy and 
chemotherapy are used for advanced cancer, the most effective approach is yet to be 
discovered.
Several growth factors, including transforming growth factor-p, epidermal growth 
factor, insulin and insulin-like growth factors (IGFs) have been implicated in the 
development of colon cancer [Schmelz et al., 2007;Coban et al., 2007]. In the last 
decade, the role of IGFs in cancer has been increasingly recognised. The IGFs are 
peptides structurally related to insulin that regulate the proliferation of several 
mammalian cells, including epithelial cells of breast, prostate, colon and lung 
[Poliak, 2000]. Abnormal expression of the IGFs, their receptors and binding 
proteins have been linked to several cancers including colorectal cancer [Mishra et 
al., 1998;Khandwala et al., 2000]. Correction of the malfunctioning genes in the form 
of gene therapy may prevent or cure cancers.
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1.1 Gene therapy in eolorectal cancer
This chapter will provide a brief outline about gene therapy and the rationale behind 
its use with relevance to colorectal cancer.
1.1.1 Gene therapy
Genes are building blocks of deoxy ribonucleic acid (DNA) which are found inside 
cells. Genes may encode enzymes or proteins and are ultimately responsible for the 
production of them. Potentially any change in gene expression, such as over­
expression, deletion and malfunction could result in cancer. There are approximately 
50,000 to 100,000 genes in the human body. Different genes are active in different 
phases of cell cycle. Gene therapy involves the introduction of genetic materials, 
which are nucleic acids, into the cells. The genetic material may be deoxy 
ribonucleic acid or ribonucleic acid (RNA), which may help to replace or correct the 
malfunction due to a single gene. Gene therapy can also be performed either to 
trigger an immune response or to produce a therapeutic substance.
In general, there are two ways of transferring genes to mammalian cells. The first 
way is transferring an exogenous gene directly into cells by local or systemic 
administration. The second way is culturing cells from a patient and transfecting 
them with the required gene in vitro and re-introducing them into the patient. It was 
Dr. W. French Anderson who performed the first government-approved human gene 
transfer for a 4-year-old girl with severe combined immunodeficiency in 1990 in the 
USA. Following the procedure the patient was not cured but her condition improved 
and she acquired resistance to frequent cold. It stimulated interest in the scientific
13
community about gene therapies. Currently several gene therapy trials are being 
carried out throughout the world especially for cancer.
1.1.2 Introduction of genes into the mammalian cell
Genes have to be transferred into a cell by means of a vector to enable them to 
function. The vectors that are used can be classified into viral and non-viral.
Viral vectors
Viral vectors can be used to introduce a DNA into eukaryotic cells. These are more 
powerful than the non-viral transfection system. A variety of viral vectors have been 
employed to deliver genes to cells to provide either transient (e.g. adenovirus, 
vaccinia virus) or permanent (e.g. retrovirus, adeno-associated virus) transgene 
expression, and each approach has its own advantages and disadvantages [Young et 
al., 2006]. Complications which may occur during virally mediated gene therapy 
include virus dissemination [Wang et al., 2003] causing toxic shock, leukaemia 
[Puck and Malech, 2006], immune reactions against the vectors causing failure of 
gene therapy, and inappropriate insertion of vectors and transgenes that may cause 
mutations leading to cancer.
Retrovirus
The first human gene therapy trial was performed by Rosenberg in 1989 using 
retrovirus [Aebersold et al., 1990]. He introduced genes encoding resistance to 
neomycin into human lymphocytes and infused them into 5 patients with advanced 
melanoma. Only one person exhibited remission. The main drawbacks of retrovirus 
are lack o f tissue specificity, low production titres and the need for cell replication 
for infectivity. A recent animal experiment showed a significant reduction of 
multiple tumour foci in the liver when cytosine deaminase (CD) gene was transferred
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using retrovirus and prodrug 5-fluorocytosine was infused into the portal circulation 
[Hiraoka et al., 2007] .
Adenovirus
Adenovirus is responsible for the common cold. Replication-deficient recombinant 
adenoviral vectors are predominantly used for colon cancer gene therapy, because 
they can be produced at a high titre and they readily infect a number of different cell 
types [Zwacka and Dunlop, 1998]. They also have a tropism for the liver and can 
infect both dividing and quiescent cells [Li et al., 2007]. Therefore, these vectors are 
also useful for gene therapy involving the liver.
Other viruses
Herpes simplex virus, which causes cold sores, can infect a wide range of dividing 
cells[Nakano et al., 2005]. Other viruses which may be useful as a vector include 
vaccinia virus, lenti virus and heamagglutinin virus of Japan.
Non-viral vectors
There are at least five non-viral methods of introducing DNA into the mammalian 
cells. They are calcium phosphate transfection [Maitra, 2005], DEAE-dextran 
transfection, electroporation [Cemazar et al., 2006], liposome mediated transfection 
[Karmali and Chaudhuri, 2006] and plasmid mediated gene transfer. The first two 
procedures produce a chemical environment that results in DNA attaching to the cell 
surface. The DNA is then endocytosed by uncharacterized pathways.
Electroporation uses an electric field to open up pores in the cell. The DNA 
presumably diffuses into the cell through the pores. So this technique can be used in 
any cell type. Electrogene therapy is an in vivo application of electroporation where
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naked plasmid DNA is injected and electric pulses are delivered directly to the tissue 
[Cemazar et al., 2006]. However, the efficiency of this method in vivo is still lower 
than virally mediated gene transfer. Nevertheless, electrically-assisted nucleic-acid 
delivery holds a great potential for the clinical application due to the lack of 
immunogenicity, easiness of the preparation of large quantities of endotoxin free 
plasmid DNA, reproducibility and the development of electro-pulsators approved for 
clinical use [Cemazar et al., 2006].
In liposome-mediated transfection, liposomes containing cationic and neutral lipids 
mediate the transfection of DNA. The advantages of this method include: a) it is easy 
to prepare (b) ability to inject large lipidiDNA complexes; and (c) low immunogenic 
response [Karmali and Chaudhuri, 2006]. The mechanism is poorly understood.
Plasmids can also be used for transferring DNAs. They are extra chromosomal DNA 
molecules which are self replicating. Escherichia coli (E.Coli) bacteria carry 
plasmids which offer resistance against antibiotics, heavy metals and obscure 
bacteriophages. Replication of these plasmids may or may not require plasmid-coded 
proteins and may or may not be synchronised with cell cycle. Some of these plasmids 
can be freely transferred from one bacteria to another. Artificial plasmids have been 
constructed in laboratories since 1970, with fragments of DNA and naturally 
occurring plasmids. All these plasmids have 3 common features. They all have a 
replicator, a selectable marker and a cloning site. A replicator is a stretch of DNA 
that contains the site at which DNA replication begins. A selectable marker is an ab 
gene encoding resistance to some antibiotics. The cloning site is a restriction 
endonuclease cleavage site into which foreign DNA can be introduced without
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interfering with the plasmids’ ability to replicate. Uptake of plasmid DNA can be 
enhanced by using a hand-held Swiss jet injector, which uses pressurized air to 
force small volumes (3-10|ul) of naked DNA into targeted tissues [Walther et al., 
2004]. The process by which plasmids are introduced into E coli is known as 
transformation. Transformation is a very important tool in recombinant DNA 
technology. The addition of new genes to a recipient cell introduces a heritable 
modification in the recipient cell's phenotype.
1.1.3 Gene therapy approaches
The gene therapy approaches currently being employed can be divided into four 
major categories [Zwacka and Dunlop, 1998] [Yamamoto et al., 2001]. They are (1) 
Enzyme/prodrug systems (suicide gene therapy) [Huang et al., 2005;Kerr et al., 
1997] (2) Gene correction (tumour suppressor gene replacement therapy and 
oncogene inactivation) [Meng and El Deiry, 1998] (3) Immune-gene therapy and (4) 
Drug resistance gene therapy.
1.1.4 Basis of gene therapy in colorectal cancer 
Virus-directed enzyme-prodrug therapy (VDEPT)
VDEPT is the gene transfer of bacterial or viral enzymes into tumour cells which 
can convert inactive prodrug into short lived toxic metabolites, limiting the toxic 
effects to the tumour cells [Walther et al., 2005]. Examples include: (1) Thymidine 
kinase and ganciclovir; (2) Cytosine deaminase and 5-fluorocytosine; and (3) 
Nitroreductase and the prodrug CB1954 [Chung-Faye et al., 2001]. One of the major 
mechanisms of the efficacy of this form of therapy is the so called ‘bystander effect’ 
[Chung-Faye et al., 2000]. This is a phenomenon by which small molecules, such as
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an active drug metabolite, are able to pass between eells via gap junetions so that 
untransfected eells are also affected. Thymidine kinase of herpes simplex can 
phosphorylate ganciclovir, which can inhibit DNA polymerase leading to cell death. 
An animal experiment on colorectal cancer showed very profound bystander effects 
when the combination of thymidine kinase/ganciclovir was used [Link, Jr. et al., 
1997].
Gene correction
Cancer may result when there is an imbalance between proto-oneogenes and tumour 
suppressor genes. Gene corrective therapy is aimed at reversing some of the genetie 
abnormalities by either introducing a tumour suppressor gene or inaetivating proto­
oncogene by an anti-sense method [Raehel Hargest, 2000]. Tumour suppressor gene 
TP53 is the most commonly mutated gene in human caneer [Linderholm et al., 2006] 
which is present in 20-69% of colorectal cancers. Its produet known as ‘p53’ 
normally regulates the cell cycle and repairs abnormal DNAs. If the DNA eannot be 
repaired by the p53, it causes growth arrest or apoptosis [Liu and Gelmann, 2002]. 
Loss of p53 leads to uncontrolled and aggressive cellular growth. In a phase I 
controlled trial, an adenovirus encoding wild type TP5 3 gene was delivered by 
hepatic artery infusion to 16 patients with TP53 mutated coloreetal liver métastasés 
[Chung-Faye and Kerr, 2000]. The side effects were fever and transient derangement 
in liver function. Although the gene was expressed in subsequently resected tumours, 
there was no significant change in radiographic appearance of the tumours. Another 
gene known as K-ras is also often mutated in colorectal cancer [Noda et al., 2006]. It 
encodes for a protein called p21 which is involved in cell signal induetion and the 
control o f cell proliferation. The K-ras mutations can be detectable in DNA purified 
from the stool [Sidransky et al., 1992]. Anti-sense oligonucleotides are specific
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sequences which bind to complementary mRNA and prevent its translocation. Anti - 
sense Bcl-2 has been shown to potentiate apoptosis in lymphoma [Keith et ah, 1995] 
and anti-sense K-ras is used in trials on patients with lung caneer.
Immune-gene therapy
Immunological mechanisms are important for elimination of cancer by human body. 
Individuals with immune deficiencies, such as HIV infection, are at high risk of 
developing cancers. Caneer cells are recognized and destroyed by CD 8+ cytotoxic T 
cells and natural killer cells. But many cancer cells escape this immune mediated 
destruction by exhibiting loss of HLA class I antigens. A Phase 1 trial of 
immunotherapy for colorectal métastasés using intra-lesional injection of HLA-B7 
cDNA with liposome on 15 patients did not show any therapeutic benefit [Rubin et 
al., 1997]. Carcinoembryonic antigen (CEA) is often expressed by colorectal cancers. 
Immunizations with dendritic cells (DC) transfected with RNA encoding tumour 
antigens, induce potent tumour antigen-specific immune responses in vitro and in 
murine models. In a Phase II study [Morse et al., 2003] on patients with resected 
hepatic métastasés of colon cancer, the safety and feasibility of administering 
autologous DC loaded with CEA mRNA was assessed. The immunizations were 
well tolerated. 9 out of 13 patients relapsed at a median of 122 days. Evidence of an 
immunologic response was demonstrated in biopsies of DC injection sites and 
peripheral blood of selected patients.
Activation of cytotoxic lymphocytes and natural killer eells, using cytokines such as 
interleukin-2 and interleukin-12 which can be transferred directly into tumour cells 
could result in an anti-tumour effect [Caporale et al., 2007;Alves et al., 2004]. In a 
Phase 1/2 clinical trial on patients with unresectable colon cancers who were treated 
with intra-tumoral injection of an adenovirus-IL-2 at the time of surgery, showed that
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one patient’s tumour expressed increased numbers of membrane bound IL-2 
receptors. Another patient showed necrosis of the tumour mass. In a study on mice 
with experimentally induced colorectal tumours, adenovirus containing mouse lL-12 
gene was injected into the tumour and it showed tumour regression and prolonged 
survival [Caruso et al., 1996].
Drug resistance gene therapy
The main limiting factor for patients undergoing chemotherapy is bone marrow 
toxicity. There is a gene called multiple drug resistance gene (M DRl) which may 
confer the bone marrow resistance to vinca alkaloids, anthrocyclins and paclitaxel 
[Ueda et al., 1986]. This gene therapy is still in an experimental stage.
New gene therapy to inhibit growth factors
The method described here is a different approach to the above, as it involves gene 
transfer of a binding protein that inhibits the effect of lGF-1. This gene therapy was 
evaluated in this project.
1.1.5 Current colorectal gene therapy trials
There are several gene therapy trials happening in the world. The trials which are 
underway in the UK are shown below *.
1) A pilot study of recombinant CEA vaccinia virus vaccine with post vaccination 
CEA peptide challenge in combination with 5-fluorouracil and folinic acid in the 
treatment o f colorectal cancer (Phase 1 subcutaneous).
2) Evaluation of the safety, biodistribution and efficacy of TroVax in patients with 
metastatic colorectal cancer (Phase 1 i.m) (Vaccinia virus and oncofetal antigen).
3) Phase 11 study of TroVax in colorectal cancer patients undergoing surgery for 
resectable liver métastasés (Pox virus and oncofoetal antigen).
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4) Gene therapy for bowel cancer that has spread to the skin (Granulocyte -  
macrophage colony stimulating factor gene and herpes simplex virus).
5) Gene therapy protocol for the evaluation of the safety and efficacy of TroVax in 
conjunction with chemotherapy in patients with metastatic colorectal cancer.
6) Phase I/II study of DNA vaccination with a CEA/pDOM fusion gene in patients 
with carcinoma expressing CEA (CAP-1 peptide from CEA and naked plasmid 
DNA).
7) A Phase II study immunologically evaluating 5T4-MVA (TroVax) in patients 
undergoing surgical resection o f colorectal liver métastasés (Vaccinia and oncofoetal 
antigen).
8) A randomised Phase II trial assessing anti-CEA, anti-MUC-1 vaccination +/- 
chemotherapy +/- GM-CSF after surgery in patients with stage II colorectal cancer 
(Poxvirus, Vaccinia virus and Carcino embryonic antigen /MUC-I).
9) Safety and Immunology evaluation of TroVax produced by the Baxter synthetic 
route in patients with stage IV colorectal carcinoma.
10) A Phase I study of adoptive transfer of autologous tumour antigen-specific T 
cells with pre-conditioning chemotherapy and intravenous IL-2 in patients with 
advanced CEA positive tumours (retrovirus and CEA plus CD3).
* reproduced from www.wiley.co.uk
Summary
Gene therapy trials are ongoing and the results are eagerly awaited. My current 
experiment attempts to alter the components of the IGF system in a colon cancer 
model by gene transfer. Therefore, the IGF system in colorectal cancer will be 
discussed in the next chapter.
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1.2 IGF system and its role in colorectal cancer
The purpose of this literature review is to provide an overview of the IGF system.
1.2.1 Biology of the IGF System
The IGF system includes ligands IGF- I and - II, their receptors, IGF-binding 
proteins (IGFBPs) and IGF proteases. Figure 1.1 is a schematic representation of the 
IGF system. Their biological features and actions are summarised in Table 1.1.
IGF-I and IGF-II
The IGFs are single-chain polypeptides with structural homology to pro-insulin. The 
IGF-I is a basic peptide with 70 amino acids and the IGF-II is slightly acidic with 67 
amino acids. IGF-I and IGF-II act on a variety of mammalian cells in an endocrine, 
paracrine and autocrine manner [Grimberg and Cohen, 2000;Hallberg et al., 2000] to 
regulate cell proliferation, apoptosis, transformation and differentiation [Leng et al., 
2001b;Moschos and Mantzoros, 2002]. Both IGF-I and -II are essential for normal 
human growth and development [Zhou et al., 2003]. Growth hormone regulates the 
expression of IGF-I gene and it thereby mediates most of its actions through IGF-I, 
but it does not control the expression of IGF-II [Yu and Rohan, 2000]. Adults have a 
higher concentration of IGF-II than IGF-I, but it is the IGF-I that plays an important 
role in postnatal growth, while the IGF-II acts mainly in embryonic and foetal life 
[Yu and Rohan, 2000]. The majority of circulating IGFs, in particular IGF-I, is 
produced by the liver, although various tissues have the capability to synthesize these 
peptides locally [Khandwala et al., 2000;Moschos and Mantzoros, 2002]. More than
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90% of the IGFs are bound to IGFBP-3 [Giovannucci, 2001;Grimberg and Cohen, 
2000] and only 1% of the IGF circulates in the free form.
IGF receptors
The actions of IGFs are mediated via type I and type II receptors (IGF-IR and IGF- 
IIR), both o f them glycoproteins, found in the cell membrane. The growth-promoting 
effects of IGFs are mediated through the IGF-IR, which contains a tyrosine-kinase 
domain resembling insulin receptor[Grimberg and Cohen, 2000]. The IGF-IR has 
two extracellular subunits (a) to bind the IGFs, and two intracellular subunits (|3) 
which contain tyrosine-kinase [Reinmuth et al., 2002b] to mediate the intracellular 
effects. In contrast to the insulin receptor, which primarily mediates metabolic 
function, the IGF-IR mediates mainly growth and differentiation [Blakesley et al.,
1996]. When activated the IGF-IR stimulates the synthesis of RNA and DNA, cell 
proliferation, differentiation and increases cell survival [Reinmuth et al., 2002b]. The 
IGF-IIR is similar to mannose-6 phosphate receptor. It is a single chain polypeptide 
with a large extracellular domain, a single transmembrane region and a small 
cytoplasmic domain. It is entirely different from the IGF-IR in that it has no tyrosine- 
kinase activity. The IGF-IIR is thought to function as a clearance receptor for IGF-II, 
thereby influencing the extracellular levels of the IGF-II [LeRoith and Roberts, 
2003]. The IGFs can also act via a hybrid receptor, which consists o f a single a  and 
(3 subunit linked by disulfide bonds. These hybrid receptors have half insulin hemi 
receptor and a dimerized IGF-IR. The IGF-IR/hybrid receptors retain the high 
affinity for IGF-I, but exhibit a dramatically decreased affinity for insulin [LeRoith 
and Roberts, 2003].
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IGF-binding proteins (IGFBPs) and IGF proteases
The effects of the IGFs are modulated by at least 10 different IGF binding proteins 
[Kim et al., 1997;Kostecka and Blahovec, 1999], six of which have a high affinity for 
IGFs (IGFBP 1-6) and four of them have a low affinity for IGF [Baxter et al., 
1998;Kim et al., 1997], also known as IGFBP-related proteins (lGFBP-rpl-4). Table 
1.2 summarises the facts related to IGFBPs 1-7.
The IGFBPs are a family of homologous proteins that are produced by many 
different tissues and all have different molecular weight, amino acid composition, 
binding properties and distribution in biological fluids [Kostecka and Blahovec, 
1999], but they all share cysteine-rich N terminal domain and C-terminal [Kim et al.,
1997]. They also have IGF-independent actions [Kim et al., 1997]. The IGFBPs 
control the distribution of IGFs because of their higher affinity to IGFs, which is 2- 
50 times higher than that of the IGF-IR [Mazerbourg et al., 2004]. IGFBP-1-5 
preferentially bind the lGF-1 over the lGF-11, but lGFBP-6 has 100-fold higher 
affinities for IGF-11 than for IGF-1 [Grimberg and Cohen, 2000]. The IGFBPs do not 
bind to the insulin [Kostecka and Blahovec, 1999;LeRoith and Roberts, 2003]. The 
key function of the IGFBPs is regulation of circulating bioavailability of the IGFs 
[Baxter, 2000]. The IGFBPs serve as carriers, mediators as well as reservoirs of IGFs 
by protecting IGFs from degradation and delivering them to appropriate tissue 
[Baxter et al., 1998;Henric Zazzi, 1998;Zazzi et al., 1998]. lGFBP-3 is the main 
binding protein, which is found in circulation in abundance, and most of the IGFs are 
bound to it. The lGFBP-3 forms a ternary complex with lGF-1 and a separate protein, 
namely 80 kDa acid-labile subunit [Poliak, 2000] to keep the lGF-1 within the
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vascular system [Sandhu et al., 2002], while the other IGFBPs form binary 
complexes with IGF-I, allowing transport o f IGFs across the capillary to various 
tissues [Sandhu et al., 2002]. IGFBPs-1-6 inhibit the action of IGFs by high affinity 
binding while IGFBP-1, -3 and - 5 also potentiate the IGF effects [Baxter, 2000]. The 
potentiation needs a decrease in binding affinity of the IGFBP for IGFs so that the 
IGFs can act on the IGF-IR. This process involves association o f IGFBP with the cell 
surface or extracellular matrix, and / or post-synthetic processing o f IGFBP, e.g., 
phosphorylation and proteolysis [Remacle-Bonnet et al., 1997]. IGFBP-1, -3 and -5 
have well-established effects that are independent of IGF-IR signalling. IGFBP-1 
exerts these effects by signalling through [a] 5[P] 1-integrin, whereas IGFBP-3 and - 
5 may have specific cell-surface receptors with serine kinase activity [Baxter, 2000].
The IGFBPs are degraded by several proteases, some of which are specific to that 
binding protein, and others are non-specific proteases that control the function and 
the tissue availability o f IGFBPs. These proteases cleave the IGFBPs into fragments 
with lower affinity for the IGFs. In the serum proteolysis of the IGFBP-3, which is 
the main binding protein, is negligible in the normal population, but it is increased in 
certain physiological conditions like pregnancy and pathological conditions like the 
post-operative period and malignancies [Baciuchka et al., 1998], which increases 
the availability of circulating free IGFs. In tissues, IGFBP proteases enhance the 
IGF-I availability by cleaving IGFBP, thereby increasing free IGF-I 
concentration[Grimberg and Cohen, 2000]. Experiments show that proteolytic 
activity is highest in the proliferating cells [Kuemmerle and Teng, 2000]. The 
biological activity of IGF is determined by the integrated actions of circulating IGF-I 
and IGFBP, and by local production of IGF, IGFBP and IGFBP protease.
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Figure 1.1 Schematic representation o f insulin-like growth faetor (IGF) system. The IGF system consists o f two growth factors 
(IGF-I and -II), two receptors (IGF-IR & -HR), 6 binding proteins and proteases. IGF-IR is proliferative in action while IGF-IIR 
clears the IGFs from eirculation. IGFBP proteases destroy the binding proteins and increases local tissue availability of the IGFs.
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Table 1.1 Insulin-like growth factors, their receptors and proteases
Reference Components Nature Location Role
[Khandwala 
et al., 2000]
IGF-I 70 residue single chain 
polypeptide
Various body fluids and 
cells
Growth, anti-apoptosis, 
mitogenesis and differentiation
[Khandwala 
et al., 2000]
IGF-II 67 residue single chain 
polypeptide
Various body fluids and 
cells
Foetal and embryonic growth
[Hakam et 
al., 1999]
IGF-IR Heterotetrameric 2(a) + 2(P) 
glycoprotein-tyrosine-kinase
Cell membrane It mediates the effect of various 
growth factors including IGF-I 
and - II and steroids. It also 
induces VEGF-mediated 
angiogenesis
[Pavelie et 
al., 2002b]
IGF-IIR Monomeric glycoprotein Cell membrane It binds to IGF-II and mannose-6 
phosphate and inhibits action of 
IGF-II
[Khandwala 
et al., 2000]
Hybrid
receptor
One alpha + one beta unit 
with one hemi insulin 
receptor
Cell membrane It binds IGFs
[Lelbach et 
al., 2005]
IGFBP*
proteases
Several types (serine 
protease,métallo proteinases, 
eathepsins and specific 
proteinases)
Various body fluids and 
cells including smooth 
muscle and fibroblast
It causes proteolysis of IGFBP 
to free IGF
IGFBP - insulin-like growth factor binding protein
27
Table 1.2 Insulin-like growth factor binding proteins
Reference IGFBPs Protein size 
(kDa)
Location ^ Role"
[Baxter,
2000]
IGFBP-1 25 -34 Various body fluids including 
amniotic fluid
Modulate the IGF effects
[Clemmons,
1993]
IGFBP-2 32-34 Various body fluids including 
CSF
Mediates TNF-a indueed apoptosis and 
stimulate cell proliferation
[Rajaram et 
al., 1997]
IGFBP-3 53 Various body fluids Main carrier protein for IGFs in cireulation 
& growth inhibitor. 90% of serum IGF is 
bound to IGFBP-3
[Zhou et al., 
2003]
IGFBP-4 24, 29 Various body fluids and 
tissues including liver, vascular 
smooth muscle
Inhibits the actions of IGFs
[Rajaram et 
al., 1997]
IGFBP-5 23 Various body fluids, 
osteoblasts, kidney, etc.
Increases mitogenesis
[Baxter,
2000]
IGFBP-6 30 -32 Serum and CSF Modulates the actions of IGFs
[Degeorges 
et al., 2000]
IGFBP-7 27 Various tissues including 
smooth muscle and 
endothelium
Modulates the actions of IGFs
All IGFBPs can act as a carrier for IGFs. ^All IGFBPs are found in serum
'’All IGFBPs except IGFBP-4 and 6 have both IGF potentiating as well as inhibiting actions under different circumstances.
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1.2.2 Studies linking the IGF system and colon cancer
Tables summarising the results of population-based, in vitro and in vivo studies 
linking the IGF system and colon cancer are shown in the appendix. Most o f the 
current knowledge about the IGF system is based on in vitro and population-based 
studies. Most population-based studies measured a few factors in the serum, and 
compared them with the incidence or development o f colorectal adenoma and 
carcinoma. Some of the studies are larger and others are smaller. Not all of them 
clearly support a linear association between IGF-I, IGF-II, IGFBPs and colorectal 
cancer. It may be due to the fact that the relation between these factors may be a 
complex one. Some studies show no association between plasma IGFBP-1 and 
IGFBP-2 and risk of colon and/or rectal cancer [Palmqvist et al., 2003], while others 
show that chronically high levels of circulating insulin and IGFs associated with a 
Western lifestyle may increase the colorectal cancer risk, possibly by decreasing the 
IGFBP-1 and increasing the bioactivity of the IGF-I [Kaaks et al., 2000]. Overall, 
the studies suggest that an increase in the IGF-I and a decrease in the IGFBP-3, 
leading to increased serum free IGF-I, may be associated with the development of 
colorectal adenoma and carcinoma [Nomura et al., 2003;Teramukai et al., 2002]. 
Renehan [Renehan et al., 2004] performed a meta-regression analysis of case- 
control studies linking the relationship between IGF-I, IGFBP-3 and cancers. Their 
analysis showed that a higher concentration of IGF-I was associated with colorectal 
cancer, but a high concentration of IGFBP-3 did not protect from colorectal cancer. It 
is possible that the case-control studies might have overestimated the relationship 
between IGFs, IGFBP-3 and colorectal cancer.
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The levels of circulating IGFs and IGFBPs have been shown as varying significantly 
between studies. The method of collection (serum or EDTA) has been suggested to 
be a source of heterogeneity [Renehan et al., 2003]. It has been found that the levels 
of IGFs were about 10% higher in serum than in plasma, the differences were 
statistically significant (P<0.001). IGF levels correlated well between serum and 
plasma samples (r >0.95, P<0.001). The IGFBP-3 levels were not different between 
serum and heparin plasma (P=0.75), but were significantly higher in these two 
specimens than in EDTA plasma (P<0.001). IGFBP-2 levels were significantly 
different among the three types of specimen (P<0.001). The values were 83% higher 
in EDTA specimen than in heparin plasma. IGFBP-6 levels were significantly higher 
in serum than in plasma (P<0.01). These indicate the fact that the method of 
collection can influence the results of the study related to the IGF system. So there is 
a need to standardize the method of collection, which will enable us to compare 
different studies and their significance. The results of in vitro and in vivo studies 
linking the IGF system and colon cancer are summarised under different headings 
down below.
1.2.3 Pathophysiological role of the IGFs
The IGF system plays a critical role in all phases of mammalian growth including 
intrauterine, childhood and puberty [Rosenfeld, 2003]. This is confirmed by the 
evidence that targeted disruption of mouse gene for IGF-II resulted in reduction of 
foetal growth, but normal postnatal growth and disrupted IGF-I gene lead to a similar 
decrease in birth weight but also persistent postnatal growth failure [Rosenfeld, 
2003]. Liver is the most frequent site of metastasis after colon cancer [Reinmuth et 
al., 2002a], which may be due to the fact that it is the liver that produces most of the
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IGFs in circulation. The IGF-I has profound impact on tumour growth by 
stimulation of cellular proliferation and inhibition of apoptosis. Wu et al. conducted a 
study involving liver-specific IGF-l-deficient (LID) mice, in which serum the lGF-1 
level was 25% of that in control mice. In LID mice, the growth of orthotopically 
transplanted colon adenocarcinoma was significantly less when compared with 
controls (31.3 versus 56.8%, P<0.01), and the appearance of a palpable caecal 
tumour not only slower (P<0.05) but also smaller (P<0.01) than that in control mice. 
The frequency of hepatic metastasis was also significantly lower in LID mice (31.3% 
versus 44.0% in control mice, P<0.05). These results support the hypothesis that 
circulating lGF-1 levels play an important role in tumour development and metastasis 
[Wu et al., 2002]. Increased systemic lGF-1 may lead to colonic tumours as 
evidenced in acromegaly patients. Malnutrition and calorie restriction may lower the 
level of the lGF-1 which may delay tumour progress. The lGF-1 also plays an 
important role in tissue angiogenesis [Akagi et al., 1998]. It upregulates VEGF 
expression in human colon cancer cells, which is mediated through hypoxia- 
inducible factor-1, [Fukuda et al., 2002] without involving IGFBP [Collard et al., 
2003]. Colorectal cancers often express 10-50 times higher levels of lGF-1 and IGF- 
11 than adjacent uninvolved colonic mucosa [Reinmuth et al., 2002a] although some 
studies found normal lGF-1 levels [Freier et al., 1999]. lGF-1 has a biphasic effect on 
colon cancer cells initially mitogenic, then mediating growth arrest and 
differentiation [Oh et al., 2001]. The lGF-1 may increase the risk of cancer either by 
its anti-apoptotic activity or by modulating the effects of sex steroids [Smith et al., 
2000].
The lGF-11 also has a place in the development of colon cancer. Experiments 
conducted by Zarrilli showed high levels of lGF-11 mRNA in proliferating Caco-2
31
cells, which decreased by more than 10-fold when the cells ceased to proliferate and 
differentiate [Zarrilli et al., 1994]. Reduced IGF-II expression was associated with a 
decrease in IGF-I receptor numbers that were high in proliferating cells. 
Exogenously added IGF-II was able to stimulate proliferation of serum-deprived 
cells in a dose-dependent fashion [Zarrilli et al., 1994]. Increased systemic IGF-II 
level does not have any predictive influence on susceptibility of colorectal cancer 
[Hassan and Macaulay, 2002]. The IGF-II acts on the IGF-I receptor in an 
autocrine/paracrine manner, and monoclonal antibody to IGF-IR(a-IR3) inhibits both 
basal and IGF-II-stimulated cell proliferation [Manousos et al., 1999].
The IGF-IR is crucial for normal growth and development because IGF-IR knockout 
mouse embryo suffer generalised organ hypoplasia and invariably dies at birth 
[Reinmuth et al., 2002b]. The IGF receptors are found in both mucosal and muscular 
layers of intestine and are mainly concentrated in the basolateral region o f crypt 
enterocytes [Howarth, 2003]. Experimental administration of IGF-I in rats showed an 
increase in crypt cell population, as well as linear and cross sectional increases in 
mucosal and muscular layers of intestine, leading to increase in gut weight [Howarth, 
2003]. The IGF-IR is essential for cell transformation that is induced by tumour-virus 
proteins and oncogene products [Yu and Rohan, 2000]. Colorectal cancer cells often 
over express IGF-I receptors [Ouban et al., 2003] and when activated by IGF-I, they 
inhibit apoptosis and allow progression through the cell cycle. Thus, IGF-I can 
influence both pre-malignant and cancerous stages [Giovannucci, 2001]. Cancer 
cells with a strong tendency to metastasize have a higher expression of IGF-IR 
[Hakam et al., I999;Yu and Rohan, 2000]. Hakam [Hakam et al., 1999] investigated 
the expression of IGF-IR in colonic adenomas, adenocarcinomas and in
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corresponding métastasés. Immunostaining for IGF-IR showed strong cytoplasmic 
positivity in 96% (34/36) carcinomas, and in 93% (25/27) métastasés. Only a faint 
cytoplasmic stain of the IGF-IR was identified in 83% (10/12) adenomas while 
normal mucosa showed negative immunostaining. But another study did not find any 
difference in the IGF-IR concentration when they compared 46 frozen sections o f 
colon cancer with 26 controls [Adenis et al., 1995]. IGF-IR activation up-regulates 
the components of the TGF-alpha autocrine loop resulting in TGFa-mediated EGFr 
activation, which was critical for the IGF-IR mediated re-entry into the cell cycle 
from the growth-arrested state [Wang et al., 2002].
The IGF-IIR antagonises the growth promoting effect of IGF-II, and loss of IGF-IIR 
is expected in cancer [Yu and Rohan, 2000]. The IGF-IIR acts like a clearance 
receptor and removes the IGF-II from the circulation. Experiments show that there is 
a rise in the IGF-II/Man-6-P receptor message in colorectal cancer, and the increase 
in IGF-II message is accompanied by a doubling of the IGF-II protein in the tumour 
tissue, compared with the adjacent normal tissue [Freier et al., 1999]. Garrouste 
isolated soluble IGF-II/mannose 6-phosphate receptors in the culture medium from 
HT-29 colonic cancer cells [Garrouste et al., 1991]. These findings suggest that the 
IGF-II/Man-6-P receptor may also be involved in the development of 
adenocarcinoma of the colon.
The IGF-I, IGF-II and IGF-IR are often over-expressed by many cancers, so that 
IGF-I and IGF-II can act in an autocrine manner [Guo et al., 1995;LeRoith and 
Roberts, 2003;Weber et al., 1999]. Most colonocytes secrete IGF-II as well as 
express the IGF-IR, but it is the sequestration of IGF-II by the IGFBPs that prevents
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the establishment of an IGF autocrine loop. One study examined the IGF-IR 
expression by the colon of Fischer 344 rats. Colonic IGF-IR mRNA levels declined 
with ageing (P<0.05) while colonic IGF-I mRNA levels were unchanged, which 
may be a protective adaptive mechanism against ageing colon [Hallberg et al., 2000]. 
Insulin, IGF-I and II induce expression of hypoxia-inducible factor-1, which is 
required for expression of genes encoding IGF-II, IGFBP-2 and IGFBP-3 [Feldser et 
al., 1999]. Colon cancer cells produce specific proteases that degrade the IGFBP 
secreted by these cells [Michell et al., 1997b] so that there will be free IGFs for 
completing autocrine loop.
1.2.4 Genetic changes and colon cancer carcinogenesis
Numerous mutagenic events can occur throughout the colon cancer development 
including loss of heterozygosity in tumour suppressor genes such as APC, MCC, 
DCC, p53 and K-ras [Takami et al., 1995]. Colon cancer tumorigenesis is a step-wise 
process [Cho and Vogelstein, 1992] in which mutations accumulate over time and 
oncogenes are activated while tumour suppressor genes are deactivated. Colon 
cancer mechanisms are discussed as common and alternate pathways.
Common pathway
Tumour suppressor genes make proteins that suppress tumour formation by limiting 
the cell growth. Mutations involving the tumour suppressor genes could result in a 
loss of their ability to restrict tumour growth [Samowitz et al., 2007;Allen, 1995]. 
Vogelstein and his colleagues found that mutations involving a tumour suppressing 
gene called the adenomatous polyposis coli (APC) gene resulted in colon cancer 
[Baba, 1997]. Normally, APC binds to b-catenin and phosphorylates it. But when
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mutations occur, b-catenin interacts with transcription factors instead of stimulating 
growth. P53 is another tumour suppressor gene which blocks the cell cycle and 
stimulates apoptosis. It is altered in more than 80% of colorectal cancers.
Alternate pathway
Hereditary non polyposis coli (HNPCC), sometimes called Lynch syndrome, 
accounts for approximately 5 - 10% of all colorectal cancer cases. Several genes 
have been identified that are linked to HNPCC. Mutations in the M LHl, MSH2, and 
MSH6 genes are the most frequent cause of HNPCC [Rahner et al., 2007;Plotz et al., 
2006]. Although multiple genes have been linked to HNPCC, most families with 
HNPCC have a mutation in only one of the genes. Genetic testing is available for the 
M LHl, MSH2, and MSH6 genes. The HNPCC genes are part of a group of genes 
called mismatch repair genes. They make proteins that repair DNA mistakes that 
occur as cells divide. If one of these genes has a mutation, the mistakes cannot be 
repaired, leading to damaged DNA and an increased risk of cancer. The risk of 
colorectal cancer in families with HNPCC is 70 - 90%, which is several times the 
risk in the general population. Women with HNPCC also have an increased risk of 
cancers o f the uterus, ovaries, stomach, small intestine, kidney and breast [Kwak and 
Chung, 2007].
1.2.5 Components of the IGF axis and colon cancer tumorigenesis
Acromegaly is a condition of growth hormone excess and is associated with 
increased proliferation of normal colonic epithelium [Palmqvist et al., 2003], and 
increased prevalence of tubulovillous adenoma and colon carcinoma [Miraki-Moud 
et al., 2001]. Growth hormone increases serum IGF-I levels [Cohen et al., 2000], In
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a retrospective study [Miraki-Moud et al., 2001], serum IGF-I, IGF-II, IGFBP-2 and 
IGFBP-3 in patients with acromegaly, and in those with colonic neoplasia without 
acromegaly, were analysed. Mean serum IGF-I and IGFBP-3 levels were 
significantly elevated in patients with acromegaly without colonic neoplasia, and in 
those with acromegaly and colonic neoplasia, and significantly reduced in those with 
colonic neoplasia without endocrine disease, compared with controls (P<0.001). 
However, median serum IGFBP-2 levels were significantly elevated in patients with 
acromegaly and colonic neoplasia (P<0.01), and in those with colonic neoplasia 
without endocrine disease (P<0.0001). The precise mechanism of development of 
colon cancer in acromegaly remains unknown. It may be due to the stimulatory role 
of excess growth hormone /IGF-I or excess IGF-II [Miraki-Moud et al., 2001]. In 
one study involving acromegaly, 5% of patients had colorectal cancer and 25% had 
colorectal adenoma [Jenkins et al., 2000]. Antagonists to growth hormone releasing 
hormone (GH-RH) inhibit the growth of HT-29 human colon cancers both in vitro 
and in vivo [Szepeshazi et al., 2000]. The effect of GH-RH antagonists may be 
mediated through reduced production and secretion of IGF-II by cancer cells. A GH 
transgenic mouse does not develop cancer, even though the serum IGF-I level is 
high.
All human genes have two copies, one is paternal and the other is maternal in origin. 
Among these two copies of gene, only one is functional and this phenomenon is 
termed genomic imprinting. Imprinting is vital for normal development, and 
disruption of imprinting mechanisms gives very similar phenotypes in mice and 
humans [Brenton et al., 1995]. The IGF-II gene is imprinted and expressed only from 
paternal allele, except from the adult liver, where the expression is biallelic because 
o f promoter switching after birth [Hu et al., 1996]. The IGF-IIR is also imprinted but
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expressed only from the maternal allele. This may mean maternally-expressed genes 
can act as growth suppressors because the function of IGF-IIR is to remove the IGF- 
II from circulation and destroy it so that less IGF-II is available to promote cell 
growth [Haig and Graham, 1991;Jirtle, 2004]. Loss of genomic imprinting (LOI) of 
the IGF-II gene involves an abnormal activation of the normally silent maternally- 
inherited allele and as a result the cells produce double the dose of IGF-II [Cruz- 
Correa et al., 2004]. LOI of the IGF-II gene is found in normal colonic mucosa of 
about 30% of colorectal cancer patients, but it is found in only 10% of healthy 
individuals.
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Figure 1.2 Vogelgram showing molecular mechanisms involved in the pathogenesis 
of colorectal cancer. Small adenoma increases in size under the influence of growth 
controlling pathways. Large adenoma becomes cancer under the influence of various 
genes and growth factors including IGF.
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Colon cancer development is a multistep process (fig 1.2). Vogelstein proposed a 
mechanism of development of hereditary colon cancer. It involves a series of 
mutations. Mutation of APC causes small adenoma formation. Subsequently it 
becomes large adenoma when K-ras mutation occurs. Large adenoma becomes 
cancer when there is mutation of genes such as P53. The exact role IGF in cancer 
formation is unclear. It appears that IGFs influence the cancer formation by acting as 
an anti-apoptotic signal which may be mediated by Bax proteins.
1.2.6 Factors influencing the IGF system 
Dairy products
Intake o f dairy products is associated with an increase in circulating IGF-I levels, but 
intake of low fat milk is associated with a lower risk of colorectal cancer, particularly 
among individuals with high IGF-II/IGFBP-3 [Ma et al., 2001]. In a nested case- 
control study [Ma et al., 2001], it was found that there was a moderate but 
statistically non-significant inverse association between intake of low-fat milk or 
calcium from dairy food and colorectal cancer risk. Intake of dairy food (especially 
low-fat milk) was positively and moderately associated with plasma levels of IGF-I, 
IGFBP-3, and IGF-I/IGFBP-3. Non-drinkers of low-fat milk with IGF-I/IGFBP-3 in 
the highest tertile had a threefold higher risk than non-drinkers of low-fat milk with 
IGF-I/IGFBP-3 in the lowest tertile (RR = 3.05; 95% Cl = 1.29 to 7.24), but no such 
increase was seen among frequent low-fat milk drinkers (RR = 1.05; 95% Cl = 0.41 
to 2.69). There was a statistically significant interaction between low-fat milk intake 
and IGF-I/IGFBP-3 in association with risk o f colorectal cancer (P =.03). Men with 
high IGF-I/IGFBP-3 who were frequent low-fat milk drinkers had a 60% lower risk 
(95% Cl = 0.17 to 0.87; P =.02) than non-drinkers o f low-fat milk.
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Chronic energy restriction reduces plasma levels of IGF-I, and IGFBP-3, increases 
plasma IGFBP-1 and IGFBP-2, and thereby protects from various cancers [Palmqvist 
et al., 2003]. On the other hand, obesity causes hyperinsulinaemia and reduction in 
plasma IGFBP-1 and IGFBP-2 [Palmqvist et al., 2003]. In one study, the mean 
serum IGF-I concentration was 13% lower in 92 vegan women, compared with 99 
meat-eaters and 101 vegetarians (P = 0.0006) [Allen et al., 2002]. The mean 
concentrations of both serum IGFBP-1 and IGFBP-2 were 20-40% higher in vegan 
women compared with meat-eaters and vegetarians (P = 0.005 and P = 0.0008 for 
IGFBP-1 and IGFBP-2, respectively). Cohort studies show that dairy products and 
milk protect against colon cancer, but the evidence has not been supported by case- 
control studies [Norat and Riboli, 2003]. No proven evidence is available regarding 
whether cheese and yoghurt protect against colon cancer [Norat and Riboli, 2003] 
through regulation of the IGF system.
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs), which may inhibit the activity of 
cyclooxygenase-2 (COX-2), reduce the IGF-IR expression in colon cancer lines, and 
inhibit IGF-II-stimulated growth and invasion in a dose-dependent manner 
[Yasumaru et al., 2003]. These changes are reversible when treated with 
prostaglandin E2 (PGE2 ) or angiotensin II [Yasumaru et al., 2003]. Therefore, 
combination therapy with NSAIDs and ACE inhibitors targeting IGF-IR might be a 
novel and potentially promising strategy for the chemo-prevention of colon cancer. 
There is also a direct correlation between COX-2 and IGF-II expression in Caco-2 
cells. The IGF-II up-regulates COX-2 expression and PGE2 synthesis in Caco-2 cells, 
which is mediated by IGF-IR [Di Popolo et al., 2000]. This is supported by the
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evidence that when IGF-IR is blocked with an antibody (a-IR3), it results in not only 
inhibition of COX-2 expression and PGE2 synthesis, but also induction of apoptosis 
in Caco-2 cells [Di Popolo et al., 2000].
Other chemicals
Retinoic acid and dexamethasone cause growth inhibition of colon cancer cells in 
vitro, which is accompanied by increased IGFBP-2 expression and specific IGFBP-2 
proteolysis, resulting in reduced affinity for IGF-II [Hoflich et al., 1998]. Suramin 
releases IGF-II from the IGF-II-IGFBP complex so that IGF-II can act on the IGF-IR 
of colon cell line [Pommier et al., 1992]. Intestinal epithelial cells respond to short- 
chain fatty acids by altering secretion of IGFBPs [Nishimura et al., 1998]. Short- 
chain fatty acids are bacterial metabolites from unabsorbed carbohydrate. Trans 
retinoic acid (Tra) inhibits Caco-2 cell proliferation in a dose-dependent manner via 
increased expression of IGFBP-6, whereas it decreases the concentrations of IGFBP- 
2 and IGFBP-4. The IGF-IR expression on colorectal adenocarcinoma cell lines is 
decreased by chemopreventive agent N-acetyl-l-cysteine [Kelly et al., 2002]. 
Conjugated linoleic acid (CLA) inhibits cell proliferation and induces apoptosis in 
HT-29 cells [Kim et al., 2003]. Levels of IGFBP-3, which may induce apoptosis by 
IGF-dependent or -independent mechanisms, are increased by butyrate and 
trichostatin A and the IGF-II augments this effect [Leng et al., 2001a]. Butyrate also 
increases the secretion of IGFBP-2 in a dose-dependent and reversible manner [Leng 
et al., 2001a;Nishimura et al., 1998].
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Chemo-radiation
Cell culture studies show that IGF-I receptor activation blocks the expected cytotoxic 
effect of 5 FU and external beam irradiation [Perer et al., 2000]. IGF-IR antagonism 
using monoclonal antibody combined with chemo-radiation, produces an increased 
cytotoxic response [Perer et al., 2000], which may be useful in humans in the near 
future.
Diabetes
Patients with type 2 diabetes mellitus are at high risk of developing colorectal cancer 
[Meyerhardt et al., 2003]. Elevated levels of post-prandial insulin and C-peptide 
increase the colorectal cancer risk [Meyerhardt et al., 2003]. Insulin may directly 
activate its own receptor, the receptors for IGF-I, hybrid insulin/IGF-I receptor, or it 
may act indirectly by increasing the bioavailability of IGF-I by altering the IGFBP 
levels [Sandhu et al., 2002].
1.2.7 IGF related properties of human colon cancer cells 
Heterogeneity
Different cancer cells behave in a different way with respect to IGF responsiveness. 
Virtually all human colon cancers express IGF-I receptors, but only 50% responds to 
growth and the mitogenic effects of exogenous IGF-I [Guo et al., 1992;Singh et al., 
1994b]. Therefore, cancer cell lines can be divided into IGF-responsive (e.g. COLO 
205, Caco-2) and IGF-non responsive (e.g. DLD-1) groups [Singh et al., 1994b]. 
Some colon cancer cells (e.g. LIM 1215) are IGF-responsive, but the IGF-II is not a 
major autocrine factor for these cells. All these suggest the existence of heterogeneity
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between colon carcinoma cell lines with respect to the role of the IGF system [Leng 
et al., 2001b].
Polarity
Colon cancer cells behave in a polarised fashion and secrete different members of the 
IGFBPs from different areas of the cell surface. Caco-2 cells secrete IGFBP-3 from 
the apical surface, IGFBP-2 predominantly from the basolateral surface, and IGFBP- 
1 and -4 from both surfaces. However, epidermal growth factor (EGF) induces 
secretion of the IGFBP-4 more from the apical surface than from the basolateral 
aspect. It does not affect the polarity of the other IGFBPs [Oguchi et al., 1993]. 
HT29-D4 human colonic carcinoma cells secrete endogenous IGF-II predominantly 
(66%) from the basolateral cell surface, where type I IGF receptors are almost all 
(>96%) localized. IGFBP-2 and IGFBP-4 are secreted primarily into the basolateral 
side (71 and 87%, respectively); whereas IGFBP-6 is targeted to the apical surface 
(76%). The differential sorting of the various forms of IGFBPs may play a 
modulatory role in the maintenance of functional polarity in the differentiated colon 
cancer cells [Remacle-Bonnet et al., 1992].
Differential expression
The majority of human colon cancer cells express IGF-II, IGFBP-2 and IGFBP-4 and 
less frequently IGFBP-3, IGFBP-5 and IGFBP-6; the levels of IGFBP-2 and IGFBP- 
6 decrease as differentiation proceeds (differentiation-dependent manner) [Mishra et 
al., 1998;Moschos and Mantzoros, 2002;Singh et al., 1996;Zhang et al., 1995]. Singh 
et al. measured the expression and secretion of IGF-II, IGFBP-2, and IGFBP-4 in 
relation to growth and differentiation of Caco-2 human colon cancer cells, which
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undergo spontaneous enterocytic differentiation in culture. Caco-2 cells 
demonstrated an initial rapid phase of growth followed by a significant retardation in 
the growth. Changes in growth and differentiation were accompanied by a > 80% 
decline in the relative concentration of IGF-II mRNA. In contrast, the relative 
mRNA concentrations of inhibitory binding proteins (IGFBP-2 and IGFBP-4) 
increased rapidly to 200% of day 2 values by days 5-7, before returning to baseline 
levels by day 13 [Singh et al., 1996]. The quantity and the type (differential 
expression) of IGFBPs and IGF-II may play a critical role in both proliferation and 
differentiation of colonocytes [Singh et al., 1994b;Singh et al., 1996]. HT29-D4 
cancer cells remain in an undifferentiated state in culture medium when they cannot 
use endogenous IGF-II as an autocrine regulatory factor [Remacle-Bonnet et al.,
1992]. The IGF-IR primarily controls the differentiation of colonic cells [Oh et al.,
1996].
1.2.8 Individual IGFBPs and their role in colorectal cancer
Among the IGFBPs, IGFBP-4 is the only inhibitory binding protein which is 
consistently inhibitory to cell growth. The IGFBP-4 is secreted by almost all colon 
cancer cell lines [Dai et al., 1997]. This protein has 40-50 times higher affinity to 
IGFs than IGF-IR. No previous studies available to date to assess its inhibitory 
nature on colon cancer in vivo. Therefore it will be discussed in detail in a separate 
section. The remaining IGFBPs are discussed down below.
IGFBP-1
IGFBP-1 is mainly produced by the liver, which is regulated by insulin [Sandhu et 
al., 2002]. It has equal affinity for IGF-I and IGF-II. It can either potentiate or inhibit 
the action of the IGFs [Hunt et al., 2002]. It can also act independent of the IGFs by
43
interacting with asPi integrin to cause cell adhesion and migration [Firth and Baxter, 
2002]. Its exact role in colon cancer is not clearly known.
IGFBP-2
IGFBP-2 is up-regulated in different pathological and unphysiological situations like 
trauma, certain tumours and starvation. Transgenic mice over- expressing IGFBP-2 
show significantly reduced body weight gain, demonstrating that IGFBP-2 is a 
negative regulator of normal somatic growth, most probably by sequestering the 
IGFs from their receptors [Hoeflich et al., 2001]. IGFBP-2 inhibits cell proliferation 
in several IGF-responsive colon carcinoma cell lines, but, in contrast, Miraki-Moud 
et al have shown that IGFBP-2-overexpressing Caeo-2 cells grow at a faster rate, 
indicating that the IGFBP-2 stimulates cell proliferation. Therefore, the IGFBP-2 can 
either inhibit or potentiate cancer cell growth under different circumstances.
In human colon cancer, IGFBP-2 mRNA is often over-expressed, and circulating 
IGFBP-2 is often elevated [Kim et al., 2002c]. The IGFBP-2 level often reflects the 
tumour grade and the stage of the disease [Hoeflich et al., 2001]. In one study, 
IGFBP-2 mRNA levels were increased 4- to 8-fold in patients with colon cancer 
compared to controls. Patients with Dukes stage C disease had the highest levels of 
IGFBP-2 mRNA. Therefore, the IGFBP-2 may be implicated in colon cancer 
métastasés and prognosis. Its sensitivity as a tumour marker increases when used in 
combination with carcinoembryonic antigen (CEA) [Renehan et al., 2000a]. Serum 
IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal 
cancer.
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IGFBP-3
Like IGF-I, most of the IGFBP-3 found in the circulation is produced by the liver 
under the influence of growth hormone. It has both IGF-I inhibiting and potentiating 
actions. High levels of circulating IGF-I, and particularly low levels of IGFBP-3, are 
associated independently with an elevated risk o f large or tubulovillous /villous 
colorectal adenoma and cancer [Giovannucci et al., 2000]. The lGFBP-3 acts 
independent of IGFs by enhancing the p53-dependent apoptotic response of 
colorectal cells to DNA damage [Williams et al., 2000] [Howarth, 2003].
IGFBP-5
lGFBP-5 expression is up-regulated by anti-proliferative agents, such as retinoic acid 
and vitamin D-related compounds. The exact role of the lGFBP-5 in colorectal 
cancer is not known. Studies involving prostate cancer cell lines show that the 
lGFBP-5 stimulates growth via IGF-dependent and -independent mechanisms 
[Schneider MR et al., 2002]. But it inhibits the growth of osteosarcoma and cervical 
cancer cell lines [Schneider MR et al., 2002]. It has both stimulatory and inhibitory 
effects on breast caneer cells, depending upon the stage [Butt et al., 2003;Perks and 
Holly, 2000]. It means that it has a complex role in cancer, which needs further 
research.
IGFBP-6
The lGFBP-6 has a high affinity for lGF-11 [Oh et al., 2001]. The lGFBP-6 was 
found to inhibit both HT-29 and Caco-2 cell proliferation, by binding to 
endogenously produced lGF-11, thereby preventing lGF-11 from interacting with the
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IGF-I receptor, to stimulate cellular proliferation by autocrine mechanism [Kim et 
al., 2002c].
IGFBP-7 (IGFBP-rP-1)
IGFBP-7 is also known as ‘mac 25’, and it shows 20-25% similarity to other IGFBPs 
[Oh et al., 1996]. The IGFBP-7 specifically binds to both IGF-I and IGF-II. In 
comparison with IGFBP-3, the IGFBP-7 has at least a 5- to 6- fold lower affinity for 
IGF-I, and a 20- to 25- fold lower affinity for IGF-II. The exact role of this binding 
protein in colon cancer is not clear.
1.2.9 Summary
The IGF system has a complex role in the development and progress of colorectal 
cancer. This system is essential for human day-to-day tissue regeneration. The 
biological activity of IGF is determined by the integrated actions of circulating IGF-I 
and IGFBP, and by local production of IGF, IGFBP and IGFBP protease. So far in 
vitro and in vivo studies, as well as population-based studies, have shown that 
inereased IGF-I and -II may be related to the development of colon cancer. Since the 
assoeiation is not elearly proven eonsistently, it appears that the ligands may play an 
adjuvant role rather than primarily inducing carcinogenesis. When activated, the 
IGF-IR not only stimulates the synthesis of RNA and DNA, cell proliferation, 
differentiation and inereases cell survival, but it also increases angiogenesis. All 
IGFBPs bind to free IGFs and inhibit their aetion on IGF-IR, whieh is vital for 
eareinogenesis. Thus, IGF-IR is more important than any other faetor because it 
mediates the growth of caneer. IGF-IR antagonism using monoclonal antibody, when 
combined with chemoradiation, produces an increased cytotoxic response, which 
may be useful in clinical situations. Manipulation of the IGF-IR may help to eontrol
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several eancers, and this needs to be studied properly. Loss of imprinting of the IGF- 
II gene is responsible for at least some eoloreetal eancers. Thus, it may be possible 
after further study to cure this LOI by insertion of correct gene copy. We do not have 
enough evidence to recommend the use of IGFBPs in clinical therapeutic trials for 
caneer. Serum IGFBP-2 reflects tumour load, so it could be used in cancer 
surveillance in patients with colorectal cancer, after further large studies. Its 
sensitivity as a tumour marker increases when used in combination with CEA. 
IGFBP-3 is the main binding protein which carries and binds more than 90% of the 
IGFs in circulation. Manipulation of the IGF-IR may help to control several eancers, 
whieh have to be studied extensively. Some of the binding proteins like IGFBP-5 and 
-7 have both stimulatory and inhibitory effects under different circumstances. If  the 
future studies show the exact circumstances under which they inhibit cancer growth, 
it can be utilised to arrest caneer growth. As stated in the meta-regression analysis 
by Renehan et al, case eontrol studies might have overestimated the magnitude of 
assoeiation between IGF and cancer. The method of collection is a source of 
heterogeneity. It has to be standardised so that all available data can be compared, 
otherwise the results of the studies done by different individuals will show different 
results. Much of our current knowledge is from in vitro studies. There is not much 
information available regarding the usage of these proteins in the prevention of 
cancer in vivo. There is, therefore, a need for further in vivo studies to enable us to 
manipulate these binding proteins, to prevent and control various cancers. As 
discussed earlier in this chapter, IGFBP-4 will be described separately in the next 
chapter.
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1.3 Biology of IGFBP-4
Among the IGFBPs, IGFBP-4 is the smallest [Zhou et al., 2003] and it exists in two 
forms: non-glycosylated (24 kDa) and N-glycosylated forms (28 kDa ) [Cheung et 
al., 1991;Ceda et al., 1991;Kelley et al., 1996]. It occurs in most biological fluids 
[van Doom et al., 2001]. By binding to IGF-I and IGF-II with similar affinities, it 
inhibits their actions under almost all in vitro and in vivo conditions. The 
glycosylation of IGFBP-4 does not affect its binding to IGF-I [Chelius et al., 2001]. 
The liver is the main source of semm IGFBP-4 [Mazerbourg et al., 2004], but it is 
abundantly expressed by many tissues, including adrenals [Ilvesmaki et al., 1993], 
Leydig cells and interstitial connective tissue of testis [Zhou and Bondy, 1993], and 
the developing embryo, with the notable exceptions of the spinal cord, specific 
cartilage groups and the thymic cortex [Cerro et al., 1993]. The semm level of intact 
IGFBP-4 is low and is influenced by vitamin D and the parathyroid hormone 
[Honda et al., 1996]. The amount of semm IGFBP-4 shows a positive correlation 
with age [Honda et al., 1996]. IGFBP-4 is expressed by several cancer cell lines 
[Bostedt et al., 2001;Ceda et al., 1991;Yi et al., 2001]. Overexpression of IGFBP-4 
has been shown to reduce the growth of some cancers [Damon et al., 1998].
1.3.1 Structure and binding characteristics of IGFBP-4
The gene that encodes IGFBP-4 is located in the chromosome region 17ql2-q21.1 
[Tonin et al., 1993]. IGFBP-4 protein has 237 aminoacids and 20 cysteines [Hwa et 
al., 1999]. When compared to other IGFBPs, IGFBP-4 has two extra cysteine 
residues in the variable region encoded by exon 2 [Qin et al., 1998]. The IGFBP-4 
has three domains [Mazerbourg et al., 2004] namely N-terminal, C-terminal and
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central domain. The binding domain of IGF-I and IGF-II involves a hydrophobie 
motif (Leu (72)-Met (80)), located in the distal part of the eonserved N-terminal 
region. N-terminal Cys residues (Cys9 and Cysl2) are more critieal than C-terminal 
Cys residues (Cys 17 and Cys20) in affecting the IGF-I and IGF-II binding. The C 
terminal fragments of IGFBP-4 do not bind to IGFs, but loss of this fragment 
decreases the affinity for the IGFs. A study [Qin et al., 1998] showed that deletion of 
Leu-Ser resulted in loss of both IGF-I and IGF-II binding, and substitution of 
Histidine to Proline abolished both IGF-I and IGF-II binding. This evidence shows 
that IGFBP-4 has a single binding site for both IGF-I and -II.
1.3.2 Biological actions of IGFBP-4
IGFBP-4 acts by binding to IGF-I and IGF-II and modulating their biological effects 
[Honda et al., 1996]. IGFBP-4 also has actions which are independent of IGF-I and 
IGF-II. Local and systemic administrations of IGFBP-4 have different effects. Single 
local administration of IGFBP-4 over the right parietal bone of mouse inhibits IGF-I- 
induced bone formation, whereas systemie administration of IGFBP-4 alone 
inereases serum levels of bone formation markers [Miyakoshi et al., 1999]. 
Overexpression of IGFBP-4 in transgenic mice resulted in decreased growth of 
thymus [Zhou et al., 2004], a reduction in weight of smooth muscle-rich tissues, 
ineluding bladder, intestine, aorta, uterus, and stomach, without any change in total 
body weight [Schneider et al., 2000;Wang et al., 1998a]. These indicates that 
IGFBP-4 is a functional antagonist of IGF-I action on smooth muscle in vivo [Wang 
et al., 1998a]. IGFBP-4 excess also inhibits cell proliferation and stimulates 
apoptosis in lymphoid tissues, but it does not affeet lymphoeyte development [Zhou 
et al., 2004]. Exogenous IGFBP-4 decreased thrombin-induced DNA synthesis of 
human aortic vascular smooth muscle eells by 64%, whereas anti-IGFBP-4 antibody
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potentiated thrombin-induced DNA synthesis [Anwar et al., 2000]. This data 
suggests that down-regulation of IGFBP-4 expression in vascular smooth muscle, 
may play a critical role in vascular growth response in normal and diseased states, by 
increasing the bioavailability of IGF-I [Anwar et al., 2000]. In addition to its anti­
proliferative action, the IGFBP-4 has been correlated to differentiation of cancer 
cells [Shen and Singh, 2004].
IGF-dependent action
It has been shown that IGFBP-4 inhibits IGF-I-stimulated DNA synthesis in both 
cancerous and non-caneerous cells [Hsieh et al., 2003], but IGFBP-4 has no effect 
on cell proliferation induced by analogs of IGF-I or IGF-II, which exhibit more than 
100-fold reduced affinity for binding to IGFBP-4. The inhibitory action of IGFBP-4 
on IGF-I-indueed DNA synthesis occurs in a concentration-dependent manner, as 
evidenced in vascular smooth muscle cells [Duan and Clemmons, 1998]. IGFBP-4 
inhibits IGF action by preventing the binding of ligand to the IGF-IR [Mohan et al., 
1995].
IGF-independent action
The IGF-independent action of IGFBP-4 is not well understood. In a study [Wright 
et al., 2002], when granulosa cells of ovary were incubated with gonadotropins and a 
IGF-IR blocker (aIR3), the IGFBP-4 continued to exert potent inhibitory effects, 
even when the action of endogenous IGF was removed from the system, 
demonstrating that its actions are independent of IGF binding. In an another study 
[Perks et al., 1999], IGFBP-4 caused marked (P < 0.01) inhibition of ceramide- 
induced apoptosis in Hs578T breast cancer cells. In IGF-insensitive Isreeo-I cells, 
reduced colony formation, but not cell proliferation and migration, was found while 
IGFBP-4 was overexpressed.
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1.3.3 Factors controlling IGFBP-4 expression 
Gene
It has been found that the 1.4 kilobase pair 5' flanking region of the IGFBP-4 gene 
containing cis elements is required for the regulation of the IGFBP-4 gene [Dai et al., 
1997]. In a recent study, a new binding site known as the Sp3 site has been shown to 
influence the expression of IGFBP-4 gene, particularly in Caco-2 cells [Shen and 
Singh, 2004;Demori et al., 2000].
Trauma and tissue regeneration
Cerebral contusions increase cortical expression of IGFBP-4 mRNA levels at the 
contusion site, and along the ipsilateral cortex [Nordqvist et al., 1997]. It has been 
shown that serum IGFBP-4 begins to increase 12-24 hours after partial hepatectomy 
[Demori et al., 2000], consistent with the increase in corresponding mRNA. These 
suggest a regulatory mechanism that modulates IGF activity during tissue 
regeneration.
Proteolysis
IGFBP-4 is subject to proteolytic cleavage by several proteases [Byun et al., 
2000;Durham et al., 1995]. One of the IGFBP-4 proteases, also known as pregnancy- 
associated plasma protein A (PAPP-A) is an important regulator of local IGF 
bioavailability and cell growth [Chen et al., 2002]. A study conducted in our 
department on 18 samples of resected colon cancer specimens, showed that PAPP-A 
is expressed by both malignant and non-malignant colon [Mark Davies, 2004]. The 
study also showed that malignant colon expresses less IGFBP-4 than the normal 
colon. This could be due to either increased proteolysis in the malignant colon or
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decreased transcription of its gene. Colo-205 secretes large quantities of IGFBP-4 
but it remains responsive to IGF-I. Analysis of the conditioned medium revealed 
cleavage of IGFBP-4 into less active fragments, which have less affinity for IGFs, 
which supports the argument that proteolytic cleavage of IGFBP-4 which controls 
the bioavailability of IGFs [Mark Davies, 2004]. Proteases cleave IGFBP-4 into two 
fragments of approximately 18 and 14 kDa, both of which have poor affinity for 
IGFs [Kelley et al., 1996;Remacle-Bonnet et al., 1997]. Sequence analysis of the 14- 
kDa carboxyl-terminal half of IGFBP-4 suggested cleavage after methionine at 
position 135 of the mature protein [Conover et al., 1995a]. In vivo and in vitro 
experiments have shown that lysosomal protease cathepsin D can also mediate 
proteolysis of IGFBP-4 [Braulke et al., 1995].
Calorie intake
In a study on rats’ stomach IGF-I and IGFBP-4 mRNA levels increased significantly 
(P<0.05) when the calorie intake was restricted [Hallberg et al., 2000]. There were 
no changes in colonic IGFBP-4 mRNA levels in aged and long-term calorie 
restricted rats. It shows that the stomach attempts to preserve IGF activity by 
increasing local expression of IGF-I and IGFBPs [Hallberg et al., 2000]. A separate 
study showed that systemic levels of IGFBP-4 did not change with a low-fat diet 
[Ngo et al., 2003].
Hormones and growth factors
It appears that several hormones and growth factors may influence the level of 
IGFBP-4 locally, but not enough to alter the levels systemically. They include IGF-I 
[Price et al., 1995],IGF-II [Feliers et al., 1999], oestrogen [Sheikh et al., 1993], IL-ip 
[Street et al., 2003], and IL-6 [Street et al., 2003;Femandez-Celemin and Thissen,
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2001]. IGFBP-4 is apparently not regulated in response to TNF-a, PDGF, TGF-(3 or 
the cAMP agonist, forskolin in multiple myeloma cells [Feliers et al., 1999]. IGFs 
may regulate their own availability through proteolytic degradation of IGFBP-4 
[Noll et al., 1996] as attachment of IGFs to IGFBP-4 result in enhancement of 
proteolysis [Clemmons, 1993]. IGFBP-3 is reported to inhibit IGFBP-4-degrading 
proteinase activity, and binding of IGFs or glycosaminoglycans to IGFBP-3 may 
induce conformational changes in the binding protein, causing disinhibition of the 
proteinase [Fowlkes et al., 1995].
Both growth hormone status and pharmacological doses of glucocorticoids do not 
affect plasma IGFBP-4 [van Doom et al., 2001] although, apparently, a weak 
positive relationship exists between the plasma IGFBP-4 and parathormone [van 
Doom et al., 2001]. Neither hypothyroidism nor hyperthyroidism influence 
circulating IGFBP-4 levels [van Doom et al., 2001] but, in a study involving rat 
hepatocytes, the IGFBP-4 levels were increased in the presence of tri-iodothyronine 
[Demori et al., 1997a]. Retinoie acid and thyroid hormone act synergistically and 
increase IGFBP-4 expression in cultured rat hepatocytes [Demori et al., 
1997b;Demori et al., 1997a;Demori et al., 2004].
1.3.4 IGFBP-4 in cancer
There is accumulated evidence showing a link between IGFBP-4 and a variety of 
cancers. Several cancer cell lines, including multiple myeloma [Feliers et al., 1999], 
neuroblastoma [Babajko and Binoux, 1996;Babajko et al., 1997], small cell and non­
small-cell lung cancer [Wegmann et al., 1993;Pavelie et al., 2002a;Bostedt et al., 
2001], mesothelioma [Hodzic et al., 1997], gastric cancer [Yi et al., 2001;Guo et al..
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1993], thyroid cancer [Bachrach et al., 1995], breast cancer [Sheikh et al., 
1992;Sheikh et al., 1993;Pekonen et al., 1992;McGuire, Jr. et al., 1992], prostate 
caneer [Conover et al., 1995b;Srinivasan et al., 1996] and colon cancer [Miehell et 
al., 1997b], bave been reported to express IGFBP-4. The role of IGFBP-4 in cancer 
is discussed below under three headings, namely in vitro, in vivo and population- 
based studies.
1.3.5 The role of IGFBP-4 from in vitro studies 
Gastrointestinal cancers
The majority of colon cancers studied were found to express IGFBP-4 [Dai et al., 
1997;Srinivasan et al., 1996]. In an in vitro study, Diehl et al [Diehl et al., 2004] 
overexpressed IGFBP-4 in colon cancer cells using murine IGFBP-4 cDNA. 
Overexpression of IGFBP-4, in IGF-insensitive colon (Isreco) cells, decreased the 
colony formation alone, without any effect on cell proliferation and migration, but in 
IGF-dependent L SI034 cells, it decreased proliferation, migration and colony 
formation, although IGF-II partly restored the first two parameters. In another IGF- 
sensitive cell, Isreeo-2, which lacks endogenous IGF expression, the colony 
formation was decreased by IGFBP-4. In a different study [Park et al., 1996], Caco-2 
cells were transfected with a human IGFBP-4 cDNA construct, and they exhibited a 
60% increase in IGFBP-4 mRNA, and secreted twice as much IGFBP-4 protein as in 
controls. The IGFBP-4 overexpressing cells proliferated at only 25% the rate of 
control cells in serum-free medium, and there was a 70% increase in expression of 
sucrase-isomaltase [Park et al., 1996]. IGFBP4 gene expression plays an important 
role in the transition from proliferation to differentiation in eolon cancer cell line 
Caco2 [Shen and Singh, 2004]. IGFBP-4 expression in Caco-2 cells correlated well
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with cell differentiation [Hoeflich et a l, 1996] and a significant up-regulation o f 
IGFBP-4 expression occurred on spontaneous differentiation in culture [Dai et al.,
1997]. Anti-sense inhibition o f IGFBP-4 mRNA confers a growth advantage to the 
cells in response to endogenous and exogenous IGFs [Dai et al., 1997]. Singh [Singh 
et al., 1994a] studied the inhibitory role of endogenous IGFBP-4 on human colon 
cancer cell line HT-29 cells. Both basal and the IGF-stimulated growth of HT-29 
cells were significantly increased over control values in the presence of IGFBP-4 
antibody, suggesting that endogenous IGFBP-4 is a potent inhibitor of the mitogenic 
effects of endogenous and exogenous IGFs [Singh et al., 1994a]. Singh et al also 
transfected eolon cancer cells with sense and anti-sense cDNA fragments of human 
IGFBP-4. Basal and the IGF-I-stimulated growth of the anti-sense cells were 
significantly higher than that of control and sense cells. The basal and the IGF-I 
stimulated growth of the sense cells was not significantly different from that of the 
control cells, suggesting that overexpression of IGFBP-4 was not inhibitory to the 
growth of the HT-29 cells.
HT29-D4 cells secreted IGF-II which became totally complexed to IGFBP-2, 
IGFBP-4 and IGFBP-6, and -15%  of IGFBP-4 was associated with the extracellular 
matrix [Remacle-Bonnet et al., 1997]. IGFBP-4 proteolysis by cell-bound plasmin 
can promote autocrine/paracrine IGF-II bio-availability in colon-cancer cells 
[Remacle-Bonnet et al., 1997]. Corking and co-worker [Gorkins et al., 2002] studied 
the effect of carbohydrate on expression of IGFBP-4 by HT-29 cell. The cells were 
grown in either glucose or galactose (glucose free) medium. Cells grown in galactose 
medium showed low IGFBP-4 levels until the cells approached confluence, at which 
point the levels increased significantly, while the cells grown in glucose medium
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showed increasing IGFBP-4 levels with increasing cell numbers, except for a 
transient decrease at confluence. HT-29 cells, when treated with retinoie acid, had 
dose-dependent increases in lGFBP-4 and reduced lGF-11 expression. In a different 
study [Akagi et al., 1998], HT29 cells were treated with lGF-1 for various time 
periods, which resulted in increased VEGF mRNA expression . When the activity of 
lGFBP-4 was blocked, it did not significantly influence the effect of lGF-1 induction 
of VEGF mRNA in the HT29 cells [Akagi et al., 1998] .
A previous study conducted in our department to assess the expression of lGFBP-4 
protein in malignant and non-malignant colonic tissue in 18 patients, showed a 
significantly lower amount of lGFBP-4 in colon cancers than in non-malignant colon 
in 16 patients (P<0.05) [Mark Davies, 2004], which was confirmed by both Western 
blot as well as immunohistochemistry [Mark Davies, 2004]. This may be due to 
increased protease activity of transformed cells. Expression o f lGFBP-4 has also 
been found in most gastric carcinoma cell lines [Guo et al., 1993;Yi et al., 2001] but 
it is important to distinguish between increased expression at the mRNA level and 
the concentration of the protein. Regrettably, this is often overlooked as the 
functional aspects of lGFBP-4 are dependent on the protein.
Neuroblastoma and glioma
It was found that rat neuroblastoma cell line secreted both glycosylated and non­
glycosylated forms of lGFBP-4, and lGF-11 treatment decreased the levels of both 
form of lGFBP-4 in the culture media [Ceda et al., 1991]. This decrease in the 
expression was dose-dependent and could be blocked by the addition o f lGF-1 to the 
cells. Although both lGF-1 and lGF-11 affected the amount of the lGFBP-4, neither 
peptide affected the expression of the mRNA of 24K lGFBP-4. Overexpression of
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intercellular communication gap junction gene connexin 43 in glioma cells, resulted 
in decreased cellular proliferation due to higher production of IGFBP-4 [Bradshaw 
et al., 1993]. In a different study, IGFBP-4 inhibited the binding of IGF-I by its 
receptors, and blunted the stimulation of [^H] thymidine incorporation by IGF-I. In 
B 104 cells, a rat neuronal cell line, IGFBP-4 is the predominantly secreted IGFBP-4 
[Cheung et al., 1994]. Exposure of B104 monolayer cultures to dexamethasone, 
reduced native IGFBP-4 abundance to <10% of that in control medium by 48 hours 
[Cheung et al., 1994]. This was due to increased IGFBP-4 activity induced by 
dexamethasone. These findings suggest a role for lGFBP-4 in neural and 
neuroblastoma cell function [Cheung et al., 1991].
Lung cancer
Not all lung cancers have been found to express IGFBP-4 [Pavelic et al., 2002a]. In a 
study involving 69 human lung carcinoma tissues >50% (35/69) of samples were 
positive for IGFBP-4 mRNA [Pavelic et al., 2002a]. In a cell culture experiment, 
IGFBP-4 levels diminished with increasing concentrations of IGFs [Bostedt et al., 
2001] in the culture media of non small cell lung cancer cells, whereas IGFBP-4- 
specific mRNA was not changed by IGF-I or IGF-II. Either IGFs may activate an 
IGFBP-4-specific metalloprotease present in culture media, or the binding of IGFs to 
IGFBP-4 may increase the susceptibility of IGFBP-4 to proteolytic degradation [Noll 
et al., 1996].
Endocrine cancers
Both human thyroid follicular carcinoma and papillary carcinoma cells produce 
IGFBP-4 [Bachrach et al., 1995;Isozaki et al., 1996;van der Laan et al., 1995]. In a 
cell culture experiment involving two human thyroid follicular carcinoma cell lines
57
(FTC-133 and FTC-236 cells), IGFBP-4 secretion was increased in the presence of 
thyroid stimulating hormone, forskolin, and epidermal growth factor, and was 
reduced by tetradecanoylphorbol acetate [Bachrach et ah, 1995]. Nodular and 
bilateral hyperplasia of the adrenal gland, as well as pheochromoctyomas showed 
higher expression of IGFBP-4 mRNA, while non-functional adrenal carcinomas and 
normal adrenals expressed less IGFBP-4 mRNA [Ilvesmaki et ah, 1998].
Breast cancer
The relationship between IGFBP-4 expression and hormonal receptors in breast 
cancer is unclear. Figueroa and co-workers studied 40 primary breast tumors 
[Figueroa et ah, 1993] and found that all of them expressed IGFBP-4 mRNA, and the 
expressions were higher in oestrogen receptor (ER)-positive specimens. Another 
study on 80 breast cancer specimens showed that IGFBP-4 was positively correlated 
with both estrogen and progesterone receptors, and inversely correlated with 
synthetic-phase (S-phase) fraction [McGuire et ah, 1994], which reflects tumour 
cellular proliferation. In contrast to these two studies, another study on 47 cancer 
specimens failed to find any relation between ER content and IGFBP-4 levels 
[Pekonen et ah, 1992]. In an experiment involving MCF-7 breast cancer cells, 
IGFBP-4 had no effect on IGF-I-induced DNA synthesis [Chen et ah, 1994] but, in 
Hs578T cells IGFBP-4 caused marked (P < 0.01) inhibition of ceramide-induced 
apoptosis [Perks et ah, 1999].
The expression of IGFBP-4 in breast cancer is modulated by various hormones. 
Treatment of MCF-7 cells with an oestrogen, 17(3-estradiol, resulted in increased 
IGFBP-4 gene expression (>3-foId) and protein secretion (>6-fold). Further evidence 
showed that anti-estrogens ICI 164384 and ICI 182780 decreased mRNA levels of
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IGFBP-4 [Coutts et al., 1994;Pratt and Poliak, 1993]. In N-nitrosomethylurea- 
induced rat mammary tumour, lGFBP-4 mRNAs decreased with ovariectomy and 
increased with hormone repletion. Another anti-oestrogen, tamoxifen, significantly 
reduces the levels of lGFBP-4 protein in the conditioned medium of MCF-7 cells 
[Pratt and Poliak, 1993]. A small study on 8 patients showed an increase in serum 
lGFBP-4 levels after tamoxifen [Gronbaek et al., 2003], which may reflect the 
systemic effect of tamoxifen.
In a different study, medroxyprogesterone acetate treatment resulted in a time- and 
dose-dependent decrease in lGFBP-4 mRNA, but RU 486 alone had little or no 
effect [Coutts et al., 1994]. A synthetic progestin, Org 2058, but not dexamethasone, 
inhibited lGFBP-4 expression. In a separate study, lGFBP-4 levels were slightly 
decreased in response to high doses of human chorionic gonadotropin [Huynh, 
1998].
It has been shown that retinoie acid increases lGFBP-4 levels in conditioned 
medium in MCF-7 breast carcinoma cell line [Adamo et al., 1992]. In contrast, 
another study showed that retinoie acid reduced transcriptional activity of the 
lGFBP-4 gene [Chambery et al., 1998]. Retinoie acid and oestrogen increased 
lGFBP-4 mRNA levels in many ER-positive cell lines, and the effect of oestrogen 
and retinoie acid in combination was additive [Sheikh et al., 1993]. Although both of 
them individually enhanced lGFBP-4 mRNA levels in ER-positive T47D cells, their 
effect in combination was antagonistic in this cell line [Sheikh et al., 1993].
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Osteosarcoma and multiple myeloma
Normal osteoblasts secrete IGFBP-4 as well as an IGF-dependent IGFBP-4 protease 
[Durham et al., 1995]. Therefore, the IGF system can influence bone growth by 
altering the levels of IGFBPs, and thereby influencing free IGFs. Fully tumourigenic 
osteosarcoma cells do not express IGFBP-4 as well as an IGF-dependent IGFBP-4 
protease [Durham et al., 1995]. Human myeloma cells express IGFBP-4 [Feliers et 
al., 1999]. In late stages of myeloma, there is increased bone destruction and 
decreased bone formation, which causes osteolytic lesions. This may be due to 
multiple myeloma cells secreting IGFBP-4, which inhibits IGF-I-stimulated bone 
formation by adjacent normal osteoblasts [Feliers et al., 1999].
Prostate cancer
Prostate carcinoma cells secrete IGFBP-4 [Drivdahl et al., 1995;Conover et al., 
1995b], as well as a general IGFBP protease and cathepsin D, both of which are 
capable of hydrolyzing all endogenous IGFBPs and, thus, modifying IGF-I action in 
prostatic cells [Conover et al., 1995b]. In one study, IGFBP-4 was overexpressed by 
transfecting malignant M l2 prostate epithelial cells with plasmid containing IGFBP- 
4 [Damon et al., 1998]. Consequently, IGF-induced proliferation was reduced in the 
IGFBP-4 transfected cells compared with control cells (P < 0.01). Colony formation 
in soft agar was inhibited for 14 days (P < 0.01). As IGFBP-4 has been suggested to 
inhibit cell growth, the reduction of IGFBP-4 expression should increase the 
availability of free IGFs, which would increase cell growth. In reality, the results 
were different. In a study [Drivdahl et al., 2001], when IGFBP-4 expression was 
inhibited with anti-sense cDNA in two prostate tumor cell lines, ALVA-31 and M l2, 
both transfected lines proliferated more slowly in monolayer culture than parental
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controls. Colony formation in soft agar was strongly inhibited in both cases. 
Apoptosis induced by the topoisomerase inhibitor, etoposide, was also enhanced in 
transfected cells. The results may be due to involvement of other binding proteins 
which influence cell growth.
1.3.6 The role of IGFBP-4 from in vivo studies
When compared to in vitro studies the numbers o f in vivo studies which demonstrate 
the effect of IGFBP-4 in cancer are much fewer and less well standardised.
Hepatocellular carcinoma
IGFBP-4 expression in pre-neoplastic and neoplastic lesions is not the same. 
Immunohistochemical studies showed increased expressions of IGF-I and IGFBP-4 
in pre-neoplastic lesions [Scharf et al., 2000]. Hepatocellular carcinoma arising in 
this model showed decreased expressions of IGF-I and IGFBP-4. The altered gene 
expression in glycogen-storing preneoplastic hepatic foci, especially the up- 
regulation of IGF-I and IGFBP-4 with the down-regulation of IGFBP-1, resemble the 
insulin-dependent regulation of these components in normal rat hepatocytes.
Prostate cancer
Damon [Damon et al., 1998] transfected prostate cancer cells with IGFBP-4 gene, 
and injected these cells subcutaneously into male athymic/nude mice. There was a 
marked delay in tumor formation in animals receiving IGFBP-4 transfected cells 
when compared with controls (P < 0.01). In a reverse experiment, IGFBP-4 
expression was inhibited with anti-sense cDNA in prostate tumor cell line. M l2, it 
also markedly reduced the rate of tumor formation and growth in male athymic nude
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mice [Drivdahl et al., 2001]. These studies demonstrated that the in vivo effect of 
altered expression of IGFBP-4 is complex and is under the influence of several 
unknown factors.
1.3.7 The role of IGFBP-4 from population and clinical studies
In a case-control study [Ng et al., 1998] involving 63 breast cancer patients, 
decreasing serum levels of IGFBP-4 (p < O.OI) were significantly associated with an 
increasing numbers of progesterone receptors in the tumour. IGFBP-4 was 
significantly (p < 0.01) associated with the risk of breast cancer.
In one study, the IGFBP-4 levels in the circulation did not show any difference in 
most of the cancer patients with solid tumours, although several children with acute 
lymphoblastic leukaemia showed increased plasma IGFBP-4 levels [van Doom et al., 
2001].
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1.4 Hypothesis
The hypothesis of the study was that gene construet containing insulin-like growth 
factor binding protein - 4 (IGFBP-4) cDNA, when administered by local injection, 
would increase the expression and secretion of IGFBP-4 protein by colorectal cancer 
cells, neighbouring cells and skeletal muscle cells. As it sequesters insulin-like 
growth factors, the IGFBP-4 may inhibit or decrease all IGF induced functions, 
including cellular proliferation and anti-apoptosis. The growth of colon cancer cells 
when deprived of IGFs may be inhibited. So when the gene is administered after the 
induction o f tumour, IGFBP-4 may delay further tumour growth and increase the 
apoptosis, leading to reduction in the size of the tumour. When the gene construct is 
administered at an early stage, IGFBP-4 may prevent or delay tumour formation 
from caneer cells.
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1.5 Objectives
The objectives of the study presented in this thesis was to treat the subcutaneously 
induced cancers with plasmids containing IGFBP-4 cDNA, and assess the effect of 
IGFBP-4 gene therapy on tumour characteristics, IGF system expression, apoptosis 
and proliferation of cancer cells.
The first step of this project was multiplication and purification of plasmid 
containing IGFBP-4 cDNA and confirmation o f its sequence, and then to induce 
subcutaneous cancers by inoculating nude mice with HT-29 cells, so that the plasmid 
containing IGFBP-4 cDNA could be administered by local injection either on day ‘0’ 
or after the development of palpable tumour.
Once attaining a reasonable size, the subcutaneous tumours were assessed for 
cellular proliferation, apoptosis and expression of components of IGF system 
including IGFBP-4. Finally Bax and Bcl-2 levels were determined to explore the 
mechanism of apoptosis.
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1.6 Research overview
As shown in the flow chart (figure 1.3) plasmids were extracted and HT-29 
adenocarcinoma cells were cultured simultaneously. Once sequencing confirmed the 
presence of IGFBP-4 cDNA insert in the plasmid, subcutaneous cancers were 
induced in nude mice. The experiments were performed in two models. In the first 
model (late gene transfer), there were two groups and the therapeutic effect of 
IGFBP-4 was assessed. In this model, the gene construct was administered once the 
tumour was established. In the second model (early gene transfer = preventive 
model), there were three groups and the role of IGFBP-4 in prevention of cancer was 
assessed. So the plasmids were administered even before the cancer was established, 
i.e. the cancer cells and plasmids were administered together. Three to four weeks 
following IGFBP-4 induction, the tumours were harvested and assessed for, mitosis, 
apoptosis, various proteins including IGF-IR, IGFBP-4, Bcl-2 and Bax by various 
laboratory based methods.
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Experimental Plan
Culture HT-29 cells Prepare plasmids
Experimental animal model
Model I (Late gene transfer - 2 groups) Model 2 (Early gene transfer -3 groups)
1 r
Administer plasmid once the tumour is 
palpable
Simultaneously administer HT-29 cells 
and plasmid together
r
Assess 1) Mitosis and apoptosis 2) Expression of IGFBP-4 
3) Mechanism of apoptosis (Bax and Bcl-2)
Figure 1.3 Overview of research planning. HT-29 cells were cultured and plasmids 
were prepared simultaneously. Then the effects of the plasmids were assessed on 
colon cancer cells in vivo at two different time periods in relation to mitosis, 
apoptosis, and expression of IGFBP-4, Bax and Bcl-2 proteins.
66
Chapter 2 Materials and methods
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2.1 Preparation o f gene construct
2.1.1 Gene construct
Mammalian expression vector peDNA3 (Invitrogen, Carlsbad, CA, USA) containing 
myosin light chain enhancer was used in this study, in which IGFBP-4 cDNA was 
inserted between Kpn I and EcoK  1 restriction sites down stream of cytomegalovirus 
(CMV) promoter. This plasmid was kindly provided as a gift by Mr Steve Coe, 
Molecular Tissue Repair Unit, Royal Free and University College Medical School, 
London.
pcDNA 3 (figure 2.1) is an artificial 5.4 kb vector, with a double stranded circular 
DNA containing 5446 nucleotides, designed for high level stable expression in most 
mammalian cells. It contains CMV intermediate-early promoter for high-level 
expression, neomycin resistance gene for selection of stable cell lines and two 
promoters (T7 and SP-6). The presence of the ampicillin gene provides resistance to 
ampicillin. Figure 2.2 shows the genetic sequence of pcDNA3. The plasmid and the 
foreign DNA that needs to be studied can be cut by restriction endonuclease, 
producing intermediates with sticky and complementary ends. The two intermediates 
recombine by base-pairing and are linked by the action of an enzyme called DNA 
ligase. Thus a new plasmid containing the foreign DNA as an insert is obtained. The 
plasmids can be easily transformed with bacteria Escherichia Coli (E.Coli).
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Figure 2.1 Structure of mammalian expression vector pcDNA 3. It is a 5.4 kb vector with a 
double stranded circular DNA containing 5446 nucleotides. It contains cytomegalovirus 
promoter for high-level expression, neomycin resistance gene for selection of stable cell 
lines and two promoters (T7 and SP-6). (Reproduced from Invitrogen, USA website)
69
pcDNA3
hCMV immediate early promoter
Poly linker
Primer binding sites
Bovine Growth Hormone polyA
Q Invitrogerr
life technologies
j  5' end o f hCMV’ promoter enhancer
2 2 4  ATATACGCGT TGACATTGAT TATTGACTAG TTATTAATAG TAATCAATTA CGGGGTCATT
I  enhancer region ( 5' end )
2 8 4  AGTTCATAGC CCATATATGG AGTTCCGCGT TACATAACTT ACGGTAAATG GCCCGCCTGG
34 4  CTGACCGCCC AACGACCCCC GCCCATTGAC GTCAATAATG ACGTATGTTC CCATAGTAAC
4 0 4  GCCAATAGGG ACTTTCCATT GACGTCAATG GGTGGACTAT TTACGGTAAA CTGCCCACTT
4 6 4  GGCAGTACAT CAAGTGTATC ATATGCCAAG TACGCCCCCT ATTGACGTCA ATGACGGTAA
5 2 4  ATGGCCCGCC TGGCATTATG CCCAGTACAT GACCTTATGG GACTTTCCTA CTTGGCAGTA
5 8 4  CATCTACGTA TTAGTCATCG CTATTACCAT GGTGATGCGG TTTTGGCAGT ACATCAATGG
API 
I  I
6 4 4  GCGTGGATAG CGGTTTGACT CACGGGGATT TCCAAGTCTC CACCCCATTG ACGTCAATGG
enhancer region (3' end) 1
7 0 4  GAGrTTGTTT TGGCACCAAA ATCAACGGGA CTTTCCAAAA TGTCGTAACA ACTCCGCCCC
CAAT TATA V endofhC M V
I I I ' I 4
7 6 4  ATTGACGCAA ATGGGCGGTA GGCGTGTACG GTGGGAGGTC TATATAAGCA GAGCTCTCTG
I putative transcripTional start___________________________ _^_________ T/ promoter___________
8 2 4  GCTAACTAGA GAACCCACTG CTTACTGGCT TATCGAAATT AATACGACTC ACTATAGGGA
Hind III Kptr I BamU ] Bst XI Eco R I
I I I  I I
8 8 4  GACCCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT GCTGGAATTC
Eco R V Bst X 1 Not I Xho I Xha I Apa 1
I I  I  I I  I  I- - - - - - - - -
9 4 4  TGCAGATATC CATCACACTG GCGGCCGCTC GAGCATGCAT CTAGAGGGCC CTATTCTATA 
Sp6 promoter
I
1 0 0 4  GTGTCACCTA AATGCTAGAG CTCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC
1064  ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT 
BGH poWA
I n
1124  CCTTTCCTAA TAAAATGAGG AAATTGCAT
NOTE: There is an ATG upstream ofttieXba I and Apa I sites
Figure 2.2 Genetic sequence o f mammalian expression vector pcDNA 3 
(Reproduced from Invitrogen, USA website)
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2.1.2 Transformation of vector
The plasmids (vector and vector with IGFBP-4 cDNA) were introduced into 
competent cells to multiply them. Competent cells are in such a state in which 
bacteria are able to take up foreign DNAs. Transformation is a process of introducing 
plasmid DNA into E.Coli or yeast. JM 109 high efficiency competent E.Coli cells 
(Promega, Madison, USA) were used in this experiment for transformation. E. Coli 
is a rod shaped bacteria with a circular chromosome of about 3 million base pairs 
long.
Procedure
Polypropylene culture tubes were chilled on ice. Frozen competent cells were 
removed from -70°C, placed on ice for 5 minutes and thawed. The competent cells 
were mixed by flickering gently and 100 pi of it was transferred to each chilled 
culture tube (x2). Fifty nanogram of DNA containing either pcDNAB with myosin 
enhancer, or pcDNA3 with myosin enhancer, and IGFBP-4 insert was added to 
competent cells. The tubes were flickered several times and kept on ice for 10 
minutes.
Subsequently the cells were heat shocked for 45 seconds in a water bath at 42°C. 
Following this, the tubes were placed on ice for 2 minutes again. Nine hundred 
microlitres of cold SOC medium (at 4°C) was added to each tube and incubated for 
60 minutes at 37°C in a shaking platform at 225 rpm. Glucose in the SOC medium 
enhances bacterial growth. The tubes were centrifuged at 1000 G for 10 minutes and 
pellets were resuspended in 200 pi of Luria - Bertani (LB) medium. The transformed 
cells were plated on LB plates containing 100 pg/ml of ampicillin, 0.5 mM of
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isopropyl-beta-D-thiogalactopyranoside (IPTG) and 40 pg/ml of X-Gal and 
incubated overnight at 37°C. On the following day, blue colonies were picked and 
serially plated. The procedure is described in the next paragraph.
2.1.3 E.Coli culture
E.Coli containing pcDNA3 with and without IGFBP-4 inserts was grown at 37°C on 
LB agar plates with 100 pg/ml ampicillin overnight. A single colony of the bacteria 
was picked up from a freshly streaked selective plate and inoculated, to produce a 
start culture of 10 ml LB medium in a 30 mis universal container containing the 
ampicillin (50 pg/ml). It was incubated for 6 hours at 37°C with vigorous shaking 
(225 rpm). 1 ml of the start culture was added to 100 mis of LB media, which was 
prepared in sterile conical flasks and incubated overnight in a rotating platform at 
225 rotations per minute at 37°C.
2.1.4 Plasmid extraction by Miniprep
Miniprep kit (Qiagen, Crawley, UK) was used for preliminary extraction of plasmids 
from E.Coli. One ml of LB medium containing overnight cultures of E.Coli was 
centrifuged in appendarf tubes at 13,000 rpm for 5 minutes. The bacterial pellets 
were resuspended in 250 pi of buffer PI, and 250 pi of buffer P2 was added, and the 
tubes were gently inverted 6 times to mix the contents. Then 350 pi of buffer N3 was 
added and the tubes were inverted 6 times to avoid any precipitation. The tubes were 
centrifuged for 10 minutes and the supernatant solution was applied to QIA prep spin 
column in a 2 ml collection tube. The spin columns/collection tubes were centrifuged 
for 1 minute and flow through was discarded.
Spin columns were washed by adding 0.75 mis of buffer PE and centrifuging them 
for 60 seconds. The flow through was discarded and centrifuged again for another 1
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minute to remove residual buffer. Then the DNA was recovered with sterile PBS. 
The plasmid DNA was stored at - 20°C.
2.1.5 Sequencing
The DNA was sequenced at MWG biotech, Ebersberg, Germany. For sequencing, 2 
pg of plasmid DNA was suspended in 20 pi in phosphate buffered saline and air 
dried in a centrifuge for 30 minutes. Sequencing results were compared with standard 
DNA sequences that are available in PubMed. It confirmed the presence of 
mammalian expression vector and IGFBP-4 cDNA in the plasmid. The results are 
shown in the appendix. Once the sequencing was confirmed, the E.Coli cells were 
grown further, and plasmids were extracted in large quantities using Endo Free Maxi 
Plasmid Extract Kit (Qiagen, Crawley, UK).
2.1.6 Plasmid extraction and purification 
Pre-procedure preparations
Plasmid DNA isolation and purification was performed using the Endo Free Plasmid 
Maxi Kit (Qiagen, Crawley, UK). Before starting the purification of the plasmid, 
RNase A solution was added to Buffer PI. One vial of RNase A was used (spinned 
down briefly before use) per bottle of Buffer PI, to give a final concentration of 100 
pg/ml. To prepare endotoxin-free 70% ethanol, 40 ml of 96 -100% ethanol was 
added to the endotoxin-free water supplied with the kit. Buffer P3 was pre-chilled to 
4°C.
Alkaline lysis o f bacterial pellet
To begin with, the bacterial cells were isolated by centrifugation at 6000G for 15 
minutes at 4°C. 6000G corresponds to 6000 rpm in Sorvall GSA rotors. All traces of
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supernatants were removed by inverting the open centrifuge tube until all medium 
had been drained. The bacterial pellet was resuspended in 10 ml of Buffer PI (to 
which RNase was already added) completely by vortexing or pipetting up and down 
until no cell clumps remain. 10 ml o f Buffer P2 was added, mixed gently but 
thoroughly by inverting 4-6 times, and incubated at room temperature for 5 minutes. 
After use, the bottle containing Buffer P2 was closed immediately to avoid 
acidification from CO2 in the air. During the incubation the QIAfllter Cartridge was 
prepared. The cap was screwed onto the outlet nozzle of the QIAfllter Maxi 
Cartridge.
Neutralisation and precipitation genomic DNA
10 ml of chilled Buffer P3 was added to the lysate and mixed gently immediately by 
inverting 4-6 times. The lysate was poured into the barrel of the QIAfllter Cartridge 
immediately and incubated at room temperature for 10 minutes.
Removal o f precipitates and endotoxins
The cap was removed from the QIAfllter Cartridge outlet nozzle and the plunger was 
gently inserted into the cartridge and the cell lysate was filtered into a 50 ml tube. 
Approximately 25 ml of the lysate was generally recovered after filtration. Then 2.5 
ml of Buffer ER was added to the filtered lysate, mixed by inverting the tube 
approximately 10 times, and incubated on ice for 30 min.
Adsorption o f plasmid DNA and washing
While the lysate was incubating, Qiagen-tip 500 was equilibrated by applying 10 ml 
of Buffer QBT, and allowed to empty by gravity flow. Flow of buffer began 
automatically by reduction in surface tension due to the presence of detergent in the 
equilibration buffer. Then the filtered lysate was applied to the Qiagen-tip and
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allowed to enter the resin by gravity flow. Once the column was empty, the Qiagen- 
tip was washed with 2 x 30 ml Buffer QC by gravity flow.
Elution o f plasmid DNA
Plasmid DNA was eluted with 15 ml of Buffer QN and collected in a 30 ml pyrogen- 
free glass tube, and the DNA was precipitated by adding 10.5 ml (0.7 volumes) room 
temperature isopropanol (VWR international, Lutterworth, UK), ft was mixed 
thoroughly and centrifuged immediately at 11,000 rpm for 30 minutes at 4°C in a 
Sorvall SS-34 rotor. The supernatant was carefully pipetted out which left the DNA 
pellet at the bottom of the glass tube.
Purification o f the plasmid DNA
The DNA pellet was washed with 5 ml of endotoxin free room temperature 70% 
ethanol and centrifuged at 9000 rpm for 10 min. The supernatant was pipetted 
without disturbing the pellet. The pellet was air-dried for 5 minutes and the DNA 
was redissolved in a suitable volume of sterile endotoxin free PBS. To determine the 
yield, DNA concentration was determined by UV spectrophotometer and the inserts 
were analysed on an agarose gel by electrophoresis.
Quantification o f the plasmid DNA
The plasmid was quantified in a Gene spec I Spectrophotometer. After opening the 
software, PBS was used as baseline and an UV spectrometry reading was obtained. 
Then the 1 pL cuvette was washed with deionised water and ethanol, and plasmid 
was quantified. When the quantification graph (figure 2.3) was not smooth, the 
plasmid was diluted and measured again. In between the measurements, the cuvette 
was cleaned with deionised water and alcohol.
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Storage o f the transformed E.Coli
One ml glycerol was added to 9 ml of LB media and autoclaved at 121°C for 15 
minutes which formed 2x freezing medium. Half ml of culture (transformed E.Coli) 
from the flask was added to 0.5 ml of this freezing medium and mixed well in a 1.5 
ml tube which was stored at -70°C.
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Figure 2.3 showing graph o f plasmid DNA which was quantified using gene spec.
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Figure 2.4 showing a typical measurement o f DNA using gene spec
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Confirmation of IGFBP-4 insert by agar gel electrophoresis
To confirm the presence of IGFBP-4 insert, plasmid DNA was eut with restriction 
endonucleases and gel electrophoresis was performed
Digestion o f plasmid DNA with restriction endonucleases
Restriction endonucleases recognise short DNA sequences and cleave the double 
stranded DNA at specific sites within, or adjaeent to, the recognition sequences. 
Restriction enzymes Eco R 1 and Kpn 1 (Boehringer Mannheim, West Sussex, UK) 
were used to digest the sequence to extraet lGFBP-4 cDNA. Buffer ‘A ’ (Boehringer 
Mannheim, West Sussex, UK) was used which has 100% activity against Eco R1 
enzyme, and 75-100% activity against Kpn 1 enzyme. Prior to gel electrophoresis, 20 
pi of digestive mixtures for each plasmid were prepared (Table 2.1). The reaction 
mixture was incubated at 37°C in a water bath using a float for 1 hour.
Table 2.1 Composition of the digestive mix for electrophoresis
Component % an tity (p l)
DNA 2
Enzyme Kpn-1 1
Enzyme EGOR-1 1
Buffer A(XIO) 2
BSA 0.5
Water 13.5
Total 20
Preparing the gel
One gram of electrophoresis grade agar was added to 100 ml of 1% TAB buffer and 
heated in a microwave oven for 1.45 minutes to dissolve it. One pi of ethadium 
bromide (Invitrogen, Paisley, UK) was added to 25 ml of gel. The ethadium bromide 
allowed easy visualisation of the DNA under UV light so that it could be
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photographed after electrophoresis. It was cooled to 55°C and poured onto a gel 
platform with a 12 lane gel comb to generate wells.
Loading and running the gel
Once the gel was set, the comb was removed. Sufficient electrophoresis buffer was 
added to the gel tank to cover the gel to a depth of about 1 mm. DNA samples were 
prepared by adding loading buffer (6%, Fermentas, York, UK). Samples were loaded 
into the wells with a pipette. One kb DNA ladder (Fermentas, York, UK) was used to 
compare the results of electrophoresis. Electrophoresis cables were attached and 
voltage was set at 80 Volt for 40 minutes (1-10 Volts/Cm of the gel). The DNA ran 
towards the positive (red) electrode. The power supply was turned off once the 
Bromophenol blue dye solution from the loading buffer had migrated to a distance 
sufficient for the separation of the DNA fragments.
Visualising the DNA
After electrophoresis the gel was taken to a UV spectrophotometer (Bio-rad Gel doc 
2000) where the bands could be visualised and printed. The bands were compared 
with a DNA ladder, and sizes of the DNA bands were identified.
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Figure 2.5 Bio-rad Gel doc 2000 for visualising DNA bands in gel. The gel is kept inside the 
white cabinet (shown in the middle o f the picture) and DNA is visualised with ultraviolet 
rays and will appear on the computer screen.
Sample 1 (vector^+ BP-4) Ikb ladder Sample 2 (vector)
f
pcDNA 3
IGFBP-4 insert i N
Figure 2.6 showing visualisation o f DNA with UV light. IGFBP-4 insert is clearly seen.
The plasmid samples were sent to MWG, Ebersberg, Germany, for confirming 
sequence again, prior to establishing the early gene transfer model.
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2.1.7 Preparation of gene construct without myosin enhancer
The aim was to produce a plasmid containing vector DNA and IGFBP-4 DNA insert 
without light chain myosin enhancer.
1. Gel electrophoresis to separate the IGFBP-4 insert and vector DNA
The plasmid containing myosin light chain and IGFBP-4 insert was quantified using 
Genespecl. The vector pcDNA 3.1 was a given as a gift by Mr David Sutton, 
Molecular Tissue Repair Unit, The Royal Free and University College Medical 
School, London. Plasmid DNA and a restriction enzymes mixture was prepared as 
shown in table 2.2 and incubated for 2 hours 30 minutes at 37°C water bath.
Table 2.2 showing DNA enzyme mixture for electrophoresis
Component IGFBP-4 mix Oa> Vector mix (ill)
DNA(plasmid) 10 2
EcoRl 1 1
Kpnl 1 1
BSA 0.5 0.5
Buffer A 2 2
Deionised water 5.5 13.5
Total 20 20
While the plasmid enzyme mixture was incubating, 1% gel was made by dissolving 1 
gram of agarose in 100 ml of TAB (1%) and heating this in a microwave oven for 
1.45 minutes. 25 ml of this solution was taken and 1 pi of ethadium bromide (Sigma- 
Aldrich, Gillingham, UK) was added. This was poured in to the electrophoresis 
instrument and a 10 well comb was used to create wells. Once the gel was set, 1 pi of 
loading dye (6%) (Fermentas, York, UK) was added to each DNA-Enzyme mix and 
poured into different wells. One kb DNA ladder (Fermentas, York, UK) was used as 
a ruler. The gel was run for 40-60 minutes at 104 volts.
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2. Extraction o f DNA front gel
The areas of gel containing IGFBP-4 insert and vector were excised under UV light 
guidance in a dark room and kept in two different appendarf tubes. DNA was 
extracted by QIAEX -  II Agarose Gel extraction method (Qiagen, Crawley, USA).
Steps of DNA extraction from gel
Gel was weighed and 3 times volumes of Buffer QXl to 1 volume of gel was added 
and vortexed. 30pl of buffer QIAEX-II solution was added to each and incubated at 
50°C water bath for 10 minutes and vortexed every 2 minutes. They were centrifuged 
for 30 seconds and supernatant removed, and the pellet was washed with 500 pi of 
buffer QXl. The pellet was washed twice with 500 pi of buffer PE (70% alcohol) 
and air dried in vacuum pump for 10 minutes to produce white DNA. 20pl of 
nuclease free, bacteria free, water was added to each. The pellet was vortexed to 
resuspend it. It was centrifuged and supernatant was stored in a clean sterile tube. A 
small amount of DNA was run in the gel to confirm that the extraction had DNA.
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Vector DNA
BP-4 insert
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Figure 2.7 showing gel electrophoresis o f plasmids which were digested with restrictive 
endonucleases. The IGFBP-4 insert is obvious.
Purification of DNA extracted from the gel
Ten microlitres of the DNA was made up to 100 pi by adding deionised water. To 
this 100 pi, 10 pi (10%) of 3 mMol sodium acetate and 2.5 times (250 pi) of 100% 
methanol were added and incubated overnight at 4°C.
Ligation o f DNA
POEM - T Easy Vector System II kit (Promega, Madison, USA) was used for 
ligation. On the first attempt the DNA mix was prepared as shown in Table 2.3.
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Table 2.3 showing the composition of DNA mix for ligation reaction
Component Quantity (pi)
2 X Rapid Ligation Buffer 5
T4 DNA Ligase 1
Vector Plasmid DNA 2
IGFBP-4 DNA 2
Total 10
The ligation mix was kept at 4°C in a cold room overnight. This had twice failed to 
yield good results. So ligation was repeated according to the manufacturer’s 
recommendations, as below (Table 2.4).
Size of IGFBP-4 insert = 2.2 kb 
Nanogram (Ng) of insert required
Size of vector = 8kb
= Ng of VectorX kb insertxratio
Kb vector
Ng of insert required = 50 ng vector x 2.2x3
8
- 41 Nanograms
On measuring with Gene spec we found that both vector and insert were 
0.07 pg/pM 70 ng/pl
Table 2.4 showing composition of ligation mix
Component Quantity (pi)
2 X Rapid Ligation Buffer 5.00
T4 DNA Ligase 1.00
Vector Plasmid DNA 0.71
IGFBP-4 DNA 0.59
Water 2.70
Total 10.00
After overnight incubation at 4°C, the competent cells (Easy Vector, Promega, 
Madison, USA) were transfected. LB agar plates were prepared. The following 
solution was used for each plate before plating the transfected cells.
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Ampicillin- 40 pi of 50 mg/ml 
IPTG -40  pi of 100 mM 
X-gal -  20 pi of 40 mg/ml
Total = 100 pi per plate 
Transfection procedure
This transfection failed twice for no obvious reasons, so transfection was repeated 
with SURE (Stop Unwanted Rearrangement Events) (Stratagene, La Jolla, 
California, USA) competent cells.
SURE transformation protocol
At first, two appendarf tubes were pre-chilled on ice. Then competent cells were 
thawed on ice, gently flickered to mix and 1 0 0  pi of cells aliquoted to each of the 
pre-chilled tubes. 1.7 pi of p-mercaptoethanol was added to each tube and incubated 
on ice for 10 minutes, and the contents were swirled every 2 minutes. Then 2 pi of 
experimental DNA was added to one aliquot and 1 pi of the pUC 18 control DNA to 
the other aliquot, the tubes were swirled gently and incubated on ice for 30 minutes. 
To facilitate the entry of DNA into the cells, they were heat pulsed in a water bath at 
42°C for 45 to 50 seconds and incubated on ice for 2 minutes. Then 0.9 ml of 
preheated warm LB medium was added, and incubated in a shaking platform at 37°C 
at 225 rpm.
Then 200 pi transformation mixture was plated on to LB plates containing 
Ampicillin, IPTG (Iso-propyl-1-thio-p-D-galactopyranoside) and X-gal (5-bromo-4- 
chloro-3-inodyl-p-D-galactopyranoside). These reagents provide blue-white 
screening. The plates were incubated overnight at 37°C. Transformation of vector
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failed four times. Finally, the gel extraction was repeated and pcDNA 3.1 plasmid 
was extracted. The gel electrophoresis showed the presence of BP-4 insert (figures 
2.8 and 2.9). Sequencing was performed in two places (Imperial College, London 
and MWG, Ebersberg, Germany). Neither of them confirmed the right sequence for 
the IGFBP-4.
V
VB
Figure 2.8 Gel electrophoresis showing plasmid o f vector (V) and vector with IGFBP-4 
insert without myosin enhancer (VB) , after cutting the plasmids with Kpn I and EcoR  I 
restriction endonucleases (Miniprep).
V
VB
Figure 2.9 Gel electrophoresis showing plasmids o f  vector with IGFBP-4 insert without 
myosin enhancer, after cutting the plasmids with Kpn I and EcoRl restriction endonucleases 
(Maxi prep). (Key: V- plasmid vector, VB- plasmid with BP-4 constmct)
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2.2 Cell culture
2.2.1 Colon cancer cell line
HT-29 is a widely studied human colon adenocarcinoma cell line. It was originally 
isolated from a primary tumour in a 44 year old Caucasian female. On culture it 
forms a well-differentiated adenocarcinoma.
2.2.2 Culture
HT-29 cells (European Collection of Animal Cell Cultures, Porton Down, Dorset, 
UK) were cultured in 75 cm^ flasks containing McCoy’s 5A Medium (GIBCO, 
Paisley, UK) enriched with glutamine (2mM), 10% foetal bovine serum and 1% 
Penicillin (5000 unit/ml), and streptomycin (5000 jug/ml) at 37°C in an atmosphere of 
5% 00%. After 48 hours, the medium was extracted, the cells were washed twice in 
10 mis of PBS, and the medium was replaced with 20 mis of fresh medium. Cells 
were cultured under standard conditions. The plastic wares were obtained from 
Marathan Ltd, London, UK.
2.2.3 Quantification and viability assessment
Prior to injection, cells were trypsinised, counted on haemocytometer and viability 
was assessed with Tryphan blue dye exclusion. Only cells with >90% viability were 
used for induction of cancer in vivo.
2.2.4 Passaging of cells
When the cells were 90% confluent they were passaged. The medium was extracted 
and the cells were washed twice in 10 mis of PBS. 2 mis of 0.25 % Trypsin-EDTA
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(Invitrogen, Carlsbad, G A, USA) was added to the flask and the cells were incubated 
at 37°C for 5 minutes. The flask was then shaken to release the cells, and it was 
confirmed with microscope. Then 5 mis of fresh medium containing serum was 
added to neutralise the trypsin. The cells were centrifuged at 900G for 5 minutes. 
The supernatant medium was discarded, and the pellets of cells were resuspended in 
10 mis of fresh medium. Two millilitres of the cell suspension was placed in each of 
75 cm^ flask and 18 mis of McCoy’s medium, enriched with foetal calf serum and 
antibiotics, was added.
2.2.5 Preparing for animal injection
Five flasks of 90% confluent cells were chosen and washed with 10 mis of PBS 
twice. Then they were trypsinised, neutralised and centrifuged at 900G for 5 minutes. 
The cells were resuspended in 10 mis of PBS (GIBCO, Paisley, UK). Cell counting 
was performed using a haemocytometer, which showed a counting of 500x10^ cells. 
The counting is accurate only between 30 and 300x10"^, so the sample was rediluted 
and recounted. 100 pi of the sample was taken and it was added to 100 pi of Tryphan 
Blue. Dead and live cells were counted. A final concentration of 12 mis of cells at 
5xlO^/ml of more than 95% viability was chosen, and 0.6 mis (3 x 1 0Vml cells in 
PBS) was injected subcutaneously into the flank of each nude mouse. In the early 
gene transfer model, 1 0  flasks full of cells were used at the same concentration.
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2.3 Animal model
The studies were conducted under a project licence (PPL70/5232, 15 October 2000) 
granted by the Home Office in accordance with the Animals (Scientific Procedures) 
Act 1986. A personal licence (PIL70/18595) was obtained from the Home Office, 
UK to carry out regulated procedures on living animals according to the Animals 
(Scientific procedures) Act 1986.
2.3.1 Animals
In the late gene transfer model, 13 male athymie M Fl nu/nu nude mice of 4-6 weeks 
age, each weighing between 25 - 30 grams, were used. The mice were bought from 
the Comparative Biology Unit, University College London, Hampstead campus, 
London. In the early gene transfer model 18 male nude mice were used. The 
particular strain lacked functioning T cells (cell mediated immunity) because it had 
no thymus, and there was no host/graft disease that could reject the tumour cells. 
Four animals were kept in each cage. The cages were clearly marked and animals 
were identified by making holes in their pinna with an ear punch.
The animals were grown and maintained under specific pathogen free conditions, 
using a laminar airflow rack, and had free access to sterilised food and autoclaved 
water. The cages were individually ventilated and the animals were provided with 
sterilized bedding. There were 12 hourly alternate light dark cycles, and only those 
wearing a gown and gloves were allowed into the room (restricted entry).
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Figure 2.10 Subcutaneous muscles o f a mouse. It shows the subcutaneous plane o f a mouse 
which has numerous skeletal muscles. (Reproduced from ‘A Colour Atlas o f Anatomy o f 
Small Laboratory Animals; Volume 2: Rat. Mouse. Hamster. Authors P.Popesko, V.Rajtova, 
J Horak, year 2003, published by Wolfe)
2.3.2 Tumour induction  
Late gene transfer model (LGTM)
Using disposable insulin syringes, nude mice were subcutaneously inoculated with 
0.6 ml of 5x10^ HT-29 cells per mouse in PBS, under light isofluorane anaesthesia. 
The animals were observed under Home Office (UK) regulations. On day 8 , 12 
animals showed palpable and visible tumours. The animals were divided into two 
groups (n=6 ), and they received either 150 pg of mammalian expression vector 
containing IGFBP-4 cDNA, or vector alone, in PBS by peritumoural injection. The 
thirteenth animal also developed a tumour at the middle of the second week. The 
animals were sacrificed on day 25.
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Early gene transfer model (EGTM)
The animals were randomly divided into 3 groups of 6  animals each. Group 1 
received just HT-29 cells alone in PBS, group 2 received a mixture of control 
plasmid and HT-29 cells, and group 3 received a mixture of HT-29 and plasmid 
containing IGFBP-4 cDNA. The procedure was carried out under light enfluorane 
general anaesthesia, and the cells/plasmid was injected into the flank subcutaneously 
with insulin syringes. Four animals were kept per cage and each cage was clearly 
marked. Animals in the cages were identified by ear punch. The animals were 
observed for their well being. The tumour size was measured at two time points. The 
experiment was terminated 4 weeks after tumour induction.
Figure 2.11 Subcutaneously induced tumours in a M F l nude mouse after inoculation with 
HT-29 cells, and the photograph was taken 2 % weeks after plasmid therapy. The tumour is 
seen as a pink lump.
2.3.3 Observation and tumour measurements
During the entire experimental period the animals were observed for their wellbeing. 
The observations include daily assessment for their activity, food and water intake.
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and their response to noise. The tumour sizes were measured in two dimensions with 
a digital vernier calliper, and the animals were weighed on a weekly basis.
2.3.4 Necropsy and tumour sampling
The experiment was terminated when the animals were moribund, or the tumour was 
>10% of body weight, and tumour tissues were harvested. The mice were killed by 
Schedule 1 method (cervical dislocation) and the tumours were dissected out, 
weighed, their sizes were measured and then divided into several portions for 
subsequent examination.
Tumour harvesting
Prior to tumour harvesting, cryovials, small universal containers and cork for frozen 
sections were clearly marked for identification. 1 0 % formalin, liquid nitrogen, 
isopentane and optimum cutting temperature compound (OCT) (VWR Ltd, 
Lutterworth, UK) were made available for tumour sampling.
Sample for histopathology
The tumours were cut longitudinally and one portion was fixed in 10% formalin 
for paraffin section.
Sample for frozen section
Frozen samples were prepared for immunostaining and TUNEL assay, by embedding 
the tissue in OCT compound and rapidly freezing them in pre-cooled isopentane 
(BDH, Lutterworth, UK). The frozen samples were stored at - 70°C.
Sample for Western blot
Uncrushed and snap frozen tumour samples were collected in special cryovials for 
Western blot, cooled in liquid nitrogen and stored at - 70°C.
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Serum
After sacrificing the animal by cervical dislocation, blood was collected by cardiac 
puncture with a 22 G needle attached to 5 ml syringe. The sample was centrifuged, 
the serum was separated and stored at -70°C. It was not possible to collect blood 
samples from all the animals (too little) and they hemolysed easily.
Muscle sample and sample for electron microscopy
Samples from skeletal muscle adjacent to the tumour were obtained for 
immunostaining. The tumour tissues were divided and ~1 mm^ samples, one from 
each of the quadrants of cancer tissue, were obtained and stored at 4°C in 
gluteraldehyde based solution for transmission electron microscopy.
2.4 Tumour histology
2.4.1 Macroscopy
The tumours were examined for any local invasion to skin and muscle, areas 
of haemorrhage or necrosis as well as local spread.
2.4.2 Haematoxylin and eosin (H&E) staining
The H&E staining was performed by Ms Maroc of the Pathology Department at the 
Hammersmith Hospital. After embedding the tissues in paraffin, consecutive 5 pm 
sections were cut and mounted on polysine slides (VWR International Ltd, 
Lutterworth, UK).
The sections were deparaffinised with 2 changes of xylene, 10 minutes each. This 
was followed by rehydration in 2 changes of absolute alcohol 5 minutes each, 95% 
alcohol for 2 minutes and 70% alcohol for 2 minutes. This procedure removed the 
xylene. Then the sections were washed briefly in distilled water to remove the 
aleohol. Nucleus was stained by incubating with Harris haematoxylin solution for 8
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minutes. Then the sections were washed in running tap water for 5 minutes. This was 
followed by incubating the sections in 1% acid alcohol for 30 seconds. The sections 
were washed with running tap water for 1 minute again, then blued in 0 .2 % ammonia 
water for 30 seconds to 1 minute, and washed in running tap water for 5 minutes. 
The slides were then rinsed in 95% alcohol, 10 dips.
The sections were counterstained with eosin Y solution for 30 seconds to 1 minute, 
and dehydrated through 95% alcohol, 2 changes o f absolute alcohol, 5 minutes each, 
then washed in 2 changes of xylene, 5 minutes each. Finally the slides were mounted 
with xylene based mounting medium. After staining with H&E, the tumour sections 
were assessed for cellular pleomorphism, gland formation, mucous production and 
necrosis.
2.4.3 Cell death scoring
The degree of cell death of the tumours was scored according to the method 
described previously by Takei et al [Sawaoka et al., 1998;Takei et al., 1990]. 
Necrosis found in the <1 %, 1-20 %, 21-40%, 41-60%, 61-80% and 81-100% of the 
region of interest was scored as 0, 1, 2, 3, 4 and 5, respectively [Sawaoka et al., 
1998;Takei et al., 1990].
2.4.4 Mitosis counting
During cellular proliferation, instead of nucleus, the chromosomes are visible as 
tangled, dark-staining threads. These are known as mitotic figures. If nuclear 
membrane is seen, it is not a mitotic figure. Mitosis (figure 2.12) reflects 
proliferation of tumour cells. So the mitotic figures were counted blindly on 10 
random high power fields (x 400) on each section which were stained with H&E
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[Mills et al., 2001]. Mitotic figures in anaphase through early telophase were 
included in the counting.
Interphase 
( § )  Prophase  
Metaphase  
( § 2 ^  Anaphase  
Telophase 
Interphase
Figure 2.12 showing the stages o f mitotic division which occurs in all mammalian cells 
except reproductive cells. It is a form o f asexual cell division. The numbers o f cells in 
mitosis is a measure o f cellular proliferation.
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2.5 Apoptosis assessment
2.5.1 TUNEL assay
Terminal deoxynucleotidyl transferase biotin-dUTP Nick End Labelling (TUNEL) 
assay was performed using Apotag-red kit (Serologicals Corporation, Temecula, CA, 
USA).
At the beginning of the experiment a few solutions were prepared. They included 
phosphate buffered saline (PBS), which was prepared by dissolving 5 tablets o f PBS 
(Sigma-Aldrich, Gillingham, UK) in 1 litre of deionised water, 5% formalin 
(prepared by diluting 10% formalin with an equal amount of PBS), ethanol-acetic 
acid mixture (prepared by adding 40 ml of ethanol to 20 ml o f acetic acid under 
hood), enzyme mixture (prepared by adding 42 pi of reaction buffer to 18 pi of TdT 
per slide) and stop wash buffer (prepared by adding 1 ml of stop wash buffer to 34 
ml of deionised water in a coplin jar). Finally, labelling rhodamine mix was prepared 
( 6 8  pi of blocking solution to be added to 62 pi of anti-digoxigenin rhodamine), 
mixed well and protected from light.
Method
Tumour sections were fixed in 5% formalin for 10 minutes at room temperature. 
Then they were washed in PBS twice, each wash for 5 minutes. This was followed 
by immersing them in pre-cooled ethanol: acetic acid mixture (2:1) for 5 minutes at - 
20°C in a coplin jar. The slides were not allowed to dry as this solvent permealises 
the cells. Then the slides were washed with PBS (2 changes of 5 minutes each) to 
remove these chemicals.
Next step was application of undiluted equilibration buffer directly to the specimen, 
and to incubate them for 10 minutes. The crucial step being application of TdT
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enzymes mixture and incubation in a humidified chamber for 1 hour at 37°C. Then 
the specimens were immersed in colpin jars containing stop wash buffer, agitated for 
15 seconds and incubated for 10 minutes at room temperature. The slides were 
washed with PBS (3 changes of 1 minute each), and anti-digoxigenin mixture 
(rhodamine) was applied and incubated in a humidified chamber at room temperature 
for 30 minutes. Exposure to light was avoided. Addition of DAPI in 1/1000 dilution 
was optional.
Finally, the slides were washed with PBS (4 changes of 2 minutes etc), protected 
from light and mounted using AF-1 (Citiflour, Leicester, UK) mounting media. Nail 
polish was used to fix the cover slip. The apoptosis was evaluated with a confocal 
microscope (Nikon, Kanagawa, Japan).
Figure 2.13 showing the Leica CM 3050 cutting machine that was used to cut the tissue 
section from frozen samples. The samples were fixed to a mount and cut to desired thickness 
at the temperature o f -20°C.
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Using the machine shown above (figure 2.13) 10 gm thick tumour sections were cut 
from frozen samples. Immediately after cutting, the sections were applied on 
polysine slides and stored at - 70°C, and used for all frozen immunostaining, 
including TUNEL assay. The slides were clearly marked with pencil/pen for 
identification, and two or three sections were applied per slide.
Figure 2.14 showing the Nikon con-focal/fluorescent microscope that was used to visualize 
tumour sections. {Key 1- Digital camera, 2 -  Fluorescence lamp, 3 -  Scanner camera, 4 -  
Platform for slides)
2.5.2 Quantification of the results
Apoptotic cells were identified by red fluorescence, and the counting was carried out 
blindly by two observers. For quantification of apoptosis, 10 random fields were
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chosen for each sample at x 200 magnification [Bruns et ah, 2000], and the average 
cell count was used. The apoptotic index was ealculated using the formula as 
described previously [Sawaoka et ah, 1998] (Apoptotic Index (%) = (apoptotic cells / 
total number of eells x 1 0 0 ) .
2.5.3 Electron microscopy
Transmission electron microscopy was performed to assess the ultra structure of 
cancer eells to confirm apoptosis and correlate them with those of TUNEL assay 
findings. The protocol for processing the tumour sample is mentioned in the 
appendix. Ultra thin tumour sections (60-90 nm) were viewed and photographed 
using a Philips CM 120 transmission electron microscope. It was performed by Mr 
Innis C lads worthy of Electron Microscopy at the Royal Free Hospital, London.
2.6 Assessment of Bcl-2 and Bax expression
Since the results of apoptotic index showed significant difference between control 
and BP-4 group tumours, the mechanism of apoptosis was assessed by measuring the 
Bax and Bel -2 proteins. Western blot was used for quantification of these proteins.
2.6.1 Western blot for Bcl-2 protein
Total protein from the tumour samples were quantified by modified Lowry protein 
assay (Pierce Biotechnology, Rockford, IL, USA).
Protein extraction
The tissue samples which were stored at -70°C were obtained and powdered by 
crushing them with the help of liquid nitrogen. Then 7 ml of preparatory buffer 
mixture (Table 2.5) was prepared in the following combination.
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Table 2.5 Composition of preparatory buffer for protein extraction
Contents Volume (pi)
Reporter Lysis Buffer (Promega) 1400
Proteinase Inhibitor 700
Phosphate Buffered Saline 4900
Five hundred microlitres of the buffer was added to each tumour sample and 
vortexed for 15 minutes. Then the samples were centrifuged for 5 minutes, and the 
supernatant solution was aliquoted in previously marked appendarf tubes (3 for each 
sample). The tubes were stored at -70°C.
Modified Lowry protein assay
This assay was performed in two steps. The first step was the preparation of standard 
dilutions of albumin, and the second step was quantification. Standard dilutions of 
bovine serum albumin (BSA) solutions were prepared in varying concentrations as 
follows (Table 2.6). One ml ampoule containing 2 mg of BSA, that was part of the 
kit, was used in the preparation of standard albumin dilutions.
Table 2.6 Standard dilutions of BSA
BSA
W
PBS (pi) Concentration (mg/pl)
0 2 0 0 0
0 2 0 0 0
8 192 0.08
16 184 0.16
24 176 0.24
32 168 0.32
40 160 0.40
80 1 2 0 0.80
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Phenol reagent (Lowry kit) was mixed with an equal amount of de-ionised water 
(100 g 1/sample). Tumour sample solutions were diluted 100 times (2 pi of sample to 
198 pi of PBS).
Procedure for protein quantification
Two hundred microlitres of sample solutions and varying dilutions of ESA were 
taken in appendarf tubes. At 15-second intervals, 1 ml of modified Lowry reagent 
was added to tumour samples, mixed well and incubated for 1 0  minutes at room 
temperature. 100 pi of prepared IX Folin-Ciocalteu reagent (Lowry kit) was added 
and vortexed to mix the contents. 15 seconds intervals between the tubes were 
maintained. All the tubes were incubated at room temperature for 30 minutes. With 
the spectrophotometer set to 750 nm, the instrument was zeroed with a cuvette filled 
only with PBS. Then the average 750 nm absorbance values o f the blank standard 
replicates was subtracted from the 750 nm absorbance values of all other individual 
standard, and unknown sample replicates. A standard curve of albumin was prepared 
by plotting the average blank-corrected 750 nm value for each BSA standard vs its 
concentration in pg/ml. Using the standard curve, the protein concentration of each 
unknown sample was determined.
100
/Figure 2.15 showing the Shmadzu UV -160 A - UV visible reading spectrophotometer. 
Sample is kept in 1 pi cuvettes inside the reader, and total protein is quantified using ultra 
violet rays.
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Figure 2.16 Standard curve that was prepared using albumin solution
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Table 2.7 Quantitative analysis for total proteins in tumours (LGTM)
No Absorption Concentration (pg/pl)
B1 1.074 55
B2 &839 42
B3 0.634 29
B4 0.565 25
B5 0.970 49
B6 1.035 53
M l 0,538 23
M2 0.479 19
M3 0798 40
M4 0.538 23
M5 0.408 15
M 6 0366 14
P 0.640 29
{Key: B1 -  6 = IGFBP-4 plasm id treated, M l-6  = control p lasm id treated, 
P  = control -  no plasm id given)
Western blot procedure
The procedure was the same for all Western blots that were performed in this project 
and only the primary antibody and running hours were different and they are 
described in appropriate places.
To begin with, a water bath was set at 95°C and run buffer-electrophoresis solution 
(Nupage buffer-MES SDS running buffer (20x), Invitrogen, Carlsbad, CA, USA) 
was prepared by adding 760 ml of deionised water to 40 ml of run buffer. About 50 
pg of protein from each sample in 10 pi of PBS was used for blotting. Initially 1 pg 
of protein in 10 pi of PBS was used, but there was no detectable protein in the 
polyvinylidine fluoride (PVDF) membrane. So, throughout the project 50 pg of 
protein was used. To these 10-pi samples, an equal volume of sample buffer 
(Laemmli, 2 x, Sigma-Aldrich Company Ltd, Gillingham, UK) was added and
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thoroughly mixed. The samples were then denatured by heating them at 95°C for 5 
minutes. Nupage - 12% Bis -Tris Gel (Invitrogen, Carlsbad, CA, USA) with 1.0 
mmxlO wells or 15 wells was used for electrophoresis. Samples plus marker (See 
Blue Plus 2 Pre-stained Standard (1%) (Invitrogen, USA) was used as a ladder. The 
power source for electrophoresis was set at 150 voltage for 2 gels (75 each) and 40 
mAmp for 2 gels (figure 2.17). The electrophoresis was run for 2 and 1/2 hours. 
Running time depended upon the size of the protein which needed to be isolated.
While the samples were running, transfer buffer, PVDF membrane, card boards and 
methanol were obtained. Nupage transfer buffer (2 0 x) (Invitrogen, USA) 10 ml was 
made up to 2 0 0  ml with deionised water for 2  gels, thick blotting cards, 2  for each 
gel, and 1 cellulose membrane for each gel (Immuno-Blot PVDF membrane. Bio­
rad, Hercules, CA, USA) were cut to the size of 8.5 x 7 . 5  cms and 20 ml of 100% 
methanol (VWR, Lutterworth, UK) was prepared.
Transfer of protein from the gel to the PVDF membrane was performed as follows. 
First the electrical power source was set at 25 volts (for any number o f gel) and 75 
amps for each gel for 45 minutes. The gel from electrophoresis was carefully isolated 
from the plastic case and immersed in the transfer buffer. The PVDF membrane was 
briefly immersed in methanol and it was followed by soaking them in transfer buffer. 
The transfer was done in a Bio-rad Transblot machine. PVDF membrane was applied 
on to a blotting card which was soaked in transfer buffer, and the gel was applied on 
the membrane. One or two blotting cards were applied on the gel and any trapped air 
in the sandwich was removed. Then electro blotting was performed. After transfer, 
the membrane was removed and soaked in ponceau solution to find out whether there
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was any protein. This solution will stain all proteins. The membrane was then 
washed with plenty of deionised water to remove the ponceau solution. This is an 
optional step.
The membrane was immersed in 1% gluteraldehyde which was prepared by adding 
1 ml of 50% solution (BDH, Lutterworth, UK) to 49 ml of deionised water. The 
membrane was incubated in 1% gluteraldehyde overnight in a cold room at 5°C.
The membrane was washed three times in deionised water, each wash for 5 minutes 
and blocked with freshly prepared 5% milk (Marvel semi-skimmed milk powder, 2.5 
gms in 50 ml of PBS). This was followed by incubating the membrane with rabbit 
polyclonal anti Bel-2 antibody (Santa-Cruz Biotechnology, Santa Cruz, CA, USA) at 
1/200 dilution (10 ml of 5% milk to 50 pi of antibody) for 2 hours 30 minutes. This 
was followed by three washes with PBS, for 5 min each, to remove any excess of 
antibody.
The membrane was incubated with goat anti -rabbit antibody horse radish peroxidase 
conjugate (Dakocytomation, Carpinteria, CA, USA) at 1/2000 dilution (5 pi of 
antibody to 10 ml of 5% milk), for 45 minutes. The membrane was washed with PBS 
three times, for 5 min each, and Super Signal West Dura Extended Duration 
Substrate (Pierce, Rockford, IE, UK), which was freshly prepared (by mixing 1:1 
solution peroxidase buffer to enhancer buffer) was applied and incubated for 5 
minutes. The excess was drained and the membrane was covered with a plastic bag 
and X-rayed (Fuji films, Kanagawa, Japan) for varying durations.
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Quantification o f Western blot result
The X-ray film was scanned in a Bio-rad scanner, and the image was analysed with 
Bio-rad densitometry analysis software for Windows 2003. The density in relation to 
volume was calculated by the software. The results were plotted in Prism 4 software 
for statistical analysis.
Figure 2.17 The power source and gel tank that were used for electrophoresis in Western 
blot. The gel is kept vertically in a plastic container containing m n buffer (shown on the 
left). The instrument on the right provides the desired voltage and current for electrophoresis.
Western blot for the early gene transfer model
In the second (early gene transfer) model the procedure for Western blot was the 
same as for the first experiment. At first, a standard albumin curve was plotted 
(figure 2.18).
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Figure 2.18 showing the standard albumin curve that was used for quantification o f proteins 
from tumour samples in the second (early gene transfer) model.
Tumour samples were crushed into powder and total protein was extracted from each 
sample. After plotting the albumin curve, total protein from each tumour sample was 
measured, as for the first experiment, with an UV spectrophotometer (Table 2.8). 
Total protein was again measured by modified Lowry assay.
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Table 2.8 Protein concentration in the tumour samples (EGTM)
Sample Absorption Concentration ( pg/pl)
PI 1.233 58A9
P2 &864 38.01
P3 0.794 34.11
P4 0 696 2&65
P5 0.674 27.44
P6 0.400 1 2 . 6 6
M l 0.725 30.29
M2 0 . 2 2 0 234
M3 0.245 3.63
M4 0.439 14.41
M5 0.410 12.81
M 6 &265 4.74
B1 0.264 4.66
B2 0348 937
B3 0.249 334
B4 0367 10.40
B5 0.342 933
B6 0.653 26.26
(Key: P l-6 : control tumours without plasm id treatment 
M l-6: tumours after control plasm id treatment 
B l-6: tumours after BP-4 plasm id treatment)
2.6.2 Western blot for Bax protein
The method is the same as for Western blot used in Bcl-2, except that rabbit primary 
polyclonal Bax antibody (Santa Cruz, USA) was used in 1/200 dilution.
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2.7 Assessment o f the IGF system
The effect of the IGFBP-4 gene therapy on components of the IGF system was 
assessed. They included IGFBP-4, IGF-I, MGF (variant o f IGF-I) and IGF-I 
receptor. Among these, IGF-I and MGF antibodies did not yield a good result, so the 
procedures for IGF-I and MGF staining were abandoned.
2.7.1 Western immunoblot for IGFBP-4
Here, primary rabbit anti-IGFBP-4 polyclonal antibody (Santa Cruz, USA) was used 
at 1/200 dilution. The remaining procedure was the same as for Bcl-2 described 
previously.
2.7.2 Immunostaining for IGFBP-4
Frozen tumour samples were cut into 10 pm thickness sections and 3 sections were 
applied per polysine slide (VWR International Ltd, Lutterworth, UK). They were 
marked and kept frozen at -70 C.
PBS was prepared by dissolving 5 tablets of PBS (Sigma-Aldrich, Gillingham, UK) 
in one litre of de-ionised water. The tumour sections were fixed with 5% formalin 
(10% formalin diluted with an equal amount of PBS) at 4°C for 10 minutes. The 
slides were washed with PBS containing 0.1% Bovine Serum Albumin (Sigma- 
Aldrich, Gillingham, UK) (prepared by adding 1 gram of BSA to 1 litre of PBS) - 
three times, each for 10 minutes. Then, circles were made around the sections with 
PAP-Pen (hydrophobic slide marker). The sections were blocked with 3% goat 
serum (Jackson Immunosearch, USA) in PBS for 30 minutes.
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The slides were dried without drying the sections. Primary rabbit antibody against 
human IGFBP-4 (anti IGFBP-4) was bought from Santa Cruz Biotechnology, USA. 
The primary antibody was tried in varying dilutions in 3% goat serum, namely 25, 
50, 100, 200 and 400 dilutions. The sections were incubated with this antibody in 
different dilutions overnight at 4°C. 1/50 dilution yielded the optimum result at the 
end which was subsequently used.
The sections were washed three times, for 10 minute each, with freshly prepared PBS 
containing 0.1 % BSA. Secondary antibody fluorescent conjugate (Goat IgG (H+L) -  
F (ab)’2 antibody, PARIS, France) was diluted in 1/50 and 1/100 using 3% goat 
serum in PBS. 1/100 yielded a better result. After the addition of secondary antibody 
the slides were incubated at room temperature for 1 hour.
The slides were washed with PBS 3 times, for 5 minutes each. Nucleus was 
counterstained with either DAPI (1/1000 dilution) or Propidium Iodide containing 
mounting media (Vectone, UK). Then an anti-fading agent AFl (Citiflour Ltd, 
Leicester, UK) was applied. A cover slip was mounted and fixed with nail polish. 
The slides were examined under a confocal microscope using fluorescent light and 
UV light for DAPI.
2.7.3 Western blot for IGF-IR
Primary rabbit polyclonal antibody (Santa Cruz, USA) was used in 1/200 dilution. 
The remaining steps were the same as for Bcl-2.
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2.8 Statistics
Statistical analysis was carried out using Excel (Microsoft Office 2000, USA) and 
Graph Pad (Prism 4 for Windows 2003 version, Graph Pad software, USA) on a 
Windows based computer. All results are expressed as mean±standard error of mean. 
The unpaired student ^-test was used for comparing two groups, and one way 
ANOVA was used for comparing three groups. Differences with 7^-value < 0.05 were 
considered significant.
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Chapter 3 Effect of IGFBP-4 gene therapy on tumour 
characteristics and IGF system expression
3.1 Introduction
Recent evidence has shown that the insulin-like growth factor (IGF) system is 
involved in normal mammalian cellular growth, as well as in the development of 
several cancers [Durai et al., 2006;Giovannucci, 2001]. The IGF system comprises of 
two ligands (IGF-I and IGF-II), two main IGF receptors (IGF-IR and IGF-IIR), six 
IGF-binding proteins (IGFBP-4) and proteases. Many colon cancer cell lines, 
including HT-29, show a dose dependent proliferation in response to IGF-I and 
IGF-II [Guo et al., 1992;Zarrilli et al., 1994]. Studies have shown that any condition 
that increases the level of free IGF, such as acromegaly, will also increases the risk 
of colon cancer. IGF-I receptor is involved in tumour growth, without which tumour 
growth is reduced [Adachi et al., 2002]. At any one time most IGF-I and -II  are 
bound to IGFBP, which modulate the bioavailability of the free IGF that induces cell 
growth. Among the IGFBPs, IGFBP-4 is secreted by almost all colon cancer cell 
lines, and it primarily functions as an inhibitory protein for colon cancer cells [Dai et 
al., 1997] by binding to both IGF-I and IGF-II with equal affinity [Zhou et a l, 2003] 
[Singh et al., 1994a]. No previous studies available to date to demonstrate the effect 
of IGFBP-4 overexpression on colon cancers in vivo. The aim of this chapter was to 
explore the effect of IGFBP-4 gene therapy on subcutaneously induced colon 
cancers. The parameters assessed include tumour characteristics, i.e., tumour volume 
and weight, cell death, mitotic figures, expressions of IGFBP-4 and IGF-IR and 
animal body weight.
I l l
3.2 M aterial and methods
Mammalian expression vector pcDNA 3 (Invitrogen, Carlsbad, CA, USA) containing 
light chain myosin enhancer was used in this study, in which IGFBP-4 cDNA was 
inserted between EcoRi and Kpnl restriction sites, downstream of cytomegalovirus 
promoter. Plasmid DNA isolation, multiplication and purification were performed 
using the Endo Free Plasmid Maxi Kit (Qiagen, Crawley, UK). The presence of the 
IGFBP-4 insert and its reading frame were confirmed by cutting the plasmid DNA 
with EcoRl and Kpnl restriction enzymes and sequencing (MWG, Ebersberg, 
Germany).
Human colon adenocarcinoma HT-29 cells were cultured in McCoy’s 5A medium 
enriched with glutamine (2 mM), 10% foetal calf serum and 1% penicillin and 
streptomycin at 3TC  in an atmosphere of 5% CO2 . Only cells with >90% viability, 
as determined by Tryphan blue exclusion, were used. A subcutaneous cancer model 
was established by inoculating with 3 x 10  ^ HT-29 cells in PBS per mouse under 
light enflurane general anaesthesia. The animals (n=6 each) also received plasmid 
(150 pg) containing lGFBP-4 cDNA (BP- 4 group), or plasmid of vector (control M), 
or just PBS (control P) at two different time periods, either on day 0 (early gene 
transfer model) or on day 8 (late gene transfer model). In the early gene transfer 
model, there were three groups (BP-4, control M and control P) and in the late gene 
transfer model, there were two groups (BP-4 and control M).
Four weeks after tumour induction, the animals were killed and tumour samples were 
obtained for histology and subsequent examination. Tumour volume (mm^) was 
calculated using the formula (the shortest diameter)  ^ x (the longest diameter) x 0.5
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[Sawaoka et al., 1998]. Full details of plasmid purification and confirmation of its 
sequence, culture of HT-29 cells, induction of tumour in animal model and tumour 
harvesting were described previously in chapter 2 under materials and methods.
3.3 Results
3.3.1 Tumour characteristics
All the animals developed subcutaneous tumour on day 10 of the experiment, in both 
early and late gene transfer models, following inoculation with HT-29 cells. The 
tumours were well localised without any visible métastasés. In the late gene transfer 
model (LGTM), the mean tumour volume was higher in the BP-4 group when 
compared with the control group, but it was not statistically significant (figure 3.1). 
Tumour weight was similar in both groups (not shown).
In the early gene transfer model (EGTM), both tumour weight and volume showed a 
reduction in animals which received plasmid treatment when compared to control P 
group tumours, although there was no statistical difference in the final tumour weight 
(1.70±0.17 vs 0.98±0.16 vs 1.19±0.25; control P vs control M vs BP-4; P= 0.06) 
(figure 3.2) or final tumour volume (2060.25±379.62 vs 829.99±194.81 vs 
1007.71±246.67; Control P vs Control M vs BP-4; P = 0.69) (figure 3.3) between 
control M and BP-4 group.
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Figure 3.1 Scatterplot showing volumes o f BP-4 and control group tumours (mm^) in the late gene transfer model up to 3 weeks following a single injection o f 
gene constructs with and without BP-4. Fig A represent tumours o f control group and Fig B represent tumours o f BP-4 group; week 1 = before plasmid 
treatment, week 2, 3 and 4 = 1 , 2  and 3 weeks after plasmid treatment. The above graph shows that the tumours slightly shrink in size from the second week 
onwards.
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3.3.2 Animal body weight
In the late gene transfer model, when the body weight of the animals were plotted 
over a period of time, it showed that the mice maintained their weight throughout the 
experimental period irrespective of the group, although the BP-4 group animals had a 
higher average body weight than the control group. Also, in the early gene transfer 
model, the average weight of all the animals remained the same throughout the 
experiment.
P = N S
Control-P Control-M BP-4
Figure 3.2 Comparison o f final tumour weights between the three groups in the early gene 
transfer model, 4 weeks after single administration o f saline (control P) or gene constructs 
with or without BP-4 (control M and BP-4 group respectively). Animals which received 
plasmid (BP-4 and control M) showed less tumour weight than those which received only 
PBS. Values are shown as mean±SEM  o f six animals in each group (Key: NS^non 
significant).
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Figure 3.3 Scatterplot showing tumour volumes o f three different groups in the early gene transfer group. Fig A represents control P tumours, Fig B 
represents BP-4 group and Fig C represents control M tumours. After plasmid therapy (Control M and BP-4) tumours showed a reduction in volume when 
compared to control P. (Key: control P - animals without any plasmid therapy, control M - animals which received control plasmid, BP-4 -anim als which 
received IGFBP-4 gene therapy).
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Figure 3.4 Comparison body weights o f nude mice in BP-4 treated and control group up to 3 
weeks following a single injection o f the gene constructs, with and without BP-4 (late gene 
transfer model). The values are depicted as mean mean±SD o f 6 animals in each group. The 
average weight o f animals in both control and BP-4 groups were maintained throughout the 
experiment.
U i
35-
30-
25-
20 -
15-
10 -
5-
0
F
0 25
Control- P
0 '  25
Control-M
0 25
BP-4
E x p e r i m e n t a l  d ay  and g r o u p
Figure 3.5 Comparison o f weights o f  nude mice (on day 0 and 25) showing no significant 
difference in the among the three groups (6 animals in each group) throughout the 
experiment in the early gene transfer model, in which animals received BP-4 gene or control 
plasmid or PBS on day ‘0 ’ (key: P  -  animals without p lasm id therapy, M  - animals which 
received control plasmid, BP-4 — animals which received IGFBP-4 gene)
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3.3.3 Tum our histology
In the late gene transfer model, the tumours were soft, and had a false capsule 
separating the tumours from the adjacent muscle, in both BP-4 and control groups. 
Occasionally, a small area of skin or muscle was attached to the tumour. 
Macroscopic examination showed no obvious areas of haemorrhage or necrosis in 
either the BP-4 treated or the control group. However, microscopic examination of 
H&E stained tumour sections showed increased areas of necrosis in the BP-4 group 
when compared with the control group. The BP-4 treated group showed a 
considerably higher cell death score when compared with control (2.33 ± 0.33 vs
1.33 ± 0.49) (figure 3.6) but the difference was not statistically significant (P=0.12).
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Figure 3.6 showing average cell death score in BP-4 and control group tumours o f the late 
gene transfer model up to 3 weeks following a single injection o f the gene constmct with and 
without BP-4. In this experiment a subcutaneous cancer was induced first in nude mice with 
HT-29 cancer cells and gene construct / control was administered as peri tumoral injection 
one week post tumour induction. Values are expressed as mean ± SEM o f 6 animals in each 
group. {Key NS^ not significant)
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Figure 3.7 Photomicrographs (xlOO) showing morphological changes after administration o f 
control plasmid (A) and plasmid vector with BP-4 insert (B) in subcutaneous tumours o f 
mouse induced with HT-29 in late gene transfer group. Large necrotic areas and loss o f 
intact cells are seen after the administration o f IGFBP-4 gene when compared with control. 
(N= areas o f cell death)
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In the early gene transfer model, the tumour morphology was similar to the late gene 
transfer model. There was an attempted glandular formation with areas of cell death. 
There was no local or distant spread of cancer. The mean area of cell death was 
significantly higher in BP-4 treated tumours, when compared with the other two 
control groups (2.20±0.22 vs 1.76±0.23 vs 0.66±0.14, BP-4 vs Control M vs Control 
P, P=0.0007). Figures 3.8, 3.9 and 3.10 show the representative histology of tumours 
after H&E staining in various groups, and figure 3.11 shows the cell death score.
Figure 3.8 Photomicrograph showing H&E staining o f subcutaneous tumour from BP-4 
group o f the early gene transfer model (xlOO). In this experiment a subcutaneous cancer was 
induced in nude mice with HT-29 cancer cells and gene construct / control was administered 
on day ‘0 ’ at the same time as tumour induction. Areas o f cavitation (arrow) and necrosis 
are present when compared to control groups which are shown on the next page.
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f p f i l
Figure 3.9 showing H&E staining o f subcutaneous tumours o f  nude mice from control M 
group o f the early gene transfer model (xlOO) which were treated with control plasmid on 
day 0. There are some areas o f cell death (arrow).
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T ^ im ir /= »  ^  i n  c V i i^ \ i7 iT ^ r r  U v f r T n  c f o i t ^ i n r r  c i i K r * n t o - n < 3 r M i c  fn rY -» /-M T rc  n n t rFigure 3.10 showing H&E staining o f subcutaneous tumours o f nude mice from control P 
group o f the early gene transfer model (xlOO) which did not receive any plasmid therapy. 
There is no obvious area o f cell death.
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Figure 3.11 Tumours o f  the early gene transfer model showing significantly higher cell death 
score in the BP-4 group compared to the control groups (P<0.01). All the animals received a 
single administration o f saline or gene construct with and without BP-4 along with colorectal 
cancer cells. Cell death score was calculated after H&E staining o f paraffin sections of 
tumour samples. Results are shown as mean±SEM  o f 6 animals in each group. {Key: P  -  
animals without plasm id therapy, M  - animals which received control plasmid, BP-4 -  
animals which received IGFBP-4 gene.)
3.3.4 Mitosis
In the late gene transfer model, the average numbers of mitotic figures were 
significantly higher in tumours of control group when compared with the BP-4 group 
(3.61± 0.27 vs 2.31± 0.32 Control vs BP-4, P=0.0067) (figure 3.12).
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Figure 3.12 Comparison of the average number of mitotie figures of subcutaneous tumours 
of the late gene transfer model per high power field (HPF) (400 magnification) between 
control and BP-4 groups (based on counting from 10 HPF). In this late gene transfer model, 
animals received gene constructs with or without IGFBP-4 cDNA on day 8 as peritumoral 
injection when tumours were palpable. Values are expressed as mean ± SEM of 6 animals 
each group, P< 0.01 control vs BP-4.
In the early gene transfer model, the effect on mitoses was similar to the late gene 
transfer model. The average numbers o f mitotic figures per field were lower in the 
BP-4 group tumours than the control group (2.03±Q.53 vs 3.13±0.99 vs 7.00±1.72, 
BP-4 vs Control M vs Control P, P=0.03) (figure 3.13).
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Figure 3.13 showing average numbers o f  mitotic figures per tumour section per field in the 
tumours o f the early gene transfer model in which the mice received gene construct with or 
without BP-4 or none at the same as tumour induction with HT-29 cells. Mitosis was 
calculated after H&E staining o f  paraffin sections o f  tumour sample. The average numbers 
o f mitotic figures were decreased after administration o f BP-4 gene when compared with 
control groups (P<0.05). Values are expressed as m ean ± SEM o f 6 animals in each group.
3.3.5 IGFBP-4 expression
Expression of IGFBP-4 by tumour tissues was detected by Western blot analysis 
(figure 3.14). In the late gene transfer model, densitometry analysis showed a 
statistically significant increase in the IGFBP-4 protein levels in the cancer tissue 
after BP-4 gene therapy when compared with the control group (15.70 ± 1.31 vs
11.61 ± 1.27, P<0.05 vs Control) (figure 3.15). On immunolocalization, the IGFBP-4 
was found both within the cancer cells and in the interstitial area. Within the cell, it 
was mainly localised in the cytoplasm. Animals that received the IGFBP-4 gene 
showed a higher expression of IGFBP-4 in the tumour, both in the cytoplasm and 
interstitium, when compared with the tumours of the control group. Two figures 
representing IGFBP-4 immunostaining are shown in the appendix.
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Figure 3.14 W estern blot showing IGFBP-4 expression by tumours o f the late gene transfer 
model in which the animals received gene constructs with or without IGFBP-4 cDNA as 
peritumoral on day 8 after induction o f subcutaneous cancers in nude mice. (Key: BP-4  -  
tumours receiving plasmid with BP-4 construct, control M  -  tumours receiving control 
plasmid therapy and Plain - tumours without any plasmid treatment)
c
3
!ûw.
<
0
*P<0.05
BP-4 Control
Figure 3.15 Quantification o f IGFBP-4 expression by densitometry analysis which showed a 
significant increase in expression o f IGFBP-4 after IGFBP-4 gene therapy (P<0.05 BP-4 vs 
control). (Key: BP-4 = IGFBP-4; C = Control; Plain = no treatment)
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Early gene transfer model 
IGFBP-4 expression
Western blot and densitometry analysis (figure 3.16) showed a decreased expression 
of IGFBP-4 by both BP-4 and control M group tumours, and an increased expression 
by Control P group (0.63±0.03 vs 0.75±0.09 vsl.04±0.06, BP-4 vs control M vs 
Control P, P=0.002).
Western blot for IGFBP-4
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Figure 3.16 Western blot for IGFBP-4 expression (a) and densitometry analysis (b) showing 
higher expression of IGFBP-4 by Control M than the other two groups (P<0.05). In this 
experiment subcutaneous cancers were induced in nude mice with HT-29 and gene 
constructs with or without BP-4 was administered at the same time (Key: control P  - tumours 
without any p lasm id  treatment, control M -  tumours receiving control p lasm id  therapy, BP-4 
- tumours receiving p lasm id  with BP-4 construct)
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3.3.6 IGF-IR expression (Late gene transfer model)
Western blot showed increased IGF-IR levels (5.08 ± 0.21 vs 3.73 ± 0.31; BP-4 vs 
Control; P<0.01) in the BP-4 group tumours compared with the control group (figure 
3.17).
Western blot for IGF-IR
180 kDa
Control M BP-4
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Figure 3.17 Western immunoblot for IGF-IR and densitometry analysis of tumours of the 
late gene transfer model in which animals received a single injection of gene constmct with 
and without BP-4. Values are shown as mean± SEM of 6 animals per group. BP-4 group 
tumours showed a higher average IGF-I receptor expression when compared with the control 
group tumours (P<0.05).
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3.4 D iscussion
Tumour volume and histology
In the late gene transfer model, the mean tumour volume of the BP-4 group was 
higher even before the plasmid administration, and it was maintained throughout the 
experiment. The mean weight of animals treated with BP-4 plasmid was also higher 
to begin with, and it was maintained throughout the experiment. Cell death score 
analysis showed that the cell death was higher in the tumours receiving BP-4 gene 
construct. This may mean that the number of dead cells (apoptotic and necrotic) 
which represent a significant part of the tumour volume, was not totally removed by 
the nude mice circulation because of lack of functional T lymphocytes. Tumour 
volume represents not only proliferating cells but also necrotic, apoptotic cells and 
tumour stroma.
In the early gene transfer model, both tumour volume and weight were less in 
animals that received plasmid treatment (BP-4 and control M) when compared with 
the control P group, although there was no difference between the BP-4 and control 
M groups. These results show that macroscopic parameters are not reliable indicators 
of the effects of gene transfer. Previous in vitro experiments have shown that IGFBP- 
4 inhibits proliferating and growth-promoting actions of the IGFs in both malignant 
and normal cells [Zhou et al., 2004;Singh et al., 1996;Singh et al., 1994a]. Results of 
our experiments support these findings. Histological examination of the IGFBP-4 
treated tumours, showed a higher cell death score and a lower mitotic count per field, 
in both early and late gene transfer models.
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Components of the IGF system
IGFBP-4 acts mainly by sequestering the IGFs and is a very important inhibitory 
binding protein of the IGF system. IGFBP-4 mRNA expression and secretion by 
various tissues are influenced by IGFBP protease [Byun et ah, 2000;Durham et ah, 
1995], nutrition [Hallberg et ah, 2000], trauma [Demori et ah, 2000], several growth 
factors and hormones [Sheikh et al., 1993]. The IGFBP-4 mRNA expression is not 
necessarily a good indicator of the amount of IGFBP-4 protein associated with the 
cells. Although several types of cancer cells express IGFBP-4 [Bostedt et al., 
2001;Ceda et al., 199I;Yi et al., 2001], and the role of IGFBP-4 has been widely 
studied in breast cancer, the results are controversial. In vitro and in vivo studies 
showed that overexpression of IGFBP-4 is inhibitory to many cancer cells [Singh et 
al., 1994a] [Damon et al., 1998]. However, there are exceptions, and reduced 
expression of lGFBP-4 may not increase cell growth in some cancers, for example, 
prostatic cancer [Drivdahl et al., 2001]. It has been shown that anti-sense inhibition 
of lGFBP-4 may confer growth advantage [Dai et al., 1997], while overexpression 
of lGFBP-4 may not be inhibitory to some colon cancer cells. To date, there are only 
two studies available in prostate cancer [Damon et al., 1998;Drivdahl et al., 2001] 
that have shown the effect of lGFBP-4 in vivo. Apart from the one study done by 
Damon et al, currently there is no in vivo evidence available to demonstrate that 
lGFBP-4 overexpression is inhibitory to cancers. In our experiment, the lGFBP-4 
protein expression of the tumour was clearly increased in the late gene transfer 
model. There was an associated increase in IGF-IR levels in BP-4 treated group 
tumours. However, lGFBP-4 was not increased in BP-4 treated tumours of the early 
gene transfer model, although skeletal muscles of BP-4 group showed an increased 
lGFBP-4 expression. These results indicate that pre-existing tumour may be a
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prerequisite for IGFBP-4 gene transfer, and there exists a feed back system, whereby 
the colon cancer cells increase the IGF-IR levels to overcome the decreasing levels 
of free IGFs.
In summary, we found that the IGFBP-4 gene therapy when delivered locally 
decreased mitosis and increased necrosis and apoptosis of subcutaneous cancer, 
although within the time period studied, the therapy did not significantly decrease the 
tumour volume. It was therefore important to know whether there had been any 
associated increase in apoptosis, and if so what was the mechanism. The next chapter 
will address these questions.
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Chapter 4 Effect of IGFBP-4 gene therapy on apoptosis of 
the cancer cells
4.1 Introduction
Apoptosis is influenced by various intracellular proteins and enzymes. Two 
important proteins which influence apoptosis are B-cell CLL/lymphoma 2 (Bcl-2), 
which is an anti-apoptotic protein, and Bcl-2-associated X protein (Bax) which 
promotes apoptosis. Bax exists in an inactive state in the cytoplasm of many cells. 
Secondary to various stimuli, Bax protein undergoes conformational changes, and 
translocates to mitochondrial membranes, where Bax releases cytochrome c [Guo et 
al., 2003]. Cytochrome c is normally found loosely associated with the inner 
membrane of the mitochondria. It catalyzes several reactions such as hydroxylation 
and aromatic oxidation and is an intermediary for apoptosis. Experiments show that 
an increase in the ratio of Bax/Bcl-2 proteins often proceeds apoptosis [Bianchi et al., 
2003;Giannakakou et al., 2001], and mutations of these genes are often associated 
with cancer [Meijerink et al., 1995;Ouyang et al., 1998;Ohtani et al., 2000]. IGFs are 
often overexpressed in cancers and are anti-apoptotic [Kang et al., 2003] in action. 
The IGFs influence the levels of Bax and Bcl-2 [Yamamura et al., 2001] and thereby 
influence apoptosis [Wang et al., 1998b]. IGF-I not only downregulate the Bax 
expression [Hong et al., 2001] but also prevent its translocation to mitochondria 
[Ness et al., 2004], inhibits the activation of caspase 3 [Linseman et al., 2002], and 
release of cytochrome c from the mitochondria [Linseman et al., 2002]. So when the 
IGFBP-4 is overexpressed the level of free IGF bioavailability decreases and one can 
expect them to increase apoptosis at least in the local tissues. The aim of this
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experimental work was to assess the effect of IGFBP-4 gene transfer on the 
apoptosis, Bax and Bcl-2 proteins expression.
4.2 Materials and methods
The animal model and tumour harvesting are described in chapter 2 under the section 
materials and methods as well as in the earlier chapter. Apoptosis was determined by 
terminal deoxynucleotidyl transferase-mediated dUDP nick end labelling (TUNEL) 
assay using Apotag-red kit (Serologicals corporation, Temecula, CA, USA) [Gavrieli 
et al., 1992] and transmission electron microscopy. Frozen sections (10 pm) of 
tumour samples were fixed with 5% formalin for 10 minutes at room temperature. 
Then they were washed with PBS followed by immersing them in pre-cooled ethanol 
: acetic acid (2:1) for 5 minutes at -20°C. The protocol recommended by the 
manufacturer was followed. TdT enzyme and anti-digoxigenin rhodamine were used 
and the slides were protected from light. Finally, the slides were washed with PBS 
and mounted using glycerol based media AF-1 (Citiflour, Leicester, UK). Confocal 
microscope (C l, Nikon, Kanagawa, Japan) was used for evaluating apoptosis. 
Apoptotic cells were identified by red fluorescence, and the counting was carried out 
blindly. For quantification of apoptosis, 10 random fields were chosen for each 
sample at x 200 magnification [Bruns et al., 2000], and the average cell count was 
used. The counting was carried out blindly by two observers (R Durai and W Yang). 
The Apoptotic Index was calculated using the formula as described previously 
[Sawaoka et al., 1998] (i.e. Apoptotic index (%) = Apoptotic cell number/Total cell 
number %100). The method of processing the tumour sections for electron 
microscopy was described previously. It was performed for the early gene transfer 
model only. The ultra thin sections (60-90 nm) were viewed and photographed using 
a Philips CM 120 transmission electron microscope.
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Bax and Bcl-2 levels were determined by Western blot. Rabbit anti-mouse Bel-2 
polyelonal antibody (Santa-Cruz Bioteehnology, Santa Cruz, CA, USA) or rabbit 
anti-mouse Bax polyclonal antibody (Santa-Cruz Biotechnology, USA) both at 1/200 
dilution were used, followed by incubation with secondary antibody conjugate with 
horse radish peroxidase (HRP) (Dako, Ely, UK) at 1/2000 dilution. The PVDF 
membrane that was used for electroblotting was illuminated with Super Signal West 
Dura Extended Duration Substrate (Pierce Biotechnology, Rockford, IE, USA), and 
exposed to X-ray film for 10 seconds (Fuji, Kanagawa, Japan).
4.3 Results
4.3.1 Apoptosis quantification by TUNEL assay
In the late gene transfer model, apoptotic cells were deteeted in considerable 
numbers in a diffusely scattered manner throughout the tumour tissue, in those 
animals which received the IGFBP-4 gene. The tumours of animals in the control 
group (figure 4.1 b) showed fewer apoptotie eells when compared to tumours of 
those animals treated with IGFBP-4 plasmid (figure 4.1a). Apoptotic Index was 
significantly higher in tumours of the BP-4 group than control (36.67 ± 7.36 vs 7.07 
± 1.91, BP-4 vs control; P = 0.003) (figure 4.3).
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Figure 4.1 Representative photomicrographs showing apoptotic cells in BP-4 (a) and control 
(b) group tumours o f  the late gene transfer model, in which animals received a single dose of 
gene construct with or without IGFBP-4 as peritumoural injection on day 8 after the 
development o f subcutaneous tumours. Apoptotic cells were detected by red fluorescence 
and nuclear morphology (arrow) (x 200).
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Figure 4.2 Photomicrograph showing fewer numbers o f apoptotic cells o f control P group 
tumours o f the late gene transfer model (where animals have not received any plasmid) when 
compared to the other two group tumours (x 200).
P<0.01
BP-4
- I — .-
Control
Figure 4.3 Comparison o f apoptotic index (average apoptotic cells per 100 tumour cells per 
field) between BP-4 and control group tumours o f the late gene transfer model, in which the 
animals received gene construct with or without IGFBP-4 gene as peritumoural injection on 
day 8. Values are expressed as mean ± SEM, 6 animals in each group, P< 0.01 BP-4 vs 
control.
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In the preventive (early gene transfer) model, TUNEL staining showed higher 
numbers of apoptotic cells in tumours of BP-4 group than control group (figures 4.4 
and 4.5). Apoptotic Index is plotted in figure 4.6. It shows that the BP-4 group 
tumours have higher numbers of apoptotic cells for every 100 cells (11.47± 1.51 vs 
3.59±0.17 vs 4 .47±0.55, BP-4 vs Control M vs Control P, P=0.0002).
Figure 4.4 TUNEL assay showing numerous apoptotic cells (x200) in tumours o f BP-4 
group o f the early gene transfer model in which animals received gene construct containing 
IGFBP-4 gene, on day 0, at the same time as tumour induction. Apoptotic cells are 
identifiable by red immunofluorescence.
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BFigure 4.5 TUNEL assay showing a very few scattered apoptotic cells in tumours o f  Control 
M (A) and Control P (B) groups o f the early gene transfer (x200), in which animals received 
either control plasmid or just PBS on day 0, along with colon cancer eells. Apoptotie cells 
are seen as red immunofluorescence (arrow).
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Figure 4.6 Comparison o f apoptotic indices o f early gene transfer model tumours among the 
three groups in which animals received gene construct with or without IGFBP-4 or none. 
BP-4 group tumours showed a higher apoptotic index than control groups. Values are shown 
as mean±SEM  o f 6 animals in each group. Standard error bar is shown. There was a 
statistical significant difference in the index between the BP-4 treated tumours and the two 
control group tumours.
4.3.2 Apoptosis assessment by electron microscopy
Electron microscopy was performed only for the preventive (early gene transfer) 
model. Apoptotic cells were confirmed by scanning the tumour sections with 
transmission electron microscopy (Figures 4.7 to 4.11). This method showed a higher 
numbers of cells undergoing apoptosis in BP-4 group tumours, while a less numbers 
of such cells were noted in the control group tumours.
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Figure 4.7 Transmission electron microscopic imaging a) low power (x710) b) high power 
(X11500) showing apoptotic cells which are seen as apoptotic bodies (arrow) with shrunken 
nucleus and condensed cytoplasm in BP-4 treated subcutaneous tumours o f the early gene 
transfer model, in which animals received gene construct containing IGFBP-4 on day 0, at
the same time as tumour induction.
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Features typical of apoptosis include compaction and segregation of the condensed 
chromatin, that adjoins the inner surface of the nuclear membrane, condensation of 
the cytoplasm, and in the late stage of apoptosis chromatin fragments will be highly 
condensed.
Fig 4.8 Electron m icroscopy (x 14400) showing apoptotic cells with dense masses o f 
chromatin, against nuclear membrane in BP-4 group tumours o f early gene transfer model in 
which nude mice received one dose o f gene constm ct containing BP-4 at the same time as 
tumour induction.
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Figure 4.9 Electron microscopy (a) low power (X 710) (b) high power (x 11500) showing 
colon cancer cells and necrotic cell. These figures belong to control P group tumours o f  the 
early gene transfer model, in which animals received animals received no gene therapy.
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Figure 4.10 Electron microscopic images o f control group M (a) (x 710) (b) (x 14400) 
tumours o f the early gene transfer model in which the animals received one dose o f  control 
plasmid on day ‘0 ’ at the same time as subcutaneous tum our induction in nude mice. These 
figures show both necrosis and apoptosis. In figure b, an apoptotic cell is seen in the centre 
o f the field with a condensed nucleus (arrow) (Key; N = Necrosis A = Apoptosis)
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Figure 4.11 Electron microscopic image (x7100) showing both necrotic and apoptotic cells 
in Control M group tumours o f  the early gene transfer model, which were treated with one 
injection o f control plasmid. Apoptosis is recognised by a condensed dark nucleus (arrow).
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4.3.3 Effect o f IG FBP-4 gene transfer on Bax and Bcl-2 proteins
In the late gene transfer model, Western blot densitometry analysis showed that the 
lGFBP-4 gene therapy significantly increased the expression of Bax (8.58 ± 1.55, 
5.18 ± 0.37, BP-4 vs Control, P<0.05) (figure 4.13 )and decreased the expression of 
Bcl-2 (10.81 ± 1.30, 12.27 ± 2.91, BP-4 vs Control, P=Not significant) in tumour 
tissues (figure 4.12).
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Figure 4.12 W estern Blot and densitometry analysis o f tumours o f the late gene transfer 
model showing lower Bcl-2 expression by BP-4 group than control. Animals received one 
peritumoural injection o f gene construct with or without lGFBP-4 on day 8, following 
induction o f subcutaneous cancer. The values were shown as mean±SEM  o f 6 animals in 
each group. (Key: B l-  B6 represents BP-4 group and 1-M 6 represents control group. P  
represents tumours without any treatment. NS -- non significant).
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Figure 4.13 Western Blot and densitometry analysis o f tumours o f the late gene transfer 
model for Bax protein, showing significantly higher expression by BP-4 group than control. 
In this model, animals received one peritumoral injection o f gene construct with or without 
IGFBP-4 on day 8, following induction o f subcutaneous colon cancer. Results were 
expressed as mean±SEM o f 6 animals per group.
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Early gene transfer (Preventive) model
In the early gene transfer model, the mean Bel-2 expression was higher (2.27±0.65 
vs 1.01±0.25 vs 6.06±1.77, Control P vs Control M vs BP-4, P<0.01) in BP-4 treated 
tumours when compared with the control group. The Bax protein expression was also 
increased in BP-4 treated tumours after early gene therapy (3.37±1.15 vs 4.11 ±1.30 
vs 6.31±1.16; Control P vs Control M vs BP-4; P=0.2357) similar to the late gene 
transfer model.
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P < 0 . 0 5 Figure 4.14 Western blot and densitometry analysis o f tumours o f early 
gene transfer model in which the animals received gene construct with or 
without IGFBP-4 or none, on day 0 at the same time as colon cancer 
induction, showed a higher expression o f Bcl-2 by BP-4 group compared 
to Control P and M. Values are shown as mean ±SEM of 6 animals in 
each group.
Control P Control M BP-4
147
W estern  b lot for B ax protein
Control MControl P
23 kDa
P=NS
ro 5.0
5  2.5
Figure 4.15 Western blot (a) and analysis by densitometry 
software (b) o f subcutaneous tumours o f early gene transfer 
model, in which animals received either plasmid with or without 
IGFBP-4 gene or none on day 0, at the same time when colon 
cancer was induced. BP-4 group tumours showed a higher 
expression of Bax protein when compared with control groups P 
and M. Values are shown as mean±SEM of 6 animals in each 
group. {NS-not significant)
Control P Control M BP-4
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4.4 D iscussion
The word ‘Apoptosis’ is derived from the Greek language meaning shredding of 
leaves. It is a form of programmed cell death that eliminates compromised or 
superfluous cells and is distinct from accidental cell death (necrosis). Apoptosis 
involves an autolytic cascade in the target cell with DNA fragmentation preceding 
cell lysis. TUNEL assay provides a reliable method to stain and visualise apoptotic 
cells. Previous in vitro experiments have shown that IGFBP-4 inhibits proliferating 
and growth-promoting actions of IGFs in both malignant and normal cells [Zhou et 
al., 2004;Singh et al., 1996;Singh et al., 1994a]. Apoptosis is an active energy- 
dependent process [Chen and Istfan, 2000]. It is observed in several conditions such 
as hormone-dependent involution of prostate and endometrium, certain viral illness, 
parenchymal atrophy after duct obstruction and in cancers after chemotherapy and 
ionizing radiation [Yu et al., 2004;Stanley Robbins et al., 1995]. During apoptosis 
cells shrink in their size and there is condensation of chromatin resulting in the 
formation of apoptotic bodies [Stanley Robbins et al., 1995]. It is characterised by 
extensive DNA fragmentation [Rojo and Gonzalez, 1998] with no accompanying 
inflammation. In contrast to this, necrosis results in cellular swelling and there is 
inflammatory response. IGFs, by their anti-apoptotic action [Nickerson et al., 1997], 
prolong cell survival. In theory, any binding protein that reduces the levels of IGFs 
should favour apoptosis. Studies have shown that both IGFBP-3 and IGFBP-6 can 
mediate apoptosis in Caco-2 [Saksena M, 2002] and neuroblastoma [Grellier et al., 
2002] respectively. IGFBP-4 excess inhibits cell proliferation and stimulates 
apoptosis in lymphoid tissues [Zhou et al., 2004]. It has been shown that the 
apoptotic effect of TGF-pi in bovine mammary epithelial cells is mediated by
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IGFBP-4 [Gajewska and Motyl, 2004;Zhou et al., 2004]. It has been suggested that 
IGFBP-4 may act by altering Bel-2 and Bax levels [Chen and Istfan, 2001;Yu et al.,
2004]. Mitochondria play an important role in the regulation of cell death. Bcl-2 
family anti-apoptotie proteins are located in the outer mitochondrial membrane and 
promote cell survival. Mitochondria also have the ability to promote apoptosis by 
releasing cytochrome c, which in turn can activate caspase-9. Caspases are cysteine 
proteases that exist within the cell as inactive pro-forms or zymogens. These 
zymogens can be cleaved to form active enzymes during apoptosis. Caspase-3 and 
easpase-6 are responsible for the cleavage of the key cellular proteins that leads to 
the typical morphological changes that occur inside the cells during apoptosis.
Evidence has shown that IGFBP-4 increases apoptosis in prostate cancer cells in 
response to induction by 6-hydroxyurea compared with the controls [Damon et al.,
1998]. The present study, for the first time, presents an evidence that the IGFBP-4 
increases apoptosis in colon cancer cells, which was confirmed by TUNEL staining 
and electron microscopy. The increase in apoptosis induced by IGFBP-4 in colon 
cancer is also in line with the studies on prostate and ovarian cancers, both of which 
suggested that the IGFBP-4 played a role as a signal for apoptosis and it was 
overexpressed in involuting prostate by mediating apoptosis [Thomas et al., 
2000;Bruyninx et al., 2000]. Although the actual mechanism of apoptosis remains to 
be explored, it can be assumed that it is either the local binding of IGF or an IGF- 
independent mechanism that mediates apoptosis. Experiments show that IGF-I 
protects HT-29 cells from apoptosis [Remacle-Bonnet et al., 2000] and blockade of 
IGF-IR increases apoptosis in the same cells [Reinmuth et al., 2002b]. In this study, 
the average numbers of mitotic figures, which reflect the proliferative action of IGFs, 
were significantly decreased after IGFBP-4 gene therapy. These provide indirect
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evidences for an IGF-dependent apoptotic and anti-mitotic actions of IGFBP-4. 
Although it is evident that cell death could occur in the centre of any fast growing 
tumour due to relative hypoxia, here in BP-4 treated animals the cell death was also 
found in the periphery of the tumour.
Results o f Western blot of our experiment showed that there was an increase in the 
expression of Bax protein in IGFBP-4 treated tumours when compared to the control 
group in both early and late gene transfer models. However, Bcl-2 was decreased in 
BP-4 treated tumours only in the late gene transfer group. The early gene transfer 
group tumours did not show such a decrease after BP-4 gene therapy. Our hypothesis 
of the mechanism of IGFBP-4 affecting the apoptosis in tumour is summarised in 
figure 4.16. The IGFBP-4 acts possibly via IGF-IR and influences Bax and possibly 
Bcl-2 proteins. In the cancer cells, Bax and Bcl-2 proteins act on caspases which 
trigger the apoptosis. Bax and Bcl-2 proteins show structural similarities with pore- 
forming proteins [Desagher and Martinou, 2000]. It has been suggested that Bax can 
form a transmembrane pore across the outer mitochondrial membrane, leading to loss 
of membrane potential and efflux of cytochrome c and the apoptosis inducing factor. 
It is thought that Bcl-2 can prevent this pore formation [Desagher and Martinou,
2000]. The hallmark of apoptosis is the cleavage of chromosomal DNA into 
nucleosomal units which is mediated by an enzyme caspase activated DNase. 
Normally, when IGF-I binds to IGF-IR, it activates phosphoinositide 3-kinase 
(PI3K), promotes cell proliferation by activating the protein kinase, and blocks 
apoptosis by inducing the phosphorylation and inhibition of proapoptotic proteins 
[Galvan et al., 2003]. This mechanism is possibly inhibited by IGFBP-4 which 
reduces the local tissue availability of free IGF-I. IGF-IR may influence apoptosis by
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acting on E-cadherin, a epithelial adhesion molecule [Mauro and Surmacz, 2004].
Evidence show that down-regulation o f E-cadherin is associated with the
dedifferentiation, progression, and metastasis of colorectal cancer [Dorudi et ah, 
1993].
IGFBP-4 and apoptosis
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Figure 4,16 The possible molecular mechanisms o f apoptosis mediated by IGFBP-4. The 
IGFBP-4 binds IGF-I and decreases its hioavailability to IGF-IR which in turn influences the
levels o f  Bax and Bcl-2 proteins. The balance between these proteins is ultimately
responsible for caspase mediated apoptosis.
This study showed that local treatment of IGFBP-4 gene therapy resulted in an 
increase in apoptosis of colon cancer in vivo. There was an associated increase in 
Bax protein suggesting that it could be the mechanism of apoptosis.
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Chapter 5 General discussion and summary
The purpose of this chapter is to examine the rationale of the methods chosen to 
investigate the hypothesis of this work. Furthermore, the results and their 
significance in the context of reported literature are discussed.
Rationale for central hypothesis
Data from previous work has shown that malignant colonic tissue expresses reduced 
amounts of IGFBP-4 when compared with adjacent, non malignant colonic mucosa. 
This protein reduces tissue availability of key growth factors implicated in the 
proliferation of cancer cells. The hypothesis of this work is that, using gene therapy 
to increase local IGFBP-4 expression may inhibit tumour growth by disrupting 
positive feed back growth cycles (figure 5.3).
Rationale for choice o f cancer model
A subcutaneous nude mouse cancer model was chosen over an orthotopic colon 
cancer model as the former allows for easier surveillance of tumour development and 
response. HT-29 cells were chosen because they are widely used, readily available 
and easy to culture.
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Rationale for choice o f gene therapy over administration offree IGFBP-4 protein 
or anti-IGF-IR
Arguably, IGF-IR activitiy could be curtailed by administration of either free 
IGFBP-4 or Anti-IGF-IR. In the first case, free IGFBP-4 would bind IGFs and 
reduce the amount of growth factor available to the IGF-IR. Anti-IGF-IR is a 
monoclonal antibody that binds to IGF-IR. Administration of this antibody would 
similarly reduce the amount of IGF-IR available to IGFs to bind to.
However, use of products which require systemic administration is dis-advantageous 
in a number of respects. Firstly, serum proteases are known to degrade free IGFBP-4 
protein in vivo, thereby reducing half-life and bio-availability. Furthermore, delivery 
of the protein is difficult: daily injections around the tumour site are impractical; 
technology allowing tissue delivery via an implanated mini osmotic pump [Fowlkes 
et al., 2006] has not been used in humans to date. Commercially available IGFB-4 
protein is considerably more costly than native expressed protein produced by gene 
transfer, and anti-IGF-IR is costly too. Finally, a proportion of the delivered protein 
or antibody will be taken up systemically and cause unwanted, non-localised 
inhibition of IGF-IR with associated untoward effect.
The ability to deliver plasmid containing IGFBP-4 cDNA via the method used in this 
work -  i.e. single peri-tumoral injection -  has the potential to allow clinical treatment 
of colon cancers accessed during colonoscopy or sigmoidoscopy.
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Rationale for non-viral (plasmid) vector over viral vector
Viral vectors have a better gene transfer rate but they may bave unwanted 
consequences as they are prone to bost-mediated immune destruction once 
recognised as non-self. Plasmid mediated gene therapy is associated with less 
antigmic stimulus [Lecbardeur et al., 2005].Viral vectors are inefficient at 
transferring big transgenes [Reid et al., 2001;Kreiss et al., 1999] and may mutate. 
Plasmids are not associated with these problems, but do not self replicate except 
during normal cell division.
Rationale for development o f two models -early and late
The first model (late gene transfer) was performed to assess the therapeutic effect of 
IGFBP-4. This effect will be useful in clinical settings such as locally advanced 
cancers, in which a patient needs palliation. The early gene transfer (Preventive) 
model may provide insight into the role of IGFBP-4 in the early stage of cancer 
establishment and growth. Comparison of both models may provide a better 
understanding of the role of IGFBP-4 in colon cancer in vivo rather than the single 
gene transfer model.
Plasmid therapy -mechanisms and effects
After administration of plasmid a proportion is taken up by proliferating colon cancer 
cells. The fate of the remaining portion is unknown, but presumumably lymphatic 
capillary clearance occurs. Adjacent tissues, such as muscle, may also clear some of 
this load.
Possible mechanism of entry o f plasmid DNA into cells include a) large membrane 
disruption, (b) small membrane pores, and (c) receptor-mediated endocytosis
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[Budker et al., 2000]. Experiments show that the major route for plasmid DNA 
nuclear entry is by passive nuclear importation during mitosis when the nuclear 
membrane temporarily breaks down [Grosse et al., 2006]. Following endocytosis of 
plasmid DNA, a large fraction of the DNA is ingested by lysosomes; it is degradation 
of plasmid DNA in these endo-lysosomes that constitutes one of the major 
impediments to efficient gene transfer. Plasmid DNA that escapes the endo- 
lysosomal compartment encounters the diffusional and metabolic barriers of the 
cytoplasm, greatly reducing the number of intact plasmids that reach the nucleosol. 
Nuclear translocation of DNA requires either the disassembly of the nuclear 
envelope or active nuclear transport via the nuclear pore complex [Lecbardeur et al.,
2005] . Little is understood about the fate of plasmid DNA after it reaches the 
nucleus [Li and Huang, 2000].
There are two potential mechanisms by which IGFBP-4 DNA is transcripted. Firstly, 
the plasmid cDNA may integrate into the DNA of the proliferating colon cancer cell 
DNA and multiplies as the native cell DNA replicates with cell division. This DNA 
produces IGFBP-4 protein by the usual mechanisms of transcription and translation. 
The second way in which IGFBP-4 is produced is by direct transcription of the 
plasmid cDNA independent of the host DNA. Figure 5.1 shows the possible 
mechanism of multiplication IGFBP-4 cDNA. Whichever mechanism is responsible, 
plasmid uptake appears to be improved when large volumes of plasmid DNA are 
administered. Rapid injection of plasmid DNA in a large volume (1.5 to 3.0 ml) 
through the portal or tail vein ean give rise to high level gene expression in mice, 
particularly in the liver [Liu et al., 1999]. Reporter gene technology has been used to 
quantify plasmid uptake and subsequent efficieny of cDNA transcription [Liu et al.,
1999].
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Similarities between human and mouse IGF system
IGF-I is synthesised as a prohormone in the liver consisting of chains A, B, C, D and 
E. The mature protein has no E chain. IGF-I is 100% identical in human, pig and 
sheep. Human IGF-I closely resembles that of rats and mice, however 3 aminoacids 
in rats and 4 aminoacids in mice are different [Daughaday and Rotwein, 1989]. The 
human 1GFBP4 gene is located on chromosome 17 [Allander et a l, 1993] and spans 
about 15 3 kb [Zazzi et al., 1998]. According to the mouse genome sequence 
determined so far, the mouse lGFBP-4 gene spans 11 3 kb on chromosome 11 
(http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=16010). Human lGFBP-4 
cDNA encodes a 258 amino acid (aa) residue precursor protein which will generate 
the 237 aa mature human lGFBP-4. The human lGFBP-4 shares approximately 90% 
amino acid sequence identity with both rats and mice lGFBP-4 
(http://marvester.embl.de/marvester/P478/P47879.html).
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Figure 5.1 Showing proposed mechanism o f integration and multiplication o f IGFBP-4 DNA. The IGFBP-4 cDNA gets integrated with 
colon cancer cell DNA and multiplies along with them. Then it will result in increased mRNA levels which will be translated into 
IGFBP-4 protein.
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Figure 5.2 showing the cellular sequence o f protein 
synthesis from IGFBP-4 gene. The DNA forms a 
messenger RNA (mRNA) which becomes 
translated into a polypeptide via tRNA. The 
polypeptide folds on itself to become protein.
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Figure 5.3 show ing diagram m atic representation o f  feedback loop o f  IG FB P-4 acting on the cells which secrete them. The IG FBP-4 binds to IGFs and 
disrupts the feedback m echanism . IGF is required for cellular grow th and proliferation. W hen there is less free IGF, cells can increase its sensitivity by 
increasing the num bers o f  IG F-IR  expression.
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The effect o f  IGFBP-4 gene transfer on apoptosis
Histopathological examination showed increased areas of cell death and fewer 
mitotic figures in tumours of BP-4 group when compared to control, in both early 
and late gene transfer models. TUNEL assay and electron microscopy both 
confirmed these dead cells as apoptotic cells. The apoptotic index of tumours of BP- 
4 group was significantly higher than control in both early and late gene transfer 
models. Apoptosis is influenced by various intracellular proteins and enzymes. IGF-I 
not only down-regulates the Bax expression [Hong et al., 2001] but also prevents its 
translocation to the mitochondria [Ness et al., 2004], inhibits the activation of 
caspase c [Linseman et al., 2002] and release of cytochrome 3 from the mitochondria 
[Linseman et al., 2002]. A fine balance between Bax and Bcl-2 proteins often 
determines the apoptotic process [Brambilla et al., 2003;Dai et al., 2000;Labat- 
Moleur et al., 1999]. Experiments show that an increase in the ratio of Bax/Bcl-2 
proteins often precedes apoptosis [Bianehi et al., 2003;Giannakakou et al., 2001]. 
Insulin-like growth factors influence the levels of Bax and Bcl-2 [Yamamura et al.,
2001] and thereby influence apoptosis [Wang et al., 1998b]. In our experiment, 
analysis of Bcl-2 and Bax expression showed higher expression of Bax by BP-4 
group tumours than the control groups. Bcl-2 results could not be correlated to 
apoptosis. The increase in Bax by both models, and a decrease in Bcl-2 in the late 
gene transfer model, supports the findings that the cellular deaths are due to 
apoptosis rather than necrosis. The Bax/Bcl-2 proteins influence the caspases, which 
in turn affect the endonucleases.
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Effect on IGFBP-4 expression
In the late gene transfer model, the IGFBP-4 expression was significantly higher in 
tumours o f the BP-4 group when compared with the control group. However in the 
early gene transfer (Preventive) model, the expression of IGFBP-4 was higher in 
control P group tumours than the other two groups (BP-4 and control M). It indicates 
that the IGFBP-4 might have been used up by the tumour, or prior establishment of 
tumour may be a pre-requisite for IGFBP-4 expression. Another possible explanation 
is tumour cells, when deprived of IGF-I for a long time may be unable to produce 
IGFBP-4.
IGFBP-4 Protein formation from IGFBP-4 gene
Protein is formed inside the cell in two steps. The first step is the formation of 
mRNA from DNA (Transcription). The mRNA has 4 bases, but uracil will replace 
thymine of DNA. The next step is translation, in which the ribosomes read the 
mRNA and translate it into aminoacid sequence.
Before the synthesis of a protein begins, the corresponding RNA molecule is 
produced by RNA transcription. One strand of the DNA double helix is used as a 
template by the RNA polymerase to synthesize a messenger RNA (mRNA). This 
mRNA migrates from the nucleus to the cytoplasm. During this step, mRNA goes 
through different types of maturation including one called splicing when the non­
coding sequences are eliminated. The coding mRNA sequence can be described as a 
unit of three nucleotides called a codon.
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Protein translation involves the transfer of information from the mRNA into a 
peptide, composed of amino acids. This process is mediated by the ribosome, with 
the adaptation of the RNA sequence into amino acids mediated by transfer RNA. 
There are > 20 different tRNA molecules. Numerous initiation and elongation factors 
also play a role. Translation requires a lot of energy, with the hydrolysis of 
approximately 4 N T P ^  NDP per amino acid added. Translation involves 3 
processes: initiation, elongation, and termination.
The ribosome binds to the mRNA at the start codon (AUG) that is recognized only 
by the initiator tRNA. The ribosome proceeds to the elongation phase of protein 
synthesis. During this stage, complexes, composed of an amino acid linked to tRNA, 
sequentially bind to the appropriate codon in mRNA by forming complementary base 
pairs with the tRNA anti-codon. The ribosome moves from codon to codon along the 
mRNA. Amino acids are added one by one, translated into polypeptide sequences 
dictated by DNA and represented by mRNA. At the end, a release factor binds to the 
stop codon, terminating translation and releasing the complete polypeptide from the 
ribosome.
The events following biosynthesis include post-translational modification and protein 
folding. During and after synthesis, polypeptide chains often fold to assume, so 
called, native secondary and tertiary structures. This is known as protein folding.
Many proteins undergo post-translational modification. This may include the 
formation of disulfide bridges or attachment of any of a number of biochemical 
functional groups, such as acetate, phosphate, various lipids and carbohydrates.
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Enzymes may also remove one or more amino acids from the leading (amino) end of 
the polypeptide chain, leaving a protein consisting of two polypeptide chains 
connected by disulfide bonds.
The IGF system and colorectal carcinogenesis
The IGF system itself is complex and it plays an important role in all stages of cancer 
formation. How and when the IGFs act on cancer cells in not clear. High blood levels 
of IGF-I is observed in patients with colon cancer [Tripkovic et al., 2007]. Low 
levels of circulating IGF-I retard the progression and metastatic potential of a 
number of cancers [Yakar et al., 2005]. IGF-II is an important regulator of tumour 
growth, both in early adenoma and in the progression to carcinoma [Christofori et al., 
1994;Hassan and Howell, 2000]. Loss of IGF-II imprinting has been shown to be 
associated with the risk o f developing colon cancer [Liou et al., 2007;Cruz-Correa et 
al., 2004]. The expression level of IGF-II was significantly higher in colorectal 
cancer than in normal colorectal mucosa [Xu et al., 1999]. IGF-IR is crucial for 
tumour transformation and survival of malignant cell, but is only partially involved 
in normal cell growth [Larsson et al., 2007]. At present there is not enough evidence 
available to prove that IGFs alone cause or initiate cancer.
Our experiments showed that IGFBP-4 gene therapy in the form of local gene 
therapy caused increased apoptosis. It did not prevent the cancer formation. The long 
term outcome of this gene therapy was unknown. Bax protein was increased in both 
early and late gene transfer models. It appears that the IGFBP-4 does not inhibit 
tumour growth in vivo. The results are summarised in figure 5.4.
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IGFBP-4 protease
IGFBP-4
tIGF-IR
► ?Bcl-2
iVEGF
► i  ProliferationTApoptosis < i,angiogenesis
Figure 5.4 showing overall results o f  both experiments. IGFBP-4 gene therapy resulted in 
increased Bax and IG F-IR  levels and these were associated with increased apoptosis and 
decreased mitosis. (Key: ?= mechanism to be studied)
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Conclusion and future recommendations
The present study showed IGFBP-4 upregulation using naked plasmid eontaining 
IGFBP-4 cDNA, whieh apparently resulted in increased apoptosis and decreased 
proliferation of the cancer cells in vivo, although there was no marked decrease in 
tumour size within the time period studied. The increase in apoptosis was possibly 
mediated by the altered expressions of Bax and Bcl-2 proteins. The gene therapy 
caused an increased expression of IGFBP-4 in an established tumour but not in the 
early gene transfer model, whieh suggests that a pre-existing tumour may be required 
for IGFBP-4 overexpression. The increased expression of IGF-IR after IGFBP-4 
gene therapy may be due to a feedback mechanism to compensate for the decreased 
free IGF level. This study showed that IGFBP-4 had some therapeutic potential. 
However, further studies are required to determine the timescale that is needed for 
the tumour size to diminish, to find out at what stage the gene therapy should 
commence, and to assess whether IGFBP-4 gene therapy can be combined with a 
low dose chemotherapeutic agent to achieve a better therapeutic effect.
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Table A 1 Clinical, epidemiological and population based studies linking IGF system and colorectal cancer
Reference
(First author, year)
Study
Type
Population Cases/control Parameters Result /conclusion
[Nomura et al, 2003] NCC 9,345 282/282 Serum IGF-I and IGFBP-3 No significant relation between IGF-I, IGFBP-3 
and CRC
[Giovannueci et al, 2000] 32,826 276/236 Plasma IGF-I and IGFBP-3 |IGF-I and |IGFBP-3 are associated with t  risk 
of large or tubulovillous/villous colorectal 
adenoma and cancer
[Kaaks et al., 2000] CC 14 275 102/200 C-peptide, IGF-I, and 
IGFBP-1, -2 and -3
CRC risk was not related to IGF-I but |  for 
highest quintile of IGFBP-3 (OR = 2.46, 95% 
Cl = 1.09-5.57)
[Ma et al., 2000] NCC 14916 193/318 Plasma IGF-I, IGF-II and 
IGFBP-3
Circulating IGF-I and IGFBP-3 are related to 
future CRC but IGF-II is not related
[Palmqvist et al, 2003] NCC NA 168/336 Plasma IGFBP-I, IGFBP-2 
and insulin
IGFBP-1 and IGFBP-2 showed no association 
while chronic hyperinsulinemia is moderately 
associated with CRC risk
[Probst-Hensch et al, 2001] Cohort 18244 135/661 Serum IGF-I, IGF-II and 
IGFBP-3
Serum IGF-I was not associated with risk of 
CRC but t circulating IGF-II and IGFBP-3 may 
indicate impending CRC
[Teramukai et al, 2002] CC 803 157/311 Plasma IGF-I and IGFBPs Non-significant |  in the prevalence odds of 
colorectal adenomas for highest versus lowest 
quartile level of IGF-I
[Hunt et al, 2002] NCC 14275 102/200 Serum IGF-II Possible t in CRC risk with IGF-II
[Ma et al, 2001] NCC 14916 193/318 Plasma IGF-I and IGFBP-3 Dairy products cause a modest tin IGF-I levels. 
Low- fat milk lowers the risk of CRC particularly 
among individual with high IGF-I/IGFBP-3
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[Miraki-Moud et al., 2001] e s NA 81/26 Serum IGF-I, IGF-II, 
IGFBP-2 and-3
IGFBP-2 may regulate the bioavailability of IGF, 
which modulate colonic cell proliferation and or 
differentiation
[Renehan et al., 2001a] Prospe
Ctive
442 53/47 Serum IGF-I and 
IGFBP-3
IGF-I and IGFBP-3 levels are related to future 
CRC risk and may predict adenoma progression
[Renehan et al., 2000a] Co NA 52/293 IGF-I ,IGF-II, IGFBP-2 and 
-3
Serum IGFBP-2 may have an adjunct role in 
CRC surveillance ( | in IGFBP-2 level post 
surgery)
[Jenkins et al., 2000] CC NA 66/0 Serum IGF-I Development of new adenomas, but not 
hyperplastic polyps, was associated with ] serum 
IGF-I (P < 0.005)
[Manousos et al., 1999] CCI NA 41/50 IGF-I, IGF-II and IGFBP-3 Individuals with IGF-I and -II values in upper 2 
tertiles had |  odds ratio for CRC (OR = 5.2,
95% Cl 1.0-26.8) compared with those in lower 
tertile
[el Atiq et al., 1994] Co NA 17/0 IGFs and IGFBPs Simultaneous elevation of serum IGFBP-2 &-3 
in CRC
[Renehan et al., 2001b] CCI NA 60/306 Sérum IGF-I, IGF-II 
IGFBP-2 and -3
IGF-II and IGFBP-2 in acromegalics but 
presence of colorectal neoplasia did not 
contribute to |  in serum IGF-II and IGFBP-2
[Renehan et al., 2000b]
CC NA 92/57 Serum IGF-I, IGF-II, 
IGFBP-2 and -3
Significant association between adenoma 
oceurrence, |  IGF-II (P<0.0001) and serum 
IGFBP-2 (P<0.0001). Removal of adenoma led 
to i in IGF-II (P<0.001) and IGFBP-2 
(P<0.001)
[Baciuchka et al., 1998] Co NA 13/0 IGFBP-3 and IGFBP-3 
protease
Inhibition of IGFBP-3 proteolysis and invasion 
of colon cancer may be related
NA - Not applicable, CC - case control, NCC -  nested case control, Co - comparative, CS-cross sectional
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Table A2 In vitro and in vivo experimental studies linking the IGF system and colon cancer
Reference
(First author, year)
Study Type Cell line Parameters Result /Conclusion
[Kansra et al., 2000] Effect of TGF-p on IGFBP-3 In vitro A variety 
of cell lines
Proliferation TGF p Î IGFBP-3; antisense inhibition of IGFBP- 
3 blocks growth-promoting effect of TGF-P in all 
cell lines
[Culouseou and 
Shoyab, 1991]
Identification of a growth nhibitor 
from serum-free conditioned 
medium
In vitro HT-29 Proliferation Isolated growth inhibitor identical to human 
IGFBP-4
[Saksena M, 2002] Effect of IGFBP-3 cDNA In vitro Caco-2 Apoptosis Colony formation [ (50%) in IGFBP-3 transfected 
cells compared to control. IGF-I |  colony 
formation in both transfected and control cells
[Kim et al., 2002e] Effect of antisense IGFBP-6 
cDNA
In vitro Caeo-2 Proliferation Antisense clones grew faster and the final density 
was 31 ±3% higher than the control
[Leng et al., 2001a] Influence of IGF-II on Butyrate 
and trichostatin A induced 
apoptosis
In vitro LIM 2405 Cell growth 
and apoptosis
IGFBP-3 levels |  by butyrate and trichostatin and 
IGF-II inhibited apoptotic effects of both agents
[Singh et al., 1994a] Effect of episomal expression of 
sense and antisense IGFBP-4 c 
DNA
In vitro HT-29 Proliferation Antisense cells showed |  basal and IGF-I- 
stimulated growth but Sense cells did not show 
any such increase, suggesting that IGFBP-4 
overexpression was not inhibitory to HT-29 cells
[Zhangetal, 1995] Expression of IGF-II and IGFBPs In vitro Caco-2 IGF-II, IGFBP 
and
differentiation
Expression of IGF-II, IGFBP-2, and IGFBP-6 is 
regulated in a differentiation-dependent manner
[Oh et al., 2001] Effect of la,25-(OH)(2)D(3) and 
Vitamin D analogues ( EB1089, 
CB1093 ), ip,25-(OH)(2)D(3)
In vitro HT-29 Proliferation All analogues except Ip ,25-(OH)(2)D(3) 
inhibited cell proliferation, but relative potencies 
of EB1089 and CB1093 were greater than that of 
native vitamin
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[Kim et al., 2002b] Effect of trans retinoic acid(Tra); 
role of IGFBP-6
In vitro Caco-2 Proliferation Dose dependent 1 proliferation caused by Tra may 
be from IGFBP-6-mediated inhibition of IGF-II
[Ewton et al., 2002] Role of IGF-I and IGF-II In vitro NIH-3T3 Differentiation
and
proliferation
IGF-I was initially mitogenic, and then caused 
growth arrest and differentiation. Concurrent 
IGFBP-3 addition blocked growth inhibition by 
IGF-I and IGF-II
[Kim et al., 2000] Effect of poly unsaturated fatty 
acid
In vitro Caco2 Proliferation, 
IGF-II and 
IGFBP-6
[ proliferation of Caco-2 may be due to t IGFBP- 
6 which binds to IGF-II
[Kim et al., 2002a] Effect of Trans-10, cis-12- 
conjugated linoleic acid (CLA)
In vitro Caco-2 Proliferation CLA inhibits Caco-2 cell growth byjlGF-II 
secretion
[Kirman et al., 2002] Effect of plasma from patients 
undergoing major surgery
In vitro HT-29 Proliferation Major open surgery led to depletion of IGFBP-3 
in blood that promote HT29 tumour cell 
proliferation in vitro
[Collard et al., 2003] Role of IGFBP-3 in sodium 
butyrate(NaBt) induced apoptosis
In vitro Adenoma
cells
Apoptosis IGFBP-3 may act as a positive regulator of NaBt- 
induced apoptosis by IGF independent mechanism
[Cho et al., 2003] Effect of CLA isomers(trans-10, 
cis-12 conjugated linoleic acid )
In vitro HT-29 Cell
proliferation
110c 12 CLA 1 IGF-II level in a dose-dependent 
manner, whereas c9tl 1 CLA had no effect
[Leng et al., 2001b] Effect of IGFBP-6 and IGF-II In vitro LIM 1215 Proliferation 
and adhesion
IGFBP-6 inhibits IGF-II-induced but not basal 
proliferation and adhesion of LIM 1215 cells
[Mishra et al., 1998] Assay of IGF-I receptor, IGF-I 
and IGFBP-2
In vitro Cancer
tissue
IGF-I, IGF-IR 
and IGFBP-2 
mRNA
IGFBP-2 mRNA f 4-8-fold in CRC than controls 
and was highest in Dukes C samples. IGFBP-2 
mRNA was localized to malignant cells and not 
to stroma
[Michell et al., 
1997b]
Expression of IGFs and IGFBPs In vitro Cancer
tissue
mRNAs of 
IGFs and
IGFBPs
Both IGF-I and IGFBP-2 mRNA were expressed 
by all normal and cancer samples but IGF-II 
mRNA was only detected in cancer tissue
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[Remacle-Bonnet et 
al., 1997]
Effect of surface-bound plasmin In vitro HT29-D4 IGFBP-4
proteolysis
Proteolysis by plasmin can promote autocrine/ 
paracrine IGF-II bio-availability in colon-cancer 
cells
[Michell et al., 
1997a]
Effect of IGF-I and Des(l,3)IGF-I In vitro COLO205
HT29
SW620
Cell sensitivity 
to IGF-I and 
IGFBPs
In all 3 cell lines, cell-conditioned media [ 
sensitivity to IGF-I but not to des(l,3)IGF-I 
suggesting that IGFBPs inhibit action of IGF-I
[Nishimura et al., 
1998]
Effect of short-chain fatty acids In vitro Caco-2 IGFBP-2 and - 
3
Butyrate t the secretion of IGFBP-2 in a dose- 
dependent and reversible manner and 1 the 
secretion of IGFBP-3
[Akagi et al., 1998] Effect of IGF-I ,Des-(l-3)-IGF-I In vitro HT29 VEGF mRNA IGF-I t the activity of VEGF promoter. IGF-I and 
Des-IGF-I had similar effects on VEGF mRNA
[Hoflich et al., 1998] Effect of IGFBP-2 on colon cancer 
cells
In vitro LS513,
HT-29
Proliferation IGFBP-2 inhibits proliferation in IGF- 
responsive colon carcinoma cell lines
[Perer et al., 2000] IGF-I receptor antagonism in 
chemoradiation therapy
In vitro SW480
cells
Inhibition IGF-IR antagonism |  the cytotoxic effect of 
chemo radiation therapy
[Di Popolo et al., 
2000]
IGF-IR and COX-2 activity In vitro Caco-2 COX-2 and 
IGF-II mRNA 
and PGE-2
Antibody to IGF-IR inhibited COX-2 mRNA 
expression and dominant negative IGF-IR \, 
COX-2 expression and activity
[Williams et al., 
2000]
Effect of IGFBP-3 In vitro Colon 
cancer cells
IGFBP-3, 
apoptosis and 
differentiation
IGFBP-3 alone have no effect on growth of colon 
cancer cells but it enhances P-53 dependent 
apoptotic response to DNA damage
[Singh et al., 1994b] Expression of IGF-II and IGFBPs 
by different colon cancer cell lines
In vitro COLO 205, 
Caco-2, 
HCT116, 
HT-29
mRNA and 
protein of IGFs 
and IGFBPs
All cell lines expressed IGFBP2 and/or IGFBP4 
mRNA and secreted IGFBP4 and/or IGFBP2; 
IGFBP 1 was not deteeted in any cell line. IGFBP3 
mRNA was detected only in IGF responsive cellS
[Freier et al., 1999] Expression of the IGFs and their 
receptors
In vitro Cancer
tissue
IGF-I ,11 and 
IGF-IR
IGF-I polypeptide, not mRNA, was present in 
small amounts in normal and malignant tissue. 
IGF-II was expressed 40 times IGF-IR 2.5 times 
and IGF-IIR 4 times more in colonic tumours
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[Reinmuth et al., 
2002a]
Transfection with a truncated 
dominant-negative form of IGF-IR 
(IGF-IRDN).
In vitro 
&
in vivo
KM12L4
nude
mouse
VEGF
expression
IGF-IRDN cells showed [ level of VEGF mRNA 
and protein. In nude mouse it led to 1 tumour 
growth,VEGF expression,& vessel count (p < .05)
[Reinmuth et al., 2002 Blockade of IGF-IR and 
angiogenesis
In vitro 
&
in vivo
HT-29
nude
mouse
VEGF 
expression, 
proliferation 
and vessel count
IGF-IR blockage inhibited HT29 growth in both 
Monolayer and soft agar (P < 0.05). In nude 
mice it led to 1 tumour growth (P < 0.05)
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Lenox or Lubria Broth (LB) Ampicillin Agar medium
10 g NaCl 
10 g Tryptone 
5g yeast extract 
1 litre of deionised water 
10 ml of lOmg/ml Ampicillin
LB plate
5gNaCl
lOg Tryptone 
5 g yeast
1ml of IN NaoH 
15g agar
1 litre o f deionised water 
Ampicillin
S.O.C Medium
0.5% Yeast extract,
2.0% tryptone 
lOmM NaCl 
2.5mM KCl 
lOmM MgC12 
20mM M gS04 
20mM glucose.
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1% Acid Alcohol Solution (for differentiation)
Hydrochloric a c id ----------------1 ml
70% ethanol---------------------- 100 ml
Mixed well.
0.2% Ammonia Water Solution (Bluing)
Ammonium hydroxide (concentrated) 2 ml
Distilled w ater-------------------------------------- 1000 ml
Mixed well.
Eosin Y Solution:
Eosin Y Stock Solution (1%)
Eosin Y  10 g
Distilled w ater------------------------------------200 ml
95% Ethanol-------------------------------------- 800 ml
Mix to dissolve and store at room temperature.
Eosin Y Working Solution (0.25%)
Eosin Y stock solution---------------------  250 ml
80% Ethanol-------------------------------------  750 ml
Glacial acetic acid (concentrated) —  5 ml 
Mix well and store at room temperature.
Haematoxylin Solution (Harris)
Potassium or ammonium (alum ) 100 g
Distilled w ater---------------------------------  1000 ml
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The solutions were heated to dissolve. Then 50 ml of 10% alcoholic haematoxylin 
solution was added and boiled for 1 minute. Then 2.5 g of mercuric oxide (red) was 
added and heated it until it becomes dark purple colour. The solution was cooled in 
cold water bath and 20 ml of glacial acetic acid (concentrated) was added. The 
solution was filtered before use.
Reagents for Electron Microscopy 
Glutaraldehyde
(20mls 20% Para formaldehyde [Analar BDH] + 16mls 25% glutaraldehyde [TAAB] 
+ 59mls phosphate buffered saline [Oxoid])
Osmium tetroxide
1% osmium tetroxide [Analar BDH] + 1.5% potassium ferricyanide [BDH] in PBS 
[Oxoid]
Toluidene blue stain
1% toluidene blue [Raymond Lamb] with 0.2% pyronine [Raymond Lamb] in 1% 
sodium tetraborate [Analar BDH].
Reynolds lead citrate
Dissolve 1.33g lead nitrate [BDH] in 15mls distilled water and 1.76g sodium citrate 
[BDH] in 15mls distilled water, mix solutions together and dissolve the resulting 
precipitate with 8 mis of IM sodium hydroxide [BDH], make up to final volume of 
50mls
Lemix epoxy resin
Lemix A (25mls) + Lemix B (55mls) + Lemix D (20mls). Poured into plastic resin 
bottle and add 2 mis of BDMA, mixed well.
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Thin section were cut with diamond knife and stained with uranyl aeetate and lead 
citrate for examination with an electron microscope. Cubes of tissue less than 2 mm^ 
in thickness were cut from the speeimen and fixed in 1.5% paraformaldehyde/1.5% 
glutaraldehyde in phosphate buffer for a minimum of 2 hours. The tissue was then 
washed with several changes of phosphate buffered saline [Oxoid] and post fixed 
using 1% osmium tetroxide / 1.5% potassium ferricyanide for 12 hours.
The tumour sections were washed with distilled water and dehydrated using graded 
alcohols 30%, 50%, 2x70% and 3x100%. They were then kept in a 50% alcohol / 
50% Lemix (TAAB) epoxy resin mixture overnight and the following day infiltrated 
with 100% lemix resin for a minimum of 6 hours. This was followed by embedding 
them in fresh lemix resin in plastic embedding capsules and polymerised in an oven 
at 70°C overnight. One pm sections were cut using glass knives on a Reichert-Jung 
ultra cut microtome, collected on glass mieroscope slides and stained using 1% 
Toluidene blue / 0.2% pyronine in 1% Borax stain.
Procedure for electron microscopy
Sixty to ninety nanometre sections were cut using a diamond knife (Diatome) and 
collected on 300 HS, 3.05 mm copper grids (Gilder). The sections were stained with 
saturated uranyl acetate in 50% ethanol (TAAB) for 5 mins, washed in a stream of 
distilled water and then stained with Reynolds’ lead citrate for 5 min. The sections 
were washed again and left to dry before viewing. The ultra thin sections (60-90 nm) 
were viewed and photographed using a Philips CM 120 transmission electron 
microscope.
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Sequencing results
Name/Label Qual Qual left right
Primer Sequence
v&cior
ASB000I077
BP4
ASB000I07S
111
ASB000ID79
>VBctor-T7 2A..726 of Litoe f'Hc
C;^ TCrAfi.aCt:iC<X*CW:CTA7/«H’|i7C2OTAPA1H:rA3AiX;:CDC?fr^ ^^
.;rr(îr:jœr:cn'Acn%%%:'\GCCArcTCi7(TiTTQCCCcrcco:r%nYiLerrærTCM%:
(:7i%%Q]rGŒy.r:i'(%:cf/::G7\%TTi':ri'AATfav;mvKîfu"Lk;rr9^^ ^
wlÊAGT.AGGTCrriAîrCTArTCTGGCOTIX'ïCKÎGrC^GGCA:^ ^
26 726 T7 7(^ ÏA!lW^v.'iâCAôG:ATQ::COTA'rXT?3:C-G:CTÇ
AGAW:A3r:IXK^ %:CrAGC03riTArCCC^ D3%0Cr;[(frA(%}3GC0CATlT,/ük}
W33CT^ T[^ r3GTTA0:Cn(:nan^ r3A%3CTACff:r?GCCAG]3CCCTr.(^
a:r:7asc7TrcTrccnM’crr:7crcGOc;Afïn':’cn^:c&GG:TTcr:axi?c^^
A^Tce;3GCcrf%i:rvTA3GGr:ca%a7Timf3aTTAOQüC'*xr7ù]nO
CTTCATrM%G7a:GGr?c^ c:rTTAü7(^ 3GCArcncf:[riüA7A3nO]3T'rTrvC6:CCr
Ti'-:iAc%r7i%AG7rrL\aiv7cr?TM7AGrrxiAc:YcrrGT
>Drj-Tv 1«..O06 of t raw f iic 
An0G3!%x%:r:f/]TGT»%703jV^ in':t42G3GGC3^  
cca/:rx]û:AGTCCir;GC(.%::i{f'it]^:e%.:cr:Y&^ 
-t::(ajCC633C»:GC0Cr:ri«âCCTGC<-03PJrvVica:tArc^  
:inüAiV-ŒAC0ür:M:raC03CœcCQDnvH%ri'G^  
:G05.:.(7n777(?jL t^AaT\:mr:frixj:iLCrrGGXATar:fri'üœ^  ^
:-rii%xx^3C703uOOC7(x::icix%:7A:co]C:a%üaf3GTG3A:%;na:crDj^  ^
c:lÛA7GGnœ^ 3Cr.'\fMi(ï:G7GTGCATGC.'«Kri0GCGaA^ ^^  ^
CI^ :<A'5COT:’rcii^î‘j33A01!y:Q37Ci".CC?£CCGA™:j^ ^^ ^^  
&D:3JJA0[H:f^ %7G:G7O:;MGA<''M:'v27TG3CCAVAll'[:6AaO^  
Gî3;GGCO«Vi>\r(=AA:<-KonAl\"l«y:C<iXœG^  ^
T0G'rcxxj\i^ î^ <CQA3Cn^ :.'«x:î^ L^ C^ ::TGGA^  
c!*v::[i'tô3ACc:CTA:A'i\"iviœccArcoxAAf:vrKXiACL^^  
pAXfiû:c-KHCn:^ ff.:rci^ 2G?.TG0ca^rn7iKifKLV^  ^
fi^ GC<^ :C'T(x>viæricox<?:icrçrriG:ifj^  
^^ Œ^ AClWTTCGAGACTGAfXfGCrGCC
>>iyo-77 1 1 L ..T :9  o f  ira-.-tf î L e  
?GTGV]CrjVV\17XrlA3A;]C:CGC:CAT[:/lC)GC7t}3;rTGTW^^
T7 7CTG:TGrn(ï:::rDcrccoGCGrGCCii’rriTQArccT^ Ga?Ac;:ntiCC?G:rco^ ^^  
C7TrCCT.WA.^ M'IGAGaAATrGr;<^ vr?[rATTGraOTJy.rKinG7C2irTCTA7 
GGtGjGTGGGfîl’CüTÔGGfilG
16 83B 17
Figure Al showing the results of sequencing analysis of the plasmids. It confirms the 
presence of IGFBP-4 cDNA insert and pcDNA3 in the samples.
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BLASTN 2.2.15 [Oct-15-20061 
Reference:
Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer,
Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman
(1997), "Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs". Nucleic Acids Res. 25:3389-3402.
RID: 1166190668-28633-200171592568.BLASTQ4
Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS,
GSS,environmental samples or Phase 0, 1 or 2 HTGS sequences)
4,658,713 sequences; 18,685,068,004 total letters
If you have any problems or questions with the results of this search
please refer to the BLAST FAQs
Query=
Length=35
Distribution of 51 Blast Hits on the Query Sequence
Distance tree of results 
Score E
Sequences producing significant alignments: (Bits) Value 
gi|l 14667554|ref]XM_001170312.H PREDICTED: Pan troglodytes s... 52.0 6e-05 
gi|l 14667552|ref]XM_511475.2| PREDICTED: Pan troglodytes simi... 52.0 6e-05 
gi|62243289|ref|NM_001552.2| Homo sapiens insulin-like growth... 52.0 6e-05 
gi|16359145|gb|BC016041.1| Homo sapiens insulin-like growth f... 52.0 6e-05 
gi|37953288|gb|AY442346.1| Homo sapiens insulin-like growth f... 52.0 6e-05 
gi|23396306|gb|AC018629.121 Homo sapiens chromosome 17, clone RP 52.0 6e-05 
gi|50484189|emb|CR603382.1| full-length cDNA clone CS0DM004YJ... 52.0 6e-05 
gi| 184815|gb|M62403.1 |HUMIGFBP5 Human insulin-like growth fac... 52.0 6e-05 
gi|2765191|emb|Y12508.1|HSIGFBP H.sapiens IGFBP-4 gene 52.0 6e-05 
gi|695253|gb|U20982.1|HSU20982 Human insulin-like growth fact... 52.0 6e-05 
gi|108764099|gb|CP000386.1| Rubrobacter xylanophilus DSM 9941, c 40.1 0.25 
gi| 109115230|reflXM 001097914.11 PREDICTED: Macaca mulatta si... 38.2 0.97 
gi| 19848415|gb|AC009630.14| Homo sapiens chromosome 8, clone RPl 38.2 0.97 
gi|39647555|emb|BX572595.11 Rhodopseudomonas palustris CGA009 co 38.2 0.97 
gi|58585231|ref]NM_001011556.1| Canis familiaris ceroid-lipof... 38.2 0.97 
gi|29294032|gb|AC092384.5| Homo sapiens chromosome 16 clone RPl 1 38.2 0.97 
gi|l 17164170|emb|AM238664.1| Streptomyces ambofaciens ATCC 23877 36.2 3.8 
gi|l 13428918|ref]XM_933347.2| PREDICTED: Homo sapiens hypothe... 36.2 3.8 
gi|l 11147037|emb|CT573213.2| Frankia alni str. ACN14A chromosome 36.2 3.8 
g i|l09122324|ref|XR_010720.11 PREDICTED: Macaca mulatta simil... 36.2 3.8 
gi|96771622|emb|AJ937741.1| Streptomyces ambofaciens ATCC 238... 36.2 3.8 
gi|94386256|ref|XM_984231.11 PREDICTED: Mus museulus hypothet... 36.2 3.8 
gi|91199575|emb|AJ937740.1| Streptomyces ambofaciens ATCC 238... 36.2 3.8 
gi|71896128|ref|NM_001031584.1] Gallus gallus POU domain, cla... 36.2 3.8 
gi|55831587|gb|AC151766.1| Omithorhynchus anatinus ehromosom... 36.2 3.8 
gi|33521039|gb|AY280635.1| Uncultured bacterium clone pbiow g... 36.2 3.8 
gi|33457241|gb|AC127554.4| Mus museulus BAC clone RP24-323K23... 36.2 3.8 
gi|28630143|gb|AC124170.3| Mus museulus BAC clone RP23-155H5 fro 36.2 3.8 
Mouse-over to show defline and scores, click to show alignments
(RID=1166190668-28633-200171592568.BLASTQ4, Pagina 1 di 10 
http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi 15/12/2006)
Figure A2 showing confirmation of IGFBP-4 cDNA in the gene contruct as per PubMed 
database.
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Table lA  Animal weight (Late gene transfer model))
Animal Week 0 Week 1 Week 2 Week 3
Ml 31 28 27.3 28
M2 31 31 32 31
M3 28 28 27.3 28
M4 31 31 31 30
M5 29 29 29.3 29
M6 29 29 29.5 29
B1 30 30 29.8 29
B2 31 32 31.2 32
B3 35 36 35.6 35
B4 33 34 34.1 34
B5 26 27 27.1 27
B6 33 33 33 33
Table IB Animal weight (Early gene transfer model)
week PI P2 P3 P4 P5 P6
1 27 28 30 28 30 31
4 29 29 30 30 27 32
M l M2 M3 M4 M5 M6
1 31 31 30 30 30 28
4 31.3 26 30.4 29.5 30.2 29.5
B1 B2 B3 B4 B5 B6
1 25 30 29 29 27 29
4 31.5 30 31 29.5 30 29.5
Key: B1-B6 = BP-4 group, Ml-M6= Control plasmid group, P I-6 Control group 
without any plasmid; 0, 1, 2, 3 and 4 = 0, 1, 2, 3 and 4 weeks following gene 
therapy.
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Table 2A Tumour size (Late gene transfer model)
Animal Week 0 (LXB) Week I Week 2 Week 3 (LXBXW)
M l 6X5.5 8X8.3 12.8X10.1 14.1X9.1X9.1
M2 7.3X6.4 10.6X6.2 15.4X11.8 20X11.1X7
M3 7.4X4.4 10.4X5.8 12.8X8.1 12.3X7.5X6.8
M4 5.2X5.1 11X8.1 11.8X9.6 12.3X9X5.4
M5 9.6X4.6 13.5X10.5 17.7X10.8 17.5X11.5X11.5
M6 2.2X2 7.8X3.9 10.5X9.4 13.2X7.2X4.7
B1 5.8X3.6 7.4X7.4 14X8.7 12.5X7.5X5.7
B2 9.9X4.6 12.4X11.7 15.9X14.8 14.4X12.6X14.6
B3 9.4X6 12.1X12.1 16.1X14.5 16.6X14.9X5.9
B4 5.8X5.3 9.5X9.5 15X12.9 15X13.2X6.5
B5 8.5X5.8 10.6X8.5 14.9X9.7 16X12X9
B6 11.2X7.5 15.8X10.3 13.4X11.2 17X13X9
Table 2B Tumour volume (mm ) (Late gene transfer model)
Animal Week 0 Week 1 Week 2 Week 3
M l 99 275 827 917
M2 170 348 1399 984
M3 120 313 663 492
M4 69 490 668 470
M5 211 956 1691 1153
M6 5 118 518 350
B1 265 885 1879 1145
B2 60 202 852 420
B3 89 428 1451 1010
B4 190 477 1076 1356
B5 470 1285 1005 1561
B6 225 899 1870 2080
Key: B1-B6 = BP-4 group, Ml-M6= Control plasmid group 
0, 1, 2 and 3=0,  1,2 and 3 weeks following gene therapy
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Table 3A Tumour size in the early gene transfer group
week PI (LXB) P2 P3 P4 P5 P6
1 12.2X7.3 10.2X8.8 12.9X8.1 9X8 9X9 8.4X6.6
4 18.5x16.6 22.8x18 20.6x12.9 16.4x15.1 15.4x12.6 15.3x13.1
M l M2 M3 M4 M5 M6
1 7.2X7.2 11X8.5 11.1X8.6 7.3X7.3 8.8X5.6 8.5x8.3
4 10.9x10.9 15.6x14.8 11.3x7.8 14x11 16.1x8.1 13x11.8
B1 B2 B3 B4 B5 B6
1 7.4X7.1 7.8X6.5 7.5X6.7 7.2X7.2 7X4.5 8.1X8.1
4 13x11.1 17.5x13.5 12.7x7.4 11.1x10.8 15x10 17.4x14.8
Table 3B Tumour volume in the early gene transfer group
Week PI P2 P3 P4 P5 P6
1 325.069 394.944 423.184 288 364.5 182.952
4 2548.93 3693.6 1714.02 1869.68 1222.45 1312.82
M l M2 M3 M4 M5 M6
1 186.517 165.775 168.338 74.925 186.624 265.721
4 1708.51 647.515 343.746 528.16 847 905.06
B1 B2 B3 B4 B5 B6
1 186.624 397.375 410.478 210.937 137.984 292.782
4 800.865 1594.69 347.726 647.352 750 1905.65
Key; Pl-6 = Plain group, Ml-6 = Control plasmid group, Bl-6 = BP-4 group 
1 and 4 = 1  and 4 weeks after plasmid therapy
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Table 4A Mitotic figures in the late gene transfer model
M l M2 M3 M4 M5 M6 B1 B2 B3 B4 B5 B6
6 0 4 7 6 1 3 1 2 2 1 0
3 0 10 2 3 5 6 3 8 4 5 2
4 4 2 5 7 5 4 3 3 2 3 2
2 2 4 3 3 3 2 0 2 2 0 1
2 3 4 1 7 2 5 0 5 0 2 4
2 0 4 0 10 1 3 0 3 2 6 0
5 2 2 6 8 4 3 0 3 3 2 2
3 2 4 11 7 3 4 0 7 3 0 2
1 3 2 2 5 1 1 0 6 2 1 1
2 1 2 5 7 2 2 1 2 1 0 2
Table 4B Mitotic figures in the early gene transfer model
B1 B2 B3 B4 B5 B6 M l M2 M3
10 5 2 5 1 0 0 2 2
1 4 1 0 1 1 1 0 2
9 2 1 0 2 2 1 4 1
2 0 2 2 1 1 0 2 0
0 2 1 2 0 1 1 1 2
M4 M5 M6 PI P2 P3 P4 P5 P6
14 3 9 6 8 5 20 5 7
7 8 4 1 8 8 9 5 8
1 5 4 4 11 15 10 32 6
13 1 5 6 4 1 17 2 3
1 0 0 0 0 2 0 4 3
Key: Cl-6 = Control plasmid group, Bl-6 = BP-4 group P I-6= Control no plasmid group
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Table 5A Cell death score in late gene transfer model
B1 B2 B3 B4 B5 B6
2 4 3 2 3 3
0 2 3 3 1 4
2 3 1 3 0 3
1 2 2 4 2 3
1 4 1 2 4 2
M l M2 M3 M4 MS M6
1 0 0 1 2 1
3 3 2 1 0 0
2 2 1 1 0 1
2 2 2 2 1 0
1 3 1 3 0 2
Table 5B Cell death score in early gene transfer model
B1 B2 B3 B4 BS B6 M l M2 M3
2 1 3 3 1 5 1 1 2
2 2 3 1 1 4 2 1 1
1 2 1 0 0 4 1 3 4
1 2 1 3 5 3 1 1 2
5 4 2 1 0 3 3 1 4
M4 MS M6 PI P2 P3 P4 PS P6
3 2 5 0 0 1 3 0 2
1 1 0 0 1 1 0 1 2
3 0 0 0 0 0 1 0 2
0 3 2 1 0 0 0 0 0
0 4 1 2 3 0 0 0 0
Key: Pl-6 = plain group, Ml-6 = Control plasmid group, 
Bl-6 = BP-4 group
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Table 6A Western blot densitometry for lGFBP-4 (EGTM)
PI P2 P3 P4 P5 P6
1.181 1.097 0.968 1.25 0.917 0.873
M l M2 M3 M4 M5 M6
0.74 0.533 0.674 0.674 0.714 1.214
BI B2 B3 B4 B5 B6
0.538 0.594 0.594 0.646 0.676 0.789
Table 6B Western blot densitometry for IGF-IR (LGTM)
Group Control M BP-4
1 3.85 4.955
2 4.751 4.313
3 3.573 5.823
4 4.434 5.101
5 2.69 4.843
6 3.138 5.484
Table 6C Western blot densitometry for Bax (EGTM)
PI P2 P3 P4 P5 P6
1.708 1.484 9.057 2.984 2.622 2.383
M l M2 M3 M4 M5 M6
2.829 4.757 1.838 10.225 1.728 3.327
B l B2 B3 B4 B5 B6
8.415 8.922 6.986 8.082 2.97 2.495
Table 6D Western blot densitometry for Bcl-2 (EGTM)
PI P2 P3 P4 P5 P6
1.082 0.944 2.163 5.106 1.248 3.081
M l M2 M3 M4 M5 M6
1.421 0.731 0.511 0.541 0.814 2.091
B l B2 B3 B4 B5 B6
7.762 12.467 7.109 6.76 1.495 0.779
Key: Pl-6 = plain group, Ml-6 = Control plasmid group, 
Bl-6 = BP-4 group
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Table 7A Western blot densitometry for Bax (LGTM)
B l B2 B3 B4 B5 B6
4.516 3.613 7.451 5.927 19.757 11.29
3.951 3.387 6.492 6.943 16.003 13.675
M l M2 M3 M4 M5 M6
7.79 5.588 5.927 5.588 4.572 4.064
5.779 5.08 5.786 5.483 4.191 2.406
Key; B1-B6 = BP-4 group, Ml-M6= Control plasmid group
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Figure A3 BP-4 immunofluorescence in tumours of BP-4 group (x400) following single 
administration of BP-4 gene construct in a previously established subcutaneous colon cancer. 
Greenish immunofluorescence (arrow) from the IGFBP-4 protein is found inside the colon 
cancer cells.
> . ' i f :
Figure A4 BP-4 treated tumour tissue stained for BP-4 immunofluorescence in the late gene 
transfer model after single administration of BP-4 gene in a previously established colon 
cancer (x200). Intracellular IGFBP-4 protein is seen as greenish immunofluorescence 
(arrow).
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